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Copy number variants (CNVs) have been implicated in the pathogenesis of clinically 
distinct neurodevelopmental disorders (NDDs), indicating common underlying 
pathophysiology. Yet, the frequency, genetic architecture, and phenotypic role of 
pathogenic CNVs in adults with co-morbid neurodevelopmental phenotypes has not 
yet been systematically investigated.  
Adults with intellectual disability (ID) and psychiatric co-morbidities were recruited 
from ID psychiatry services across the UK (N=202).  Using a genotype-first approach, 
chromosomal microarray analysis (CMA) was undertaken, and variants were 
categorised using the NHS regional genetics service (RGCs) clinical pipeline. Genetic 
and phenotypic data was combined with two independent samples to enable frequency 
analyses (N=599). Targeted recruitment of individuals with 2q13 CNVs was 
undertaken via a patient support group, RGCs and the online rare CNV database 
DECIPHER (N=25). 
The frequency of pathogenic CNVs was 11%, rising to 13% in the replication cohort. 
Both novel and recurrent loci were found to harbour pathogenic CNVs, with 70% at 
established NDD risk loci. A significantly higher population frequency of CNVs was 
identified in NDD risk regions (10%), compared with schizophrenia (3.1%, p<0.0001) 
and ID/autism spectrum disorder (6.5%, p<0.0008) populations. Phenotypic 
characterisation of CNVs at the 2q13 region suggests an early-onset neuropsychiatric 
phenotype with a high incidence of attention deficit hyperactivity disorder (ADHD) 
and challenging behaviours.  
There is a high yield of pathogenic CNVs in patients with co-morbid 
neurodevelopmental phenotypes. In the main part, distinct loci are not involved in co-
morbid NDD risk, but risk arises from the same loci identified in single disorder 
cohorts.  Detailed phenotypic investigation of the 2q13 locus indicates that pleiotropy 
exists, however there is a preferential psychiatric outcome – in this instance ADHD.  
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Understanding the factors which modulate a CNV region with a high general risk for 
NDDs to a preferential neuropathological pathway will be key to understanding the 






“All men dream: but not equally. Those who dream by night in the dusty 
recesses of their minds wake in the day to find that it was vanity: but the 
dreamers of the day are dangerous men, for they may act their dreams 
with open eyes, to make it possible.” T.E. Lawrence 
Undertaking a PhD once seemed like an unattainable dream to me. There have been 
many people who have supported me on this journey, without whom I would not be 
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Firstly, I would like to thank my research supervisors. I worked with Dr Andrew 
McQuillin and Dr Nick Bass as a Research Assistant prior to starting my PhD, and it 
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coding. Nick’s clinical expertise has been invaluable throughout my PhD and his 
comprehensive editing of my work has enabled me to significantly develop my skills 
in academic writing. Professor David Skuse also took on the role as supervisor for my 
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Chapter 1 Introduction 
Parts of this chapter have been adapted from the following book chapter:  
Wolfe, K., Strydom, A., Bass, N. (2017) Genetics of Intellectual Disability, In Kerr, 
M., Seminars in Psychiatry, Royal College of Psychiatrists, Cambridge University 
Press. (In press) 
1.1 Terminologies 
Two of the main terminologies that will be utilised throughout this thesis have 
differential usage in the published literature and are discussed here for clarification. 
Neurodevelopmental disorders (NDDs) are a highly heterogeneous group of disorders 
characterised by perturbed cognition, communication, behaviours, and motor 
functioning, as a result of atypical brain development1. Intellectual disabilities (ID), 
autism spectrum disorders (ASD), attention deficit hyperactivity disorder (ADHD) and 
epilepsy are all considered to be NDDs. The category also extends to include 
neuropsychiatric disorders, such as schizophrenia2. There has been a shift in 
understanding in psychiatry, whereby many later-onset psychiatric disorders are now 
understood to have their origins in the developmental period. For example, cognitive 
deficits in schizophrenia have been shown to be present prior to the onset of the 
disorder3. However, the terms neurodevelopmental and neuropsychiatric disorder are 
still often used interchangeably in the published literature. Some authors have coined 
new terminology to describe this phenomenon, for example Moreno-De-Luca et al. 
suggested developmental brain dysfunction as a term to describe the group of 
neurodevelopmental and neuropsychiatric disorders that encompass various clinical 
diagnoses1. In the main discussion of this thesis I use the term NDDs for simplicity, 
however the exact phenotypic composition of each sample is provided in the method 
sections of the individual chapters. 
Pathogenic is a term that is also often used variably in the published literature. Broadly 
speaking, a genetic variant can be said to be pathogenic if it causes disease. However, 
the usage of this term has been complicated by the discovery that a genetic variant, 
which is thought to cause disease in some individuals, can be present in other 
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individuals with no apparent effect. This is discussed in detail in the context of copy 
number variations (CNVs) in 1.3.2. Where relevant, the exact meaning of the term 
pathogenic has been discussed in the method sections of the individual chapters. 
1.2 A brief history of genetic investigations for neurodevelopmental disorders 
In the last century there has been a revolution in the genetic investigation of NDDs. In 
the 1950s, a technique for visualisation of the complete set of chromosomes (also 
known as the karyotype) under optical microscopes was developed4. This cytogenetic 
technique enabled the identification of abnormalities of chromosome number 
(aneuploidies) and large structural abnormalities, such as translocations. 
Translocations involve the movement of stretches of deoxyribonucleic acid (DNA) 
between chromosomes and can be balanced or unbalanced, depending on whether 
there is an overall loss or gain of genetic material. One example of a disorder arising 
from aneuploidy is Klinefelter syndrome, a disorder whereby there is an extra copy of 
the X chromosome causing ID and various psychiatric phenotypes5.  
The 1970s and 1980s saw the development of molecular genetic techniques to 
manipulate DNA – such as the polymerase chain reaction (PCR). PCR became a core 
technique in molecular genetics, as it can be used to generate millions of copies of 
specific segments of the genome for a variety of subsequent genetic assays. With the 
identification of polymorphic DNA markers and application of PCR, genetic linkage 
analysis became a powerful tool for gene discovery. Linkage analysis is based on the 
concept that polymorphic DNA markers of known chromosomal position can be used 
to approximately locate disease causing genetic variation through analysis of the co-
segregation of specific alleles of the markers and the disease within families. This was 
predominantly successful for disorders with Mendelian patterns of inheritance. 
Mendelian disorders are caused by mutations of bases within a single gene, for 
autosomal dominant disorders only one copy of the mutated gene is required to give 
rise to the disease phenotype, whereas in autosomal recessive conditions two abnormal 
copies of the gene are required.  
An example of a disorder which can be mapped by linkage analysis is phenylketonuria 
(PKU), an autosomal recessive disorder that can lead to the development of ID, 
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seizures, heart problems, and a range of psychiatric phenotypes6. PKU arises due to 
mutations in the phenylalanine hydroxylase (PAH) gene. The gene encodes an enzyme 
that catalyses the breakdown of the amino acid phenylalanine. Mutations result in 
enzyme deficiency and a resultant toxic build-up of phenylalanine in the brain and 
body. Delineation of the inheritance pattern and metabolic pathology of PKU occurred 
before the PAH gene was mapped to chromosome 12 in the 1980s7. The enzyme 
deficiency can be ameliorated by implementation of a low-phenylalanine diet, 
preventing the development of ID and other disease pathology. Newborn screening 
programmes for PKU have been widely implemented and have proven to be very 
successful8.  
Around the same time, deletions and duplications of sections of the chromosome were 
identified as being involved in the aetiology of NDDs. For example, in 1981 an 
interstitial deletion of the paternal chromosome was identified at the 15q11–q13 locus 
which causes Prader–Willi syndrome (PWS)9. PWS has a characteristic clinical 
phenotype, comprising: childhood-onset obesity with extreme hyperphagia, mild ID, 
a recognisable pattern of dysmorphism, hypogonadism and growth insufficiencies. 
Behavioural problems, including tantrums and compulsive traits, are estimated to 
affect 70–90% of individuals. ASD is also present in approximately 25% of cases, and 
psychosis in 5–10%10. PWS is a disorder of DNA methylation, an important 
mechanism by which genes are switched on or off, resulting in changes in gene 
activity. Normally, genes from both the maternal and paternal chromosomes are 
expressed, however, in a process called genomic imprinting, one of the parental genes 
is imprinted (epigenetically silenced by DNA methylation) and therefore only one 
active copy of the gene is present in the offspring. In PWS a set of genes in the 15q11-
13 region are imprinted (turned off), on the maternal chromosome, so deletion of the 
equivalent region on the paternal chromosome results in the lack of any active copies 
of these genes. 
Angelman syndrome (AS) is the reciprocal condition to PWS, arising through a 
deletion of the maternal chromosome in the imprinted 15q11-q13 region. A set of 
genes in this region are imprinted (turned off) on the paternal chromosome, so deletion 
of the region from the maternal chromosome results in lack of any active copies of 
these genes. AS presents with a very different phenotype – comprising: severe ID, 
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virtual absence of speech, seizure disorders and mild dysmorphisms. The behavioural 
phenotype is particularly distinct, with hyperactivity, frequent laughter, and motor 
stereotypies11. It is still unclear which imprinted gene(s) contribute to PWS, however, 
it is known that the gene encoding ubiquitin–protein ligase E3A (UBE3A) explains 
many of the manifestations of AS and single-gene mutations can also give rise to the 
disorder12. 
The Human Genome Initiative, more commonly known as the Human Genome Project 
(HGP), was conceived in 1986 and set out to sequence all 3 billion base pairs of the 
human genome. The sequence was made publically available and has enabled the 
development of bioinformatic resources, which provide powerful tools for genetic 
investigation and clinical genetics13. Furthermore, the HGP provided the driving force 
behind the development of high-throughput next-generation sequencing (NGS). NGS 
technologies have made it possible to rapidly sequence the whole protein-coding 
region of the genome – whole-exome sequencing (WES) – or even the whole genome 
–  whole-genome sequencing (WGS), at a low cost. NGS is a very powerful tool for 
identifying pathological single-base changes in the DNA sequence, which are referred 
to as single nucleotide variants (SNVs). In particular, NGS has facilitated the 
identification of de novo mutations. By definition, de novo mutations are not present 
in the parents and have arisen for the first time during egg or sperm cell formation, or 
in early embryonic development. A combination of the ability to map changes in a 
genetic sequence to a specific gene and technological developments, enabling 
detection of submicroscopic structural variations, also gave rise to copy number 
variants (CNVs) being identified as an important class of genetic variation in NDDs. 
1.3 Copy number variations 
CNVs are structural variants of at least 1kb in size that are present at a variable copy 
number in comparison with a reference genome14. Studies of healthy control 
populations have revealed that large-scale copy number polymorphisms are common 
throughout the human genome15,16, and approximately 12% of the genome comprises 
CNVs17. Whilst there are many CNVs that are neutral in function, if the deletion (loss) 
or duplication (gain) of genetic material affects a dosage-sensitive gene this can lead 
to changes in gene expression and protein function. These variants are under negative 
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genetic selection, with a general trend of reduced fecundity as the severity of the 
phenotype increases18. Thus, rare variants of recent origin are the primary contributors 
to genetic risk, and it is the rare CNVs (typically defined as occurring at a frequency 
of <1% in the general population) that are most frequently associated with disease19. 
Particular regions of the genome are more prone to CNV. Low copy repeats (LCRs), 
also known as segmental duplications, are regions which contain repetitive DNA 
sequences. Genomic regions rich in LCRs are predisposed to non-allelic homologous 
recombination (NAHR), whereby recombination errors occur between two sequences 
with high similarity. NAHR is one of the primary mechanisms giving rise to CNVs, 
and it has been estimated that there are approximately 130 hotspots in the human 
genome which are vulnerable to CNV caused by NAHR20. As a result of this 
mechanisms multiple CNVs, which are nearly identical to one another, can arise 
independently in different individuals. These recurrent de novo CNVs have a major 
role in the pathogenesis of NDDs. Other mechanisms of structural variation include: 
non-homologous end joining, fork stalling and template switching, and L1-mediated 
retrotransposition21. Equally, non-recurrent CNVs, rearrangements which arise in 
regions that don’t contain LCRs and differ in size between patients, are another 
pathological mechanism22. 
1.3.1 Chromosomal microarray analysis 
DNA microarrays, also known as nucleic acid arrays, are small slides to which 
thousands of nucleic acid probes are bound. This enables hundreds of thousands of 
genotyping reactions to be carried out simultaneously. Currently there are two main 
types of microarray used for chromosomal microarray analysis (CMA), microarray-
based comparative genomic hybridization (array CGH) and single nucleotide 
polymorphism (SNP) microarrays. In array CGH, DNA from the patient and a 
reference control are differentially fluorescently labelled and changes in genomic copy 
number, using probes at varying intervals, are made visible by differences in 
florescence levels23. SNP platforms were primarily developed to detect changes to 
single bases of the DNA sequence. However, it is also possible to determine genomic 
copy number using SNP arrays by detecting changes in the intensity information of 
segments of DNA24. 
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1.3.2 Clinical applications of chromosomal microarray analysis 
In 2010, a consensus statement from the International Standard Cytogenomic Array 
Consortium recommended CMA as one of the first-line cytogenetic tests, replacing 
karyotyping, for postnatal investigation of idiopathic developmental delay (DD), ID, 
multiple congenital abnormalities (MCA) and ASD25. Historically medical genetics 
has adopted a phenotype-first approach, whereby a collection of patients with similar 
phenotypes are investigated with the aim of mapping the pathological genetic variant. 
The advantage of CMA is that it adopts a genotype-first model, whereby a reverse 
strategy is employed of identifying pathogenic genetic variants and analysing 
associated phenotypes26. Currently, clinical screening for pathogenic CNVs is not 
available for other psychiatric disorders, although there is ongoing debate about 
whether to introduce CMA testing for individuals with schizophrenia27,28. 
A major challenge in the clinical application of CMA has been the interpretation of 
CNV pathogenicity. Typically, variants are categorised into three main categories; 
pathogenic, variants of unknown significance (VOUS); and benign. Factors that 
influence variant categorisation include: the inheritance pattern (whether the CNV is 
inherited or arises de novo in the individual), the size and genetic content of the CNV 
(large CNVs affecting brain expressed genes are more likely to be pathogenic), the 
likely functional consequence of gene disruption, and whether the CNV is present in 
healthy control datasets14.  
One measure which attempts to quantify the functional consequence of CNV is the 
haploinsufficiency index. Haploinsufficiency is the inability of a gene to retain a 
normal function when only one copy of the gene is present, in other words a measure 
of the tolerance of particular genes to CNV deletions29. A comparable methodology 
predicting the functional consequence of CNV duplications is yet to be developed. 
Increasingly online datasets are being utilised to aid the categorisation of variants. The 
Database of Genomic Variants (DGV) catalogues variation seen in healthy control 
populations and therefore contains CNVs not thought to be implicated in disease30. 
Whereas the DatabasE of genomiC varIation and Phenotype in Humans using Ensembl 
Resources (DECIPHER) is an international online research portal which facilitates 
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anonymised data sharing for rare CNVs, primarily ascertained in children with 
developmental disorders of unknown cause31.  
A confounding factor in interpreting pathogenicity has been the variable penetrance 
and expressivity of many CNVs. Penetrance is the proportion of people with a 
particular genotype who exhibit the phenotype associated with that genotype. A 
disorder is said to have reduced (or incomplete) penetrance when the aberrant 
genotype is present in the absence of the associated phenotype. Expressivity refers to 
the severity of the associated phenotype32. Down syndrome (trisomy of chromosome 
21) is an example of a genetic disorder with full penetrance, in that all individuals with 
trisomy 21 present with features of Down syndrome, including some degree of 
intellectual impairment. However, there is considerable variation in the associated 
phenotypes, for example, some individuals with Down syndrome may have an 
intelligence quotient (IQ) in the borderline range (IQ 70-85), whilst others are more 
severely affected with an IQ below 3533. The expressivity of the phenotype can be 
influenced by the degree of genetic pleiotropy, whereby the altered function of a gene 
can cause diverse phenotypic outcomes. For example, exonic deletions of the Neurexin 
1 (NRXN1) gene have been identified in studies of ID, ASD, and schizophrenia34. A 
growing area of discovery is CNVs which are known as neurosusceptibility loci, 
whereby CNVs are present in the general population but are enriched in NDDs35. 
Whilst guidelines exist for the categorisation of CNVs there remains an element of 
subjectivity in clinical interpretation and designation of CNV pathogenicity continues 
to be a moveable field. For example, one study re-interpreted CNV results from 67 
individuals with idiopathic ID two years after the initial analysis and found a 
statistically significant increase in potentially pathogenic CNVs36. I will now further 
discuss the genetic underpinnings of three primary disorders – ID, schizophrenia, and 
ASD – as a prelude to considering combined neuropathological mechanisms.  
1.4 Intellectual Disabilities 
1.4.1 Clinical characteristics and aetiology 
ID is traditionally defined as significant impairments in intellectual and adaptive 
functioning with onset before the age of 18 years36. Before the age of five years 
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functioning is measured on a developmental, rather than intelligence coefficient, so it 
is more typical to talk about DD, although DD does not inevitability lead to ID in 
adulthood37. The International Classification of Diseases 10th Revision (ICD-10) 
criteria for ID refer to the historic term mental retardation, however this will be 
updated in the ICD-11 revision and I will use the term ID throughout the text38. The 
first axis of the ICD-10 diagnostic guidelines for ID describes the degree, or level of 
ID, segregated by scores on IQ scales39. ID is typically equated with a score of 2 or 
more standard deviations (less than 70) below the population mean on IQ tests2. Axes 
II-V of the ICD-10 criteria characterise the presence of associated physical, mental 
and psychosocial disorders39. ID is estimated to affect 2-3% of the general population 
and for approximately 50% of individuals with ID the cause is unknown36. 
The phenotype of ID can be highly variable in terms of severity and the domains of 
intellectual function that are affected. ID also often co-occurs with other medical and 
psychiatric phenotypes, such as congenital malformations, epilepsy and ASD. ID can, 
thus, be divided into two broad categories: syndromic ID, whereby there is a co-
occurrence of particular clinical phenotypes, and non-syndromic ID. Typically, 
homogenous syndromic phenotypes are caused by large de novo events40. The 
presence of syndromic features can guide genetic investigations, for example testing 
for trisomy 21 in Down’s syndrome or single-gene testing for PKU. Whereas, genome-
wide CMA enables systematic investigation of the genome in the absence of 
syndromic features37. ID is frequently associated with co-morbid psychiatric disorders 
and/or behavioural problems. For example, the point prevalence of psychosis has been 
estimated as 10 times higher in ID41. Recent estimates from United Kingdom (UK) 
primary care records show that approximately 21% of individuals with ID have a 
psychiatric disorder and 25% have some record of challenging behaviours. More than 
two thirds of these individuals had a record of prescription of any psychotropic drug, 
with more than a quarter receiving an antipsychotic42. 
The extreme heterogeneity of ID has confounded the understanding of pathological 
mechanisms. ID has typically been considered to lie at the extreme end of the normal 
IQ distribution in the general population. However, recent research, evaluating 
1,000,000 sibling pairs and 9,000 twin pairs, has revealed that the factors influencing 
severe ID differ from those influencing mild ID. Whereas, mild ID and IQ in the 
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normal range can be considered on the same spectrum, severe ID is thought to be a 
distinct disorder43. Therefore, the severity of ID, the presence of syndromic features 
and the range of associated medical and psychiatric phenotypes are important factors 
for consideration. 
1.4.2 Genetic risk factors  
Investigation of CNVs in DD/ID has predominantly occurred in paediatric cohorts. 
Analysis of 14 recurrent CNV regions in 15,749 cases referred for diagnostic testing 
(referrals for testing were due to a combination of DD/ID, MCA, dysmorphologies 
and ASD) and 10,118 controls identified 14 deletions and 7 duplications that were 
significantly overrepresented in cases44. Another large analysis of pathogenic CNVs 
in children with similar phenotypes was undertaken by Cooper et al. in 15,767 cases 
and 8,329 controls45. Over 8% of cases carried an imbalance at one of 45 previously 
documented genomic disorder loci. A CNV burden analysis was undertaken between 
the cases and controls, excluding common CNVs (>1% population frequency). At a 
threshold of >400kb ~25.7% (4,047) cases harbored an event of at least this size, as 
compared to 11.5% of the controls. The authors conclude from this that ~14.2% of 
disease in cases is caused by CNVs >400 kb, however this conclusion presumes that 
the percentage difference, or the excess between the cases and controls, is responsible 
for disease. Whereas, it may be that that some of these large CNVs do not contribute 
to the disease phenotype. Also, the authors did not consider genes disrupted by the 
CNVs in this analysis, and it may be that CNVs of differing size are more relevant to 
the phenotypic differences between cases and controls.  
A refined CNV morbidity map, comprising data from 29,085 children with ID and 
MCA (some of which were included in the previous analysis) went on to identify 70 
CNV regions significantly associated with DD46. It is through this mechanism of 
integrating data from large datasets that new CNV syndromes are being verified and 
characterised, for example the 17q21.31 microdeletion syndrome, a multisystem 
disorder characterised by ID, distinctive facial dysmorphisms, and hypotonia47.  
Investigation of rare SNVs has also served to elucidate the aetiology of ID, particularly 
for sporadic moderate–severe ID. An early exome sequencing study focusing on de 
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novo SNVs analysed ten patient–parent trios and identified an average of five 
candidate non-synonymous de novo mutations per affected individual48. Non-
synonymous exonic mutations alter the normal amino acid sequence, which can result 
in changes in protein configuration and gene function. WGS is now also being applied 
to the study of ID. One of the first WGS studies comprised patient–parent trios in a 
cohort of 50 patients with severe idiopathic ID. The cohort had previously undergone 
extensive genetic testing, including single-gene testing, CMA and exome sequencing 
analysis. The diagnostic yield for WGS was 42%, in comparison with an average 
diagnostic yield of 12% for CMA and 27% for WES49. Interestingly, the variants 
identified were all in the coding regions of the genome and had been missed by 
limitations of the previous technologies, which highlights that intragenic variant 
interpretation remains challenging. The technological advances afforded by NGS have 
enabled rapid progress in our understanding of the genetics of ID over the last decade 
and over 700 ID relevant genes have now been identified2. 
Another major contribution to the literature on the genetic aetiology of ID has arisen 
from the UK-based Deciphering Developmental Disorders (DDD) study. The study 
aims to apply CMA and sequencing methods to families affected by severe 
developmental disorders, approximately 87% of whom had DD/ID, and the majority 
of which had no previous family history of the disorder. A combined exome and array 
based approach has enabled the detection of novel genes associated with 
developmental disorders50. The most recent results from an exome sequencing analysis 
of 4,293 families, meta-analysed with 3,287 cases from similar populations, yielded 
94 genes which were enriched for damaging de novo mutations (DNMs). Overall 42% 
of the cohort carried pathogenic DNMs with an estimated prevalence of between 1 in 
213 to 1 in 448 births, with prevalence increasing with parental age51.  
1.5 Schizophrenia 
1.5.1 Clinical characteristics and aetiology 
The core features of schizophrenia are positive symptoms (delusions and/or 
hallucinations – also known as psychotic symptoms), negative symptoms (lack of 
motivation and social withdrawal) and cognitive impairments52. Initial models of 
schizophrenia pathology centered around the dopamine hypothesis. The fact that 
 31 
psychosis can be induced by drugs which activate the dopamine system, and that 
antipsychotic drugs target the dopamine D2/3 receptors, highlighted the system as a 
likely candidate for disease pathology53. However, the neurodevelopmental hypothesis 
gained traction following evidence from longitudinal studies showing that cognitive 
impairments preceeded the prodromal phase of psychosis and onset of clinical 
symptoms3,54. Furthermore, various prenatal and environmental risk factors were 
shown to increase risk for schizophrenia. More recently an integrated 
sociodevelopmental-cognitive model has been proposed, which incorporates the role 
of social risk factors for schizophrenia alongside the dopamine and 
neurodevelopmental hypotheses53. 
Support for a genetic component to schizophrenia susceptibility has been provided by 
numerous twin studies55–57. Latest estimates indicate that the concordance rate of 
schizophrenia is 33% in monozygotic twins and 7% in dizygotic twins, with an 
estimated heritability of 79%57. Heritability estimates of schizophrenia are second 
highest among major psychiatric disorders, with ASD being the highest58. However, 
the finding of 33% concordance in monozygotic twins also indicates a significant role 
for environmental factors in risk for developing schizophrenia57. 
1.5.2 Rare genetic risk factors 
The strongest known genetic risk factors for schizophrenia are pathogenic CNVs, 
which typically have a low population frequency but confer significant risk for 
development of the disorder (ORs 2-60)59. In an early CNV study, Kirov et al. found 
2 CNVs, a deletion at 2p16.3 and a duplication at 15q13.1, thought to be associated 
with schizophrenia60. The genes involved, NRXN1 and APBA2, code for proteins 
involved in synaptic development and functioning. Another rare CNV study was 
conducted by Walsh et al., comprising 150 patients with schizophrenia or 
schizoaffective disorder and 268 healthy controls. They identified that individuals with 
schizophrenia were more than three times likely to harbor CNVs that deleted or 
duplicate one or more genes (P = 0.0008). The significance of this finding increased 
when considering patients with an early age-of-onset (<18 years)61. 
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Later, CNV analyses in 6,882 schizophrenia cases and 6,316 controls, identified 11 of 
15 regions that were significantly associated with schizophrenia risk. The strongest 
support was for CNV duplications at the 16p11.2 locus and the AS/PWS critical 
region. Whereas, the strongest support for CNV deletions was at the 22q11.2, 1q21.1, 
2p16.3 (NRXN1) and 15q11.2 loci. Overall 2.5% of schizophrenia patients and 0.9% 
of controls had CNVs at one or more of these 15 loci62. The latest CNV analysis from 
the Psychiatric Genomics Consortium (PGC), an international collaboration of 
psychiatric disorder researchers, comprised 21,094 cases and 20,227 controls. The 
study found a global enrichment of CNV burden in cases (OR=1.11) compared to 
controls. Gene set analysis revealed that most of the signal was driven by deletion 
CNVs in synaptic or other neuronal component gene sets59.  
The role of rare SNVs in risk for schizophrenia has also been explored with the 
increasing application of exome sequencing technologies. A de novo paradigm 
analysis in 623 schizophrenia trios and controls identified a significant enrichment of 
non-synonymous mutations in genes encoding synaptic proteins in cases. This 
enrichment was particularly observed in glutamatergic postsynaptic proteins and 
interaction proteins modulating synaptic strength63. Concurrent analyses of the exome 
sequences of 2,536 schizophrenia cases and 2,543 controls confirmed an enrichment 
of rare mutations (defined as less than 1 in 10,000) in similar synaptic gene sets64. 
Furthermore, exome sequencing of 12,332 unrelated individuals, 4,877 of whom were 
affected with schizophrenia, has highlighted the role of inherited rare variants in risk 
for schizophrenia. The excess rare variant burden identified in this study, ~0.25 per 
person, compared with results from de novo paradigms, suggests that this observed 
excess must arise from inherited variants65. 
Singh et al. carried out a comprehensive meta-analysis of three different types of rare 
variant data – WES data, de novo variants from family based trio data, and CNV data 
– in cohorts of individuals with schizophrenia and healthy controls. Combined analysis 
identified that schizophrenia cases have a significantly higher burden of rare damaging 
variants in 3,488 genes, which are typically depleted for loss-of-function variants. 
These loss-of-function intolerant genes were identified by analysing exomes from 
healthy controls, without a known psychiatric diagnosis, in the Exome Aggregation 
Consortium (ExAC) exome database66. The risk variants are concentrated in risk genes 
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for NDDs in patients with schizophrenia who also have ID, and these patients have a 
higher burden of rare, damaging variants. However, the significant enrichment persists 
in other genes when excluding these co-morbid cases, meaning rare variants also 
confer risk for individuals with schizophrenia without ID67.  
1.5.3 Common genetic risk factors  
It is now understood that polygenic disorders are not caused by a single genetic event, 
but are the aggregate effect of multiple individual gene events and significant 
environmental contributions26. Schizophrenia has been shown to be polygenic in 
nature, involving thousands of common SNPs, with very small individual effect sizes 
that increase the risk for developing the disorder by 1.1- to 2-fold27. Study of case-
control frequencies of common SNPs is traditionally undertaken using a genome wide 
association study (GWAS) method. Since the first GWAS in 2009 there have been 
concurrent increases in the sample sizes of GWAS studies and the number of loci 
associated with schizophrenia68. The latest PGC GWAS, comprising 36,989 cases and 
113,075 controls, identified 108 loci achieving genome wide significance for 
association with schizophrenia69. Some of the GWAS hits tie in with existing 
hypotheses, such as involvement of the dopamine receptor D2 (DRD2) gene and 
abnormal dopamine signaling. Support for the involvement of acquired immunity is 
derived from the robust association of the major histocompatibility complex (MHC) 
region on chromosome 668. Further work to delineate the signal at this locus has 
identified a large number of common, functionally distinct, structural variants 
affecting the complement component 4 (C4) genes. Increased risk of developing 
schizophrenia was particularly associated with variants that increase expression of the 
C4A gene, which potentially drives pathological synapse loss in schizophrenia70. 
The polygenic risk score method has been developed to aggregate the effect of  
multiple SNPs of small effect into a combined composite score. Thus, a schizophrenia 
polygenic risk score, provides a quantitative measure of genetic predisposition to 
developing schizophrenia. A discovery dataset, a GWAS with available effect sizes, is 
used to weight a target dataset that has genome-wide genotype data71. Although the 
discriminative accuracy of risk scores is not yet sufficient for screening in clinical 
populations72, the score constitutes a powerful research tool. The schizophrenia 
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polygenic risk score was found to be the highest, out of ten complex traits, for 
predicting case-control status, with the best area under the receiver operating curve 
(AUC) 0.8273. 
The relationship between rare and common genetic variants and how these separable 
factors interact to contribute to risk of developing schizophrenia is an evolving area of 
research. Investigation of patients with schizophrenia who carry rare pathogenic CNVs 
has found that these patients still carry an excess of common risk alleles74. This 
provides support for a polygenic threshold model, whereby individuals with high 
penetrance schizophrenia variants possess many genetic risk factors, and it is the 
combination of these factors that is sufficient to surpass a threshold for clinical 
diagnosis.  
1.6 Autism spectrum disorders 
1.6.1 Clinical characteristics and aetiology 
ASDs are characterised by a triad of impairments, comprising social and 
communication difficulties, stereotyped and repetitive behaviours and/or a restricted 
range of interests75. An interesting feature of ASDs are that they operate across the 
spectrum of IQ, with ASD being observed in individuals with extremely high and low 
IQ. Increased risk for ASD is well documented in ID and approximately one-third of 
individuals with chromosomal and genetic abnormalities have significant autistic 
traits76. Psychological investigation of ASDs has revealed cognitive deficits in theory 
of mind, the ability to understand other people’s mental states, central coherence, and 
the ability to integrate information at different levels77. At a biological level 
abnormalities in dopamine signaling have been proposed as a model of ASD 
pathogenicity78. Finally, the observation of seizures and sensory hyperactivity being 
frequently associated, provides support for a cortical hyperexcitability model of 
ASD79. 
Evidence for a genetic component to the aetiology of ASD has been provided by 
family studies. The recurrence risk of ASD in siblings of ASD probands has been 
estimated at 10.9%, with approximately 20% of siblings displaying some phenotypic 
features of ASD80. Twin studies have revealed higher concordance rates, with 
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approximately 31% of dizygotic and 88% of monozygotic twins being concordant for 
ASD81. 
1.6.2 Rare genetic risk factors 
There is a large body of research on the role of rare pathogenic CNVs in ASDs. Weiss 
et al. found a recurrent deletion and reciprocal duplication at 16p11.2 that confers risk 
for DD and ASD, accounting for approximately 1% of cases82. Many studies have 
focused on distinguishing between simplex ASD, whereby only one family member is 
affected, and multiplex ASD, whereby multiple family members are affected. Early 
evidence that these two classes (simplex vs multiplex) are indeed genetically distinct 
was provided by the observation that de novo CNVs were more frequent in simplex 
families83. CNV analysis in 1124 simplex families identified significant associations 
with rare recurrent de novo CNVs at numerous loci and concluded that large de novo 
CNV confer substantial risks (OR=5.6) for ASD84. Regional analysis of pathogenic 
CNVs has showed an overall enrichment of brain-expressed genes in probands85, as 
compared to controls. Numerous functional gene networks have been implicated, 
including: the ubiquitination system, neuronal cell-adhesion molecules75, cellular 
proliferation, projection and motility86. One of the largest de novo CNV studies in 
ASD to date, comprising 2,591 families, found a strong association for ASD risk at six 
loci (1q21.1, 3q29, 7q11.23, 16p11.2, 15q11.2-13, and 22q11.2). It was also 
established that small CNVs tend to encompass high risk ASD genes, whereas large 
CNVs encompass multiple ASD genes of modest effect size87. 
There are also converging lines of evidence for the role of rare SNVs in ASD risk. 
Exome sequencing of 175 autism trios found that whilst the overall rate of de novo 
SNV mutation was not significantly elevated from that expected by chance, the set of 
genes affected were highly biologically related to each other and/or had been 
previously identified as ASD/ID candidate genes88. The findings indicate the 
polygenic nature of ASD, whereby mutations in any of a large number of genes 
increases risk for ASD by 5- to 20-fold. Two concurrent exome sequencing 
publications further delineated the relationship between SNV and risk for ASD. 
Firstly, an integrated model, accounting for de novo and inherited variants, implicated 
a large number of genes in risk for ASD, particularly those involved in synaptic 
 36 
formation, transcriptional regulation and chromatin-remodelling pathways89. 
Inclusion of inherited variants was thought to be critical, given the large number of 
ASD risk genes and the fact that many occur in loci with incomplete penetrance. 
Investigation of de novo mutation subtypes in 2,500 simplex families also revealed 
that ~43% of likely gene disrupting events (nonsense, frameshift and splice site 
mutations) in probands contribute towards risk of developing ASD90. 
1.6.3 Common genetic risk factors 
Common genetic risk factors have also been shown to play an important role in the 
risk of developing ASD. Common genotyped SNPs are estimated to account for at 
least 20% of ASD liability91, highlighting that a proportion of the genetic risk for ASD 
resides within common variants92. The ASD working group of the PGC, failed to find 
any genome-wide significant SNPs in a recently published discovery sample (7,387 
ASD cases and 8,567 controls)93. Given the likelihood that these results reflect a lack 
of statistical power to detect an association, with the need for larger sample sizes, the 
authors also undertook a meta-analysis utilising two independent samples. This meta-
analysis revealed a genome-wide significant association at the 10q24.32 locus and a 
significant concordance between the direction of effect of the top markers in the 
discovery sample and the two independent samples. 
Recent work has further investigated the role of common polygenic variation in ASD 
and the relationship this has with rare variants. Firstly, data from 6,454 simplex 
families has revealed that polygenic risk for ASD is over-transmitted to probands, but 
not to unaffected siblings. This increase in parental polygenic risk transmission was 
still observed in the probands who had a contributing de novo variant94. Genome-wide 
common and rare variant genetic links between ASDs and typical variation in social 
and communication difficulties have also been identified in a large general population 
cohort91. This supports a continuum model, whereby multiple types of genetic risk for 
ASDs influence a continuum of traits, the severe tail of which could results in a 
diagnosis of ASD or another NDD. 
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1.7 Genetic overlap across neurodevelopmental disorders 
Wide-scale genetic screening has revealed that many variants have broad – and often 
co-morbid – NDD phenotypes, which cross traditional diagnostic boundaries. For 
example, we have already seen that 16p11.2 duplications and mutations affecting the 
NRXN1 gene are involved in the aetiology of DD/ID, schizophrenia and ASD. These 
cross-disorder findings are supported by the results of epidemiological studies, which 
have identified that increased general, rather than specific, risk for neuropsychiatric 
disorders is conferred by having a mother with schizophrenia, bipolar affective 
disorder (BPAD) or unipolar major depression95. Doherty and Owen have proposed 
that psychiatric disorders lie on a neurodevelopmental continuum, with ID being the 
most severe brain insult, followed by ASD, schizophrenia and mood disorders. The 
NDD gradient is indexed by the severity of the mutational load and cognitive 
impairment, which has implications for developing new methods of stratifying patients 
for research96. Cross-disorder research is a growing area of activity in psychiatric 
genetics and this section will provide an overview of key findings in the field. 
1.7.1 Rare variant studies 
The degree of phenotypic variability associated with pathogenic CNVs encompasses 
both early-onset neurodevelopmental disorders and adult-onset psychiatric disorders. 
Several CNVs, including those at the 1q21.1, 16p11.2, 17q12, and 22q11.2 loci, have 
been identified in individuals ascertained for different neurodevelopmental 
phenotypes21. All of the 11 robustly associated schizophrenia risk CNVs have been 
implicated in risk for other NDDs97. Likewise, all of the six main CNV risk loci for 
ASD have been shown to confer risk for ID87. I have selected two recurrent CNV loci, 
which are commonly associated with risk for multiple NDDs, for detailed discussion 
–  22q11.2 and 16p11.2 deletions and duplications.  
Clinical presentation of the 22q11.2 deletion syndrome (also known as 
velocardiofacial syndrome or DiGeorge syndrome) is highly variable, with more than 
180 clinical features described98. The 22q11.2 deletion syndrome is the strongest 
known risk factor for psychotic disorders, with prevalence rates as high as 30%99. It 
has been estimated that up to 60% of children with 22q11.2 deletions meet the criteria 
for at least one psychiatric diagnosis, notably ADHD and anxiety disorders100. The 
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22q11.2 duplication syndrome shares some features with the reciprocal deletion, 
however the phenotype is generally mild in comparison with the deletion and familial 
transmission is frequently observed101. Psychiatric and behavioural problems include 
ASD, which occurs in approximately 14-25% of carriers. Interestingly, psychosis 
phenotypes, which are common in the deletion carriers, are infrequently observed and 
the 22q11.2 duplication has been proposed as a protective variant for schizophrenia102. 
The 16p11.2 deletion syndrome is commonly associated with ID, macrocephaly, 
seizures and obesity. Zufferey et al. collected phenotypic data on 285 16p11.2 deletion 
carriers and found that their full scale IQ is typically two standard deviations lower 
than non-carrier relatives. Furthermore, more than 80% of 16p11.2 deletion carriers 
exhibit psychiatric disorders, of which 15% of children present with ASD103. Moreno-
De-Luca et al. investigated the clinical variability of de novo 16p11.2 deletions in 56 
individuals, undertaking a novel family-based study design. They identified significant 
parent-proband correlations on measures of cognition, social behaviour and 
neuromotor performance, such that the impairments in probands were most profound 
in domains where their parents are already showing lower quantitative performance104. 
This provides support for a model whereby family background has an effect on 
phenotypic variability. The clinical features of the 16p11.2 duplication syndrome 
exhibit a mirror phenotype to the deletion, for example, the duplication has been 
associated with microcephaly and a reduced body mass index. IQ testing in the 
duplication carriers revealed a higher variance than in deletion carriers105. A meta-
analysis of 16p11.2 duplication studies found that the disorder confers a 14-fold 
increased risk of psychosis and a 16-fold increased risk of schizophrenia106. 
Kirov et al. assessed the penetrance of CNVs at previously established risk loci for 
NDDs. The penetrance for schizophrenia was compared with a group of early-onset 
developmental disorders – DD, ASD, and congenital malformations. Almost all CNVs 
had higher rates in the early-onset developmental disorders group. The average 
penetrance, for developing any of the associated disorders, was 41%. It was concluded 
that most of the CNVs are highly pathogenic and are therefore more likely to cause 
earlier-onset disorders rather than schizophrenia107. 
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There is, however, evidence to suggest a degree of specificity in the NDD risk 
conferred by separate CNV loci. Moreno de Luca et al. investigated the prevalence of 
deletions and duplications at four commonly implicated NDD risk loci (7q11.23, 
15q11.2-13.1, 16p11.2 and 22q11.2) in ID, ASD, schizophrenia and controls. They 
found that some CNVs show increased risk for all disorders (e.g. 16p11.2 duplications) 
whereas others showed a degree of specificity (e.g. 22q11.2 duplications are rarely 
observed in schizophrenia and 7q11.23 deletions show risk for ID but are rarely 
observed in ASD)108. This pattern of asymmetric risk provides support for both shared 
and distinct genetic aetiology, likely due to differing dosage effects and 
neuropathological mechanisms at different CNV loci.  
Evidence has also emerged from exome sequencing studies for shared genetic 
aetiology between NDDs. Analysis of 57 schizophrenia trios identified de novo 
mutations in numerous genes that have been previously implicated in risk for ASD and 
ID, with an enrichment in genes involved in chromatin modification109. Singh et al. 
undertook a large WES in schizophrenia patients (4,264 cases and 1,077 patient-parent 
trios) and controls (n=9,343), identifying a significant enrichment of rare loss of 
function variants in the SET Domain Containing 1A (SETD1A) gene in schizophrenia 
patients. The SETD1A gene encodes a methyltransferase involved in the catalysis of 
lysine residues in histone H3. Interestingly, seven out of the ten schizophrenia patients 
identified with this variant also had learning difficulties and further variant carriers 
were identified by investigating severe developmental disorder cohorts110. Large 
exome sequencing studies in ASD have revealed similar findings, with 107 genes 
strongly enriched for ASD overlapping with 21 candidate genes for intellectual 
disability, 3 for epilepsy and 17 for schizophrenia111. 
1.7.2 Common variant studies 
Results of GWAS studies have revealed that SNPs at the same genetic loci harbour 
variants which are associated with multiple seemingly clinically distinct traits, for 
example the calcium channel, voltage-dependent, L-type, alpha 1C subunit 
(CACNA1C) gene has been implicated in risk for both schizophrenia and BPAD112. A 
large schizophrenia GWAS study found an association between schizophrenia and 
BPAD samples, whereas no association was found with six non-psychiatric disorder 
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samples113. Results from the latest ASD GWAS also identified a strong genetic 
correlation between ASD and schizophrenia, and ASD GWAS results overlap with 
regions previously implicated in risk for schizophrenia93. 
Formation of the cross disorder group of the PGC has facilitated further analysis of 
GWAS data from five psychiatric disorders (schizophrenia, BPAD, ASD, major 
depressive disorder (MDD), and ADHD). Genetic correlation using common SNPs 
was high between schizophrenia and BPAD. Three disorders – schizophrenia, BPAD, 
ADHD – also showed moderate associations with MDD114. Also joint analysis, 
including data from all five psychiatric disorders, revealed four genome-wide 
significant loci, including the CACNA1C gene – which also showed a significant 
association when only considering the schizophrenia group115. 
1.7.3 Healthy control studies  
The role of pathogenic CNVs in NDD aetiology has been further complicated by the 
finding that virtually every CNV that is associated with a psychiatric disorder is 
present at a low frequency in populations that are ascertained as healthy controls21. 
Stefansson et al. found that population controls who carry these pathogenic CNVs 
have a global assessment of functioning score 0.7 standard deviations (SDs) lower than 
population controls who don’t carry the pathogenic CNV. Cognitive testing revealed 
that these controls perform at an intermediary level between schizophrenia patients 
and population controls, both of whom did not carry a pathogenic CNV. Additionally, 
pathogenic CNVs do not all affect the same cognitive domains, so factors influencing 
cognitive deficits vary from one CNV region to another. Structural MRI was also 
performed on carriers of 15q11.2 (BP1-BP2) CNVs and reciprocal changes in the same 
anatomical regions were identified for deletion and duplication carriers, showing – for 
the first time – a dosage dependent effect of the CNV on brain structure116.  
The role of CNVs in a general population cohort was also examined by Männik et al. 
using a random sample of individuals (N=7,877) from the biobank of Estonia. 
Phenotypic analysis of the 56 carriers of syndrome-associated CNVs revealed that 
these individuals had cognitive and psychiatric co-morbidities and low educational 
attainment117. Further insight into the cognitive impact of pathogenic CNVs in control 
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populations has been provided by other analyses in large population datasets. The UK 
Biobank is a large general population dataset of ~500,000 adults that includes 
genotyping, imaging and cognitive data118. Kendall et al. assessed the cognitive 
performance of carriers of 53 NDD CNVs (total N=1,571). The majority of CNV 
carriers had impaired performance on cognitive tests, as well as lower educational and 
occupational attainment. Similar to the findings from Stefansson et al., the cognitive 
deficits were modest as compared to the deficits observed in schizophrenia patients119. 
1.7.4 Cross-disorder analyses aid gene discovery 
The complexity with case-control association analyses is that huge sample sizes are 
required to detect very rare variants. One approach which has been adopted in cross-
disorder research is to firstly identify clinically significant CNVs relevant to broader 
NDDs then test for these in single disorder cohorts. This approach has been successful 
in identifying new rare variants for ASD120 and for schizophrenia97. Gonzalez-Mantilla 
et al. undertook joint analysis of genetic and phenotypic data encompassing six NDDs 
(DD/ID, ASD, ADHD, schizophrenia, BPAD, and/or epilepsy). They focused on 
pathogenic loss of function variants affecting at least two unrelated individuals 
(N=1,960). The cross-disorder approach enabled the addition of 33 genes to the 
knowledge base and increased the evidence level for 18 genes. The study found 
significant phenotypic heterogeneity, with the majority of genes (32.8) being 
associated with two disorders and two genes, NRXN1 and PARK2, being associated 
with all six disorders. Although the picture was complex, with certain genes showing 
enrichment for particular disorders121. 
1.8 Thesis rationale and overview 
In summary, pathogenic CNVs are rare at the individual locus level, but are 
collectively common risk factors for developing a range of NDDs. Almost all 
pathogenic CNVs identified thus far are most frequent in patient groups with severe 
early-onset developmental disorders107. They also present the greatest known genetic 
risk factors for psychiatric disorders to date1. Some of these CNVs show increased risk 
for various psychiatric disorders, whereas others show a degree of specificity (such as 
the 22q11.2 deletion CNV increasing risk for psychosis)108.  
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Historically large-scale CNV research has predominantly taken place in paediatric 
cohorts referred for clinical genetic testing45,46. The limitations of this approach are 
that the available phenotype data is limited to the reason for the referral to genetic 
services. The cohort is both weakly phenotyped, with important phenotypic 
information missing, and encompasses a broad range of severe developmental 
phenotypes. Furthermore, the developmental nature of the cohort means that later-
onset psychiatric phenotypes  cannot be captured at the point of analysis. Other CNV 
research has taken place in cohorts with a single psychiatric diagnosis59. 
The discovery of CMA technologies has changed the face of clinical genetic testing 
for children presenting with various developmental disorders. CMA is now being 
applied as one of the first-line routine genetic investigations in many healthcare 
systems25. This genotype-first approach is particularly advantageous when the patient 
presents with a non-specific phenotype and there are no suspected syndromic forms of 
ID for targeted genetic testing. However, genetic investigations have not been a routine 
part of the assessment of adults with ID presenting to psychiatric services122. Clinical 
genetic testing is not routine for any other psychiatric disorders – although 
implementing CNV testing in schizophrenia is an item of recent debate123.  
Following the recognition that both rare and common variants implicated in risk for 
NDDs transcend clinical diagnostic boundaries, there has been a rise in cross disorder 
research – whereby different single disorder cohorts are tested for the same genetic 
variants. However, there remains a deficit of research on co-morbid phenotypes – 
whereby individuals present with more than one psychiatric diagnosis. Prior to the 
work described in this thesis no investigations of pathogenic CNVs in adults with co-
morbid NDDs have taken place. Researching this population has the advantage that 
the typical age of onset for psychiatric disorders has passed. This has the potential to 
reveal novel CNVs implicated in co-morbid CNV risk and/or identify previously 
established pathogenic CNVs that have a higher frequency in co-morbid phenotypes.  
The work presented in this thesis aims to research this novel population; with Chapter 
2Chapter 1 taking a clinical perspective, with a survey of psychiatrists involved in their 
care; Chapter 3 and Chapter 4 undertaking CMA to investigate the type and 
architecture of pathogenic CNVs, as compared to other populations in the literature; 
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Chapter 5 undertaking follow-up in-depth phenotyping of individuals with 2q13 CNVs 
to inform genotype-phenotype correlations of individuals with these rare CNVs; and, 
finally, Chapter 6 investigating the relative CNV burden as compared to other cohorts.
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Chapter 2 Survey of intellectual disability genetic testing practices 
in child and adult psychiatry 
Parts of this chapter have been adapted from the following published journal article:  
Wolfe, K., Stueber, K., McQuillin, A., Jichi, F., Patch, C., Flinter, F., Strydom, A. & 
Bass, N. (2017) Genetic testing in intellectual disability psychiatry: Opinions and 
practices of UK child and intellectual disability psychiatrists. Journal of Applied 
Research in Intellectual Disabilities. 1–12. PMID: 28833975. 
I undertook all statistical analyses, drafted and revised the manuscript. Study design, 
survey development and data collection were conducted by: KS, AM, CP, FF, AS, and 
NB. FJ advised on the statistical analyses.  
2.1 Introduction 
A definition of ID and prevalence estimates have previously been described in section 
1.4.1. The rate of psychiatric disorders among individuals with ID is approximately 4 
to 5 times higher than in the general population124. Despite this, psychiatric disorders 
in ID are often underdiagnosed. One reason for this is diagnostic overshadowing, 
whereby symptoms which would normally be attributed to a psychiatric disorder are 
instead viewed as being a component of the existing ID diagnosis. The lack of 
appropriate diagnostic criteria and paucity of suitable assessment measures also serve 
to compound psychiatric diagnoses in ID. Individuals with ID have been shown to 
experience poorer health, compared to the general population, and are subject to health 
inequalities125. Increasingly, ID services are adopting a bio-psychosocial approach, 
considering biological, psychological and social causes, in the assessment and 
treatment of mental health problems in individuals with ID126. Personalised care and 
health action plans, including annual health checks, are also being put into place to 
help prevent health inequalities127. 
An overview of the developments in genetic testing for ID has been covered in 1.2-
1.4.2. Investigation of the cause of DD/ID predominately occurs at onset in childhood 
and there is no formalised system of diagnostic review. In childhood patients may 
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initially present to a Paediatrician or a Child and Adolescent Psychiatrist. Whereas, in 
adulthood patients present to ID Psychiatrists, a subspecialty of psychiatry with 
specialist consultant accreditation, or other treating clinicians, such as neurologists – 
for instance if the cause of epilepsy is being investigated in an individual with ID. ID 
psychiatrists sit within learning disability services, which usually comprise an 
interdisciplinary community-based health and social care team. Services generally 
have a high threshold for eligibility (IQ<70 as well as significant impairment of 
functioning, which has been present from childhood). Referrals to services are 
typically made by general practitioners (GPs), who have a key role in managing co-
morbid physical illnesses, although some services also accept referrals from patients, 
carers, or social services126. There are 23 National Health Service (NHS) Regional 
Genetics Centres (RGCs) across the UK, to which treating clinicians can make 
referrals for genetic testing services for patients and their families.  
Inequalities in access to genetic testing have been reported across different medical 
specialisms and there is a shift towards mainstreaming of genetic practices, with 
clinicians being encouraged to order genetic tests directly to improve uptake and 
access128. It has previously been discussed that recommendations have been made for 
CMA to be one of the primary genetic tests for DD/ID, MCA and ASD25. However, 
evidence suggests that the uptake of testing for genomic disorders in routine clinical 
psychiatric practice has been slow28. However, little of known about the current 
practices of psychiatrists working with patients with intellectual disabilities. 
2.2 Aims 
This chapter aims to determine current knowledge and genetic testing practices of 
psychiatrists working with individuals with ID. Furthermore, potential differences 
between child and adult sub-specialties will be investigated. 
2.3 Methods 
Psychiatrists working in UK child and adolescent mental health services (CAMHS) 
and adult ID psychiatry services were surveyed as to their attitudes towards and current 
use of genetic investigations using an online survey. 
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2.3.1 Survey development and administration 
The survey questions were developed through consultation with ID psychiatrists, a 
clinical geneticist, a genetic counsellor, a genetic researcher and a statistician. The 
primary themes under investigation were: attitudes towards genetic testing, ordering 
of genetic tests, confidence and training in the genetic testing process, concerns about 
genetic testing, feedback of genetic test results, and experiences of referring to genetic 
services. Following a pilot, a number of the questions were amended and the 
opportunity for open text responses was enabled. The 28-item self-administered 
survey was composed of yes/no responses, multiple choice Likert-scale questions, 
numeric outcomes and free text responses (see the associated publication for a copy of 
the survey questions). The survey was programmed not to force answers to questions 
and enable completion of the survey with missing responses. The survey was 
administered via the online service tool Survey Monkey (SurveyMonkey Inc. Palo 
Alto, California, USA).   
2.3.2 Survey participants  
The survey was distributed to members of the Faculty of Child and Adolescent 
Psychiatry and members of the Faculty of Psychiatry of Intellectual Disability via the 
Royal College of Psychiatrists mailing list. Psychiatrists were invited by email to 
participate in the survey. A participation reminder was sent after 1 week. Respondents 
were removed from the analysis if they were junior trainees or listed professions other 
than CAMHS psychiatry and adult ID psychiatry, if they lived outside the UK and if 
they had not seen any patients with DD/ID in the previous 12 months. 
2.3.3 Statistical analysis 
Quantitative statistical analyses were undertaken using IBM SPSS Statistics for 
Windows, Version 22.0 (IBM Corp, Armonk, NY, USA). The analysis compared 
CAMHS psychiatrists (referred to henceforth as child psychiatrists) and adult ID 
psychiatrists (referred to henceforth as ID psychiatrists). Continuous outcome 
variables were analysed using a t-test where the data was normally distributed and 
Mann-Whitney U test for non-normally distributed data. The chi-squared test was 
utilised to test categorical outcome variables. Binary logistic regression was 
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undertaken to test univariable factors related to ordering a genetic test. For Likert scale 
responses the data was collapsed from 5 to 3 scale responses by merging ‘strongly 
agree’ with ‘agree’ and ‘strongly disagree’ with ‘disagree’, or ‘very frequently’ with 
‘frequently’ and ‘very rarely’ with ‘rarely’. The 5 category scale was retained for all 
statistical analyses and categories were only collapsed to simplify presentation of the 
descriptive findings. Participants were asked whether they felt confident in 8 aspects 
of the genetic testing process. To compare these confidence ratings a composite 
confidence score was generated by assigning the 5 point Likert scale responses a 
confidence value ranging from 1 for strongly disagree to 5 for strongly agree.  These 
scores were then summed across the eight confidence measures to obtain an overall 
composite confidence score. Where analyses have been undertaken on a subset of the 
dataset due to missing values the number of respondents in the analysis has been 
indicated. A Bonferroni correction was applied and significance has been set at 0.006 
to account for multiple testing. 
2.3.4 Thematic analysis 
Open text responses were thematically coded using Nvivo qualitative data analysis 
software (QSR International Pty Ltd. Version 10, 2012).  Three open text questions 
were included in the survey, focusing on the benefits and concerns of genetic testing 
in clinical practice. A word cloud was generated using all open text responses and 
word frequency analysis was undertaken using Nvivo. Word stemming was 
undertaken to combine variations of words from the same root (e.g. genetic and 
genetics). All words mentioned greater than 5 times, excluding common words, were 
inputed into Wordle129 for the creation of the word cloud. 
2.4 Results 
Responses were received from 215 clinicians, comprising 121 child psychiatrists 
(56%) and 94 ID psychiatrists (44%); 56% were females (n=121) compared with males 
(n=94, 44%). The majority of respondents worked in England (n=170, 80%), followed 
by Scotland (n=29, 14%), Wales (n=9, 4%) and Northern Ireland (n=5, 2%). The 
majority of respondents worked in community teams (n=115, 57%) followed by 
specialist assessment inpatient units (n=23, 11%) and specialist referral centres 
(outpatient) (n=19, 9%). A further 46 respondents (23%) reported that they worked in 
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more than one of these settings. The median number of years working in the speciality 
was 10 (child psychiatrists 10 years, ID psychiatrists 11 years).  
2.4.1 Sociodemographic factors  
Available demographic factors, sex and place of work, were compared between the 
child and ID psychiatrist groups, see Table 2-1 Sociodemographic factors of child and 
ID psychiatristsTable 2-1. Chi-squared tests were undertaken and a significant 
difference between the groups was identified for sex (χ²=17.06, p<0.000). 







Female  83 38 
Male 38 56 
Place of work 
England 96 74 
Scotland 15 14 
Wales  5 4 
Northern Ireland 4 1 
2.4.2 Attitudes towards genetic testing  
Respondents were asked to estimate the percentage of people with ID for whom 
genetic factors make a significant contribution towards the cause of their ID. Estimates 
from child psychiatrists (Mean=42%, SD=24.7, Range=2-100%) were comparable to 
those of ID psychiatrists (Mean=39.6%, SD=23.1, Range=3-90%) (n=206, Mean 
difference =2.4, 95% CI (-4.25, 8.1) p=0.48). The respondents were also asked to 
estimate the percentage of patients on their caseloads with an established genetic 
diagnosis. This serves as a proxy of the actual number of patients on the caseload, 
given that psychiatrists may misestimate this figure. Child and ID psychiatrists both 
estimated a low percentage of patients on their caseload as having an established 
genetic diagnosis. ID psychiatrists estimated a higher percentage of their own patients 
to have an established genetic diagnosis (Median=10%, Range=0-70%) compared to 
child psychiatrists (Median=5%, Range=0-100%), (n=205, U=3661.5, Mean rank = 
120 vs Mean rank = 90, p=<0.001). 
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2.4.3 Ordering of genetic tests 
More ID psychiatrists (77%), compared with child psychiatrists (56%), had ordered a 
genetic test in the last 10 years (n=162, χ²=8.08, p=0.004). Respondent’s estimates of 
the percentage of ID caused by genetic factors did not influence the likelihood of them 
ordering a genetic test (n=157, OR 1.01, 95% CI (0.99-1.03), p=0.19). The percentage 
of patients on respondents’ caseloads with an established genetic diagnosis also did 
not affect the likelihood of ordering a genetic test (n= 156, OR 1.02, 95% CI (0.99-
1.05), p=0.33). 
2.4.4 Confidence in the genetic testing process 
Respondents were asked how confident they felt in eight aspects of the genetic testing 
process, as presented in Table 2-2. Child psychiatrists had a lower average total 
confidence score (Mean=22.1, SD=6.8) in comparison with ID psychiatrists 
(Mean=27.4, SD=5.5). (n=186, Mean difference=5.3, 95% CI (3.42, 7.1), p=<0.001). 
In comparison with child psychiatrists, ID psychiatrists agreed that they were 
confident in: knowledge of genetic tests (69% vs 29%); assessing for dysmorphic 
features (63% vs 47%); ordering (47% vs 24%) and interpreting genetic tests (35% vs 
12%); genetic counselling (22% vs 12%) and feeding back test results to patients (64% 
vs 32%) and their families (68% vs 34%). 
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Table 2-2: Self rated confidence scores of child and ID psychiatrists (n=186) in eight areas of the 
genetic testing process 





Knowledge of genetic tests 
Child 52 (50%) 23 (22%) 30 (29%) 
ID 11 (14%) 14 (17%) 56 (69%) 
Assessing for dysmorphic 
features 
Child 34 (32%) 22 (21%) 49 (47%) 
ID 14 (17%) 16 (20%) 51 (63%) 
Assessment of capacity to 
consent 
Child 10 (10%) 12 (11%) 83 (79%) 
ID 2 (3%) 6 (7%) 73 (90%) 
Ordering genetic tests 
Child 55 (52%) 25 (24%) 25 (24%) 
ID 16 (20%) 27 (33%) 38 (47%) 
Interpreting genetic  test results 
Child 70 (67%) 22 (21%) 13 (12%) 
ID 31 (38%) 22 (27%) 28 (35%) 
Feedback to patients 
Child 43 (41%) 28 (27%) 34 (32%) 
ID 13 (16%) 16 (20%) 52 (64%) 
Feedback to family/carers 
Child 41 (39%) 28 (27%) 36 (34%) 
ID 14 (17%) 12 (15%) 55 (68%) 
Genetic counselling 
Child 71 (68%) 21 (20%) 13 (12%) 
ID 36 (44%) 27 (33%) 18 (22%) 
 
2.4.5 Concerns with the genetic testing process 
Respondents were asked what their main concerns were in relation to the genetic 
testing process, see Table 2-3. Both child and ID psychiatrists agreed that lack of 
available treatment was one of the main concerns (58% vs 51% respectively). Another 
main concern was lack of resources, 54% of child and ID psychiatrists agreed that this 
was a concern. Implications for insurance were a greater concern for child psychiatrists 
in comparison to ID psychiatrists (50% vs 38%), whereas issues around counselling 
were a greater concern for ID psychiatrists (53% vs 43%). 
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Table 2-3: Concerns child and ID psychiatrists (n=195) report in ten areas of the genetic testing 
process 





Stigma (-ve) of patients/families 
having a genetic diagnosis 
Child 42 (39%) 39 (36%) 27 (25%) 
ID 39 (45%) 21 (24%) 27 (31%) 
Lack of available treatment 
Child 26 (24%) 19 (18%) 62 (58%) 
ID 27 (31%) 16 (18%) 44 (51%) 
Lack of resources 
Child 23 (22%) 26 (24%) 58 (54%) 
ID 21 (24%) 19 (22%) 46 (54%) 
Implications for insurance 
Child 23 (22%) 30 (28%) 53 (50%) 
ID 30 (35%) 24 (28%) 33 (38%) 
Misuse of results 
Child 22 (21%) 39 (37%) 45 (43%) 
ID 37 (43%) 17 (20%) 32 (37%) 
Difficulty obtaining a family 
history 
Child 40 (37%) 39 (36%) 28 (26%) 
ID 27 (31%) 19 (22%) 41 (47%) 
Obtaining a sample 
Child 38 (36%) 37 (71%) 31 (29%) 
ID 35 (40%) 23 (26%) 29 (33%) 
Issues around counselling 
Child 37 (35%) 24 (22%) 46 (43%) 
ID 22 (25%) 19 (22%) 46 (53%) 
Issues around capacity to 
consent 
Child 31 (29%) 32 (30%) 44 (41%) 
ID 36 (41%) 13 (15%) 38 (44%) 
 
2.4.6 Feedback of results and clinical management 
As seen in Figure 2-1 both child and ID psychiatrists agreed that a genetic diagnosis 
is more beneficial for family members than patients. In comparison with child 
psychiatrists, ID psychiatrists were more inclined to agree that a diagnosis is beneficial 
for family members (85% vs 78%) (Figure 2-1 A) and patients (58% vs 50%) (Figure 
2-1 B). 
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Figure 2-1: Percentage of child (n=72) and ID psychiatrists (n=81) who feel that a genetic 
diagnosis is helpful for family members (A) and patients with ID (B) 
 
Respondents were also asked how they fed back results to their patients with ID, more 
than one response could be selected. Of the 146 respondents 8 (5%) had utilised 
videos, 20 (14%) had received input from speech and language therapists, 48 (33%) 
had used easy read materials, and 98 (67%) had used none of these aids. Responses 
were comparable for child and ID psychiatrists. 
Figure 2-2 shows respondents’ views and experiences of clinical management changes 
following genetic diagnoses. Respondents agreed that a genetic diagnosis would help 
with patient clinical management (75%  ID vs 62% child) (Figure 2-2 A), however 
few agreed that they had seen frequent management changes in their patients (11%  ID 
vs 12% child) (Figure 2-2 B). 
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Figure 2-2: Percentage of child and ID psychiatrists who feel that that a genetic diagnosis is 
helpful for patient management (A) (child n=121, ID n=94) and who report that genetic 
information has helped their patient management (B) (child n=73, ID n=82) 
 
2.4.7 Referral to genetics services 
Respondents were asked if they had ever ordered a genetic test or made a referral to a 
clinical genetics service. Those who had made a referral were also asked to estimate 
the number of referrals in last year. A significantly higher percentage of ID 
psychiatrists, compared with child psychiatrists had ordered a test or made a referral 
(90% vs 68%, n=214, χ²=15.92, p =<0.001). ID psychiatrists also referred more 
patients per year to the genetics clinic compared with child psychiatrists (n=153, 
Range = ID 0-25, child 0-10, U= 2161.5, Mean rank = 87 vs Mean rank = 67, p=0.004).  
Respondents were asked what the main reasons for referral to clinical genetics services 
were. Of the 155 respondents the most frequent reason for referral was presence of 
dysmorphic features (46% child, 57% ID) followed by intellectual disabilities (31% 
child, 38% ID). The least likely reason for referral was pharmacological treatment (2% 
both child and ID). 
2.4.8 Service structure and training 
Both ID and child psychiatrists agreed that closer links with regional genetics services 
would be helpful (83% vs 72%, n=197). Respondents were also in agreement that they 
would prefer to refer to a regional genetics service rather than order a genetic test 
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themselves (child 85%, 77% ID n=195). Finally there was a consensus that further 
training in genetics would be beneficial (child 71%, 66% ID, n=195). 
2.4.9 Thematic analysis 
Four main themes were identified from the 76 respondents who completed the open 
response questions comprising: family concerns, clinical management, and access to 
services and training.  
Of the 23 respondents who reported family concerns, the most frequent benefits 
identified were relief from guilt and increased understanding of the patient’s condition, 
followed by ability to access a support group and family planning. Respondents who 
discussed clinical management tended to mention the positive aspects, such as tailored 
medical and psychiatric interventions and clarification of syndrome specific 
behaviours. Only three respondents stated that they did not think a genetic diagnosis 
was helpful for clinical management. One respondent commented:  
“it is something of a paradox that the advances in the understanding of 
genetics and its potential impact upon our patient group has not 
translated into a significant increase in the use of genetic testing to help 
with diagnosis and care planning.  I can only surmise that the social 
model of Disability as outlined in Valuing People has steered the 
diagnostic process away from genetic labelling”. 
Access to genetics services was mentioned by 22 respondents, who described 
problems with referring to genetics services and the variable levels of knowledge of 
professionals involved in the pathway. There was concern that psychiatrists, who have 
not specialised in genetics, do not have the skills to order genetic tests directly. Good 
working relationships with genetics services were said to be a valuable resource. Five 
child psychiatrists stated that they would defer to their paediatric colleagues to make 
decisions about genetic testing.  
Several respondents felt that current training in genetics was insufficient and that 
training is not keeping abreast of technological advances. It was suggested that quick 
reference guides and screening tools would be valuable resources to support the 
decision making process. See Figure 2-3 for a word cloud of the most frequently used 
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words in the open text responses (results from both professional groups as responses 
were comparable for child and ID psychiatrists) and a summary of positive and 
negative opinions for each of the main themes. 
Figure 2-3: Word cloud of words mentioned 5 or more times from open text responses with 
larger words mentioned more frequently. Positive and negative responses from the main themes 
are displayed in the text boxes 
 
2.5 Discussion 
The survey results reveal that the majority of child and ID psychiatrists working with 
patients with ID are already ordering genetic tests or making referrals to genetics 
services. However, there are several disparities in clinical genetic practices. In 
comparison with child psychiatrists, ID psychiatrists reported: a higher number of 
patients with genetic diagnoses, greater confidence in the genetic testing process, 
higher numbers of tests ordered and more patients referred per year to genetics 
services.  
Respondents were asked to estimate the percentage of ID caused by genetic factors. 
The responses varied greatly, with some respondents estimating as low as 2% and 
others as high as 100%. Although both child and ID psychiatrists had similar mean 
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estimates (39.6% and 42%) of the percentage ID caused by genetic factors, these 
estimates were much higher than the estimated percentage of patients on caseloads 
with a known genetic diagnosis (median=10% ID and median=5% child). As we did 
not have access to the medical records, it is unclear whether psychiatrists accurately 
estimated the number of patients on their caseload with a genetic diagnosis. This would 
ideally be clarified in the first instance to test whether psychiatrists are misestimating 
the number of genetic diagnoses on their caseload, or if they do actually have a low 
proportion of patients with genetic diagnoses. Furthermore, it would be interesting to 
investigate whether genetic diagnoses are being reported to all professionals involved 
in the individual’s care. For example, following genetic diagnosis what is the process 
to communicate this to the patient’s GP and learning disability services, and for what 
proportion of cases is this being miscommunicated. This will be particularly important 
for individuals with ID and co-morbid diagnoses who are under the care of multiple 
medical professionals. 
A high proportion of ID psychiatrists (77%) and just over half of child psychiatrists 
had directly ordered a genetic test. In comparison with child psychiatrists, ID 
psychiatrists were significantly more likely to order a genetic test and also referred 
more patients to the genetics clinic per year. This may have in part been a reflection 
of the ID psychiatrist’s greater reported confidence in the genetic testing process. As 
evidenced in Table 2-2, ID psychiatrists were significantly more confident in all 
aspects of the testing process, apart from capacity testing which is likely to be more 
complex in adulthood.  
The finding that adult ID psychiatrists are more confident in the genetic testing process 
is somewhat surprising, given that clinical genetic testing in DD/ID is only routine in 
childhood. In childhood clinical care plans are not yet in place, so it is more important 
to determine any underlying genetic diagnoses that may have implications for patient 
management. Furthermore, it is more pertinent at this stage for family members to 
receive information on recurrence risk to inform family planning decisions. Given 
these factors, one could assume that child psychiatrists have more experience, and 
therefore confidence, in genetic testing practices. However, one explanation for ID 
psychiatrists being more confident and ordering more genetic tests is due to the 
different structures of child and adult ID psychiatry services. Whereas, adult ID 
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psychiatrists are often the primary clinician involved in genetic referrals, in childhood 
pediatricians are often the first point of contact for patients and the child psychiatrists 
only become involved at a later stage. In support of this, a number of child psychiatrists 
reported in the qualitative analysis that they would defer to paediatric colleagues for 
opinions on genetic testing. 
The survey highlighted a number of barriers to genetic testing in clinical ID services. 
Both child and ID psychiatrists reported that they were concerned about lack of 
available resources for genetic testing and the lack of available treatment options for 
patients. Interestingly child psychiatrists had specific concerns about implications for 
insurance. The Department of Health have released a moratorium extending until 2019 
whereby the only genetic test required to be disclosed is for Huntington’s disease on 
life insurance sums worth more than £500,000130. Therefore results from CMA should 
have no impact on insurance premiums and this misconception could be a barrier to 
clinicians ordering/referring for genetic testing. ID psychiatrists expressed concern 
about issues surrounding counselling. Feedback of genetic diagnoses to adults with ID 
could be more complex than feedback to parents of children with ID and this could be 
an important area for additional resources and research. 
Although 77% of ID psychiatrists and 56% of child psychiatrists had directly ordered 
a genetic test, both child (85%) and ID (77%) psychiatrists agreed that they would 
prefer to refer to an RGC. However, links with NHS RGCs appeared to be variable. 
Some respondents reported good links with their local genetics services, whilst others 
felt that access to service was a barrier to referring for genetic testing. Both ID (83%) 
and child psychiatrists (72%) felt that better links with genetics services would be 
beneficial. Many of these clinicians felt that they do not have the knowledge or training 
to order genetic tests directly. This finding is supported by another survey, which 
found ID psychiatrists lacked adequate knowledge about genetic testing processes131.  
The majority of respondents expressed a wish for further training (71% child, 66% 
ID). Neither child and adolescent nor ID psychiatry curricula currently have learning 
objectives that specifically cover genetic disorders associated with ID132. The curricula 
also fail to cover the genetic work-up and basic genetic counselling skills that are 
required to take more of an active role in identifying and managing patients with 
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genetic disorders. However, there are several recent initiatives to improve the 
psychiatry curriculum. For example, the Gatsby-Wellcome initiative aims to ensure 
that training focuses more on scientific advances in basic and clinical neurosciences133. 
It is, therefore, hoped that future cohorts of psychiatrists will be more confident in 
utilising technological advancements in the assessment and management of their 
patients. 
One of the reasons for undertaking genetic investigations is that a genetic diagnosis is 
likely to provide information about specific associated medical and psychiatric 
phenotypes and thus could improve treatment plans and clinical management for the 
patient. Whilst the majority of respondents felt that a genetic diagnosis would help 
with clinical management, fewer patients on their caseloads had a genetic diagnosis 
than they would expect and clinical management changes following genetic diagnoses 
were not frequently seen in practice. There are published medical guidelines available 
for several genetic disorders, for example via the Orphanet portal for rare diseases134, 
and information guides on an extensive range of chromosomal disorders are available 
from the support group Unique135. It would be of interest for further research to 
investigate whether psychiatrists are aware of these guidelines when they receive a 
genetic diagnosis for their patient.  
Another important consideration is that knowledge of behavioural phenotypes can 
place psychiatrists in a better position to deliver appropriate interventions and 
environmental adaptations. Whilst there is within syndrome variation it has been 
shown that certain behavioural features, such as repetitive and self-injurious 
behaviours, are more common in particular syndromes. There are also implications for 
health screening, for example gastro-intestinal problems are common in Cornelia de 
Lange syndrome and can exacerbate self-injurious behaviours136. A recent survey of 
ID professionals found that nine out of ten professionals interviewed felt that specific 
knowledge of a neurodevelopmental syndrome should play a key role in healthcare 
provision. A specific genetic diagnosis was particularly thought to prompt proactive 
screening for related physical and mental health problems, which is of particular 
benefit for patients with severe impairments127.  One of the main challenges in practice 
is that individual syndromes are rare and psychiatrists are unlikely to care for many 
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individuals with the same disorder, although the overall burden of rare syndromic 
disorders is substantial. 
Both child and ID psychiatrists agreed that receiving a genetic diagnosis was more 
beneficial for family members than for the patient. Research has shown that there is a 
benefit to mothers in receiving a diagnosis for a child with ID; however there is a lack 
of research as to the impact of a genetic diagnosis for adults with ID137. Several 
respondents reported that a diagnosis can help to alleviate guilt for family members, 
as well as increasing understanding of the patient’s syndrome specific behaviours and 
enabling valuable access to support groups. It seems that respondents were able to 
report on a range of psychosocial benefits, which could indirectly improve patient 
management, however tangible changes in clinical decision making following a 
genetic diagnosis were less easy to define.  
The limitations of this survey are that it was self-reported, which could have led to 
biases in estimations. There may have been an  ascertainment bias in the clinicians 
who chose to respond to the survey. It may be that clinicians who already had an 
interest in genetics were more inclined to respond, or perhaps those clinicians who had 
more extreme views on genetics. If the respondents were self-selected as individuals 
who knew more about genetics, then the lack of confidence and knowledge identified 
in the survey would be even greater than initially indicated. There was a significant 
difference identified between the child and ID psychiatrist groups on the demographic 
of sex. It may be that there are sex differences in views and practices relating to genetic 
testing, which could inflate the differences between groups. No previous research on 
the impact of sex on clinician’s genetic practices could be identified, however it is 
important to consider this as a potential factor in the interpretation of these findings. 
This survey specifically focused on psychiatrists, who are one of the medical 
specialists frequently in contact with patients with ID in the UK. These findings may 
not be generalisable to other countries where services are organised differently  
2.6 Conclusion 
Whilst a high number of child and ID psychiatrists appear to already be ordering 
genetic tests there remains a preference for referring directly to clinical genetics 
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services. Respondents highlighted several areas of the genetic testing process in which 
they particularly lack confidence, such as indications for testing, interpretation and 
feedback of genetic results. Child psychiatrists in particular felt less confident, ordered 
fewer genetic tests and referred fewer patients to genetic services. 
Genetic investigations are continuing to advance at a very rapid pace, with WES and 
WGS beginning to enter clinical practice. For example, recent WES study identified 
42% pathogenic DNMs in a cohort with severe developmental disorders51. In 
conjunction with other genetic investigations it is likely that a genetic diagnosis will 
be identifiable in a much higher proportion of patients with ID in the future. This 
should facilitate early diagnosis and tailored interventions for patients and their 
families. However, as the landscape of genetic investigations becomes more complex 
it is going to be a challenge for psychiatrists to keep pace of developments. 
Improvements in training and closer links with genetics services would appear to be 
key areas to address to meet this challenge. Phenotypic data from existing large DD/ID 
genetic investigations is limited, in that it is primarily focused on paediatric cohorts 
and is often restricted to the primary indication for CMA testing138. Thus, there is a 
need for research in adult ID psychiatry services, which offer a unique opportunity to 
delineate the neuropsychiatric phenotype of emerging NDD risk CNVs.  
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Chapter 3 The frequency and architecture of pathogenic CNVs in 
adults with idiopathic ID and co-morbid psychiatric disorders 
Parts of this chapter have been adapted from the following published journal article:  
Wolfe, K., Strydom, A., Morrogh, D., Carter, J., Cutajar, P., Eyeoyibo, M., Hassiotis, 
A., McCarthy, J., Mukherjee, R., Paschos, D., Perumal, N., Read, S., Shankar, R., 
Sharif, Saif., Thirulokachandran, S., Thygesen, J. H., Patch, C., Ogilvie, C., Flinter, 
F., McQuillin, A., Bass, N. (2017) Chromosomal microarray testing in adults with 
intellectual disability presenting with comorbid psychiatric disorders. European 
Journal of Human Genetics. 25: 66–72. PMID: 27650969. 
I undertook and supervised participant recruitment (including psychiatric 
phenotyping), analysed the phenotypic data, and wrote and revised the manuscript for 
publication. Study design and analytical input from AS, AM, NB. CNV calling and 
pathogenicity ratings: DM and JC. Participant recruitment: PC, ME, AH, JMc, RM, 
DM, NP, SR, RS, SS, ST. Critical review of the manuscript was undertaken by all 
authors.  
3.1 Introduction 
An overview of the biological underpinnings of CNVs, CMA technologies, the clinical 
definition of ID, and the involvement of CNVs in psychiatric risk has been covered in 
Chapter 1.  
Approximately 50% of adult ID is idiopathic or of unknown cause36. A large 
proportion of individuals with idiopathic ID have psychiatric co-morbidities139. There 
is evidence to suggest that there is an increased burden of CNVs as the severity of the 
neurodevelopmental phenotype increases140, and that ID plus co-morbid mental 
disorders may contribute a higher CNV burden than ID alone141. Also, a recent 
investigation in a cohort of schizophrenia patients identified a significant increase in 
the yield of pathogenic CNVs as IQ decreased142. Despite this, the majority of the CNV 
research to date has focused on paediatric cohorts, whereby later-onset medical and 
psychiatric phenotypes cannot be reliably ascertained. Given that the investigation of 
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the cause of ID predominately occurs at diagnosis in childhood, there is a large cohort 
of adults, many with later onset psychiatric disorders, who have not had a diagnostic 
assessment utilising the latest genetic technologies143.  
3.2 Aims 
The target population for this study was adults with ID (>18 years of age). Adults were 
selected, as phenotyping in children is limited by the fact that development is on-going 
and the typical age of onset for many psychiatric disorders is yet to be reached. We 
focused recruitment on adults with ID who also had challenging behaviours and/or one 
or more psychiatric diagnosis. This more severe co-morbid phenotype was selected as 
severity of phenotype has previously been associated with a greater CNV burden140, 
and this population has never previously been investigated for pathogenic CNVs. 
This study aimed to: (i) determine the yield of undiagnosed pathogenic CNVs in adults 
accessing ID psychiatry services in the UK, (ii) identify the architecture of CNVs 
involved in co-morbid NDD risk and the implicated genetic loci, (iii) describe the 
phenotypic presentation of adults with pathogenic CNVs, (iv) compare the psychiatric 
phenotype of patients with pathogenic and non-pathogenic CNVs. 
3.3 Methods  
3.3.1 Study design and participant recruitment 
Ethical approval for the study was attained from the North Wales Research Ethics 
Committee West, reference 11/WA/0370. Recruitment was undertaken with the 
support of the Mental Health Research Network (MHRN), which is part of the 
National Institute for Health Research and aims to facilitate mental health research 
within the NHS. Recruitment took place at 32 NHS trusts and 1 non-NHS provider 
across England. Consultant Psychiatrists in Intellectual Disabilities acted as local 
principle investigators (PIs) at each site. PIs identified eligible participants from their 
caseloads based upon the study inclusion criteria. Inclusion criteria were: i) idiopathic 
ID; ii) one or more psychiatric diagnoses and/or significant challenging behaviours; 
and iii) over 18 years of age. Idiopathic ID was defined as no clear genetic or 
environmental cause of ID – to the best of the PI’s knowledge. 
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Capacity to consent to the research project was assessed by the participant’s 
Consultant Psychiatrist in accordance with the Mental Capacity Act 2005144. For 
eligible participants who were deemed to have capacity to consent to the study, 
information was provided in-person utilising Easy read information sheets and consent 
was provided via Easy read consent forms. This was undertaken by the patient’s 
psychiatrist, by myself or by a Clinical Studies Officer or Research Nurse employed 
by the MHRN. All MHRN staff received training on the study protocol. In the absence 
of capacity consultees, primarily family members or carers, were identified to give 
advice as to the person’s likely wishes regarding participation in accordance with the 
MCA guidance on nominating a consultee145. Participants, or their consultees, were 
given the option for the genetic results to be fed back to the treating psychiatrist, or 
another clinician involved in their care, such as the GP. 
Clinical data including developmental, medical and psychiatric history (ICD-10 
diagnoses)146, was collected from an informant and/or medical records. General 
observations for dysmorphic features were made using a dysmorphology checklist, 
containing facial and bodily dysmorphisms. Measurements of height, head 
circumference and weight, where available, were also collected by the clinician or 
researcher. Photographs were taken (where consent was given) for corroboration by 
the study team.  
Detailed psychiatric and behavioural phenotyping was undertaken using the Mini 
Psychiatric Assessment Schedule for Adults with Developmental Disabilities (Mini 
PAS-ADD) and Behaviour Problems Inventory – short form (BPI-S). The Mini PAS-
ADD assesses psychiatric symptoms in seven diagnostic areas and provides threshold 
scores for symptoms that are likely to warrant a diagnosis in conjunction with a clinical 
assessment147. The BPI-S measures challenging behaviours over the previous six 
months and provides weekly frequency scores of behaviours on three domains, self-
injurious behaviour, aggressive/destructive behaviour and stereotyped behaviour148. 
3.3.2 Genetic analysis and feedback 
Participants were given the option to provide either a blood or saliva sample, 24% 
provided blood and 76% provided saliva. The saliva samples were collected using the 
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Oragene DNA collection kits (DNA Genotek Inc, Ontario, Canada). DNA extraction 
arrayCGH analysis was undertaken at the North East Thames Regional Genetics 
Service Laboratory on the Nimblegen 135K platform (Roche NimbleGen, Wisconsin, 
USA). Arrays were processed and CNVs were reported using in-house clinical 
diagnostic laboratory protocols, in keeping with the Association for Clinical Genetic 
Science (ACGS) best practice guidelines149.  
CNVs referred to as pathogenic include pathogenic causative CNVs and pathogenic 
susceptibility CNVs, both of which are thought to affect gene function in view of the 
associated phenotype150. As discussed in Chapter 1 there are many factors that 
influence variant categorisation. Some CNVs were classed as variants of unknown 
significance (VOUS) likely pathogenic. This categorisation typically arises when there 
is an existing single case report with similar CNV breakpoints and phenotype to the 
patient under investigation, or when a gene within the CNV interval has a compelling 
function relevant to the patient phenotype. In both instances there is insufficient 
evidence in published literature, or previous reported occurrences of the CNV, to 
warrant it being classified as pathogenic14. There is no uniform method of dealing with 
VOUS CNVs and some published manuscripts combine the VOUS likely pathogenic 
and pathogenic categories in their analyses142,151. However, VOUS likely pathogenic 
are not reported back to patients and their families. In order to take a conservative 
approach and focus on variants that are clinically reportable we did not include VOUS 
likely pathogenic in the pathogenic category. All pathogenic CNVs were added to the 
DECIPHER genome browser152. 
Pathogenic CNVs were fed back in writing to the participants’ treating psychiatrist. 
The cytogenetic report and associated publications were provided alongside 
chromosomal disorder guides from the support group Unique where available135. 
There is a paucity of appropriate and accessible information for adults with ID 
receiving diagnoses. The study team developed easy to read materials to aid feedback 
for some of the clinically relevant CNVs. Psychiatrists also had the opportunity to 
speak with a member of the research team regarding the result prior to feeding this 
back to their patients and family members and/or carers. Referral to the RGCs for 
genetic counselling was recommended for all pathogenic results.  
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A feedback survey was sent to the treating psychiatrist of participant’s with pathogenic 
CNVs one month after the genetic feedback was provided. The survey aimed to assess 
the clinician’s experience of feeding back the genetic test result and to determine 
whether there had been any clinical management changes following the genetic 
diagnosis, see appendix for details of the questions included in the survey. 
3.3.3 Statistical analysis 
Statistical analyses were undertaken using IBM SPSS Statistics for Windows, Version 
22.0. Univariate binary logistic regression was performed using Mini PAS-ADD 
thresholds and history of involuntary in-patient admission, including forensic in-
patient section, as predictor variables. The binary outcome variable was presence or 
absence of a pathogenic CNV. 
3.4 Results 
3.4.1 Frequency of pathogenic CNVs 
202 adults with idiopathic ID and co-morbid psychiatric disorders/challenging 
behaviours were recruited to the study (63% male; mean age 37 years, range 18-78 
years; 74% White British). The yield of pathogenic CNVs, including chromosomal 
abnormalities, was 11% (22/202). A further 62% of participants had a least one CNV 
classed as VOUS (126/202) and 27% (54/202) had likely benign CNVs only. An 
overview of pathogenic CNVs is presented in Figure 3-1, with detailed genetic and phenotypic 
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data presented in Figure 3-1: Overview of pathogenic CNVs identified in a sample of 202 adults 
with idiopathic intellectual disabilities and co-morbid psychiatric disorders 
 
Mb = megabases. Kb = kilobases, N= number of participants, BP = breakpoints 
 
Table 3-1 and Table 3-2. A comparison of psychiatric diagnoses, subclinical symptoms 
and section history for likely pathogenic versus likely benign (including VOUS) CNVs 
is provided in Table 3-3. There were 21 participants on a forensic in-patient section 
(section 37 or section 37/41) at the time of recruitment and no other participants had a 
forensic section history. In all, 6/21 (28.6%) forensic in-patients carried pathogenic 
CNVs compared with 16/181 (8.8%) in participants not on a forensic in-patient 
section. Thus the proportion of pathogenic CNV carriers in forensic in-patients was 
higher with an OR of 4.1 (95% CI 1.40–12.04, P=0.01). However, if a Bonferroni 
correction was applied to account for multiple testing the level of significance would 
be set to p=0.007, therefore this finding would not survive a multiple testing 
correction. 
3.4.2 Type of pathogenic CNVs 
The majority of CNVs (64%, 14/22) were observed in regions of the genome prone to 
recurrent CNV, where pathogenic CNVs have previously been described for various 
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NDDs. The second largest group was very rare CNVs, not occurring at recurrent loci, 
which were either large in size (range 1.5-9.1Mb) or in known neurodevelopmental 
genes (6/22, 27%), finally two participants had large chromosomal abnormalities 





Figure 3-1: Overview of pathogenic CNVs identified in a sample of 202 adults with idiopathic intellectual disabilities and co-morbid psychiatric disorders 
 


















Mini PAS-ADD BPI-S Ethnicity 
327138 2p16.3 Loss chr2:51,196,189-51,745,529 Female 21 Moderate PD PSY, UNS - - + 
White 
(British) 
327136 2q13 Loss chr2:111,391,616-113,103,446 Male 19 Mild ASD ANX, PSY + + + 
White 
(British) 









Gain chr6:195,429-7,392,549 Male 49 
 
Mild 
ANX, DEP HYP, PSY, ASD - + + 
White 
(British) 






Loss chr12:79,534,629-84,535,827 Male 31 Mild 
SCZ, ALC, 
FOR 










None met - - - 
White 
(British) 
327128 15q11.2 Loss chr15:22,759,710-23,071,809 Female 42 Moderate BP 
DEP, ANX, HYP, 
OCD, PSY, UNS 
















N/A - + - 
White 
(British) 
327123 15q12-13.1 Loss chr15:26,587,699-29,576,869 Male 28 Severe 
ASD, 
ADHD 






Loss chr15:30,461,189-32,804,210 Male 25 Mild ASD2 None met - - - 
White 
(British) 







Chromosomal region coordinates in hg19 using the HGVS standard nomenclature; Size, size of CNV in kilobase pairs; Age, age at date of recruitment; Level of ID, taken from 
medical records in accordance with the UK ICD-10 diagnostic system:  50-69: Mild, 35-49: Moderate, 20-34: Severe, Mini PAS-ADD, Psychiatric Assessment Schedules for 
Adults with Developmental Disabilities thresholds met (in last 2 years); BPI-S, The Behaviour Problems Inventory-Short Form (Self-injurious behaviour, aggressive/destructive, 
stereotyped) items scored as + when behaviour occurs at least weekly; PD, Personality Disorder; PSY, Psychosis; UNS, Unspecified Disorder; ASD, Autistic Spectrum Disorder; 
ANX, Anxiety Disorder; ALC alcohol abuse; FOR on forensic in-patient section; N/A, Not Available; DEP, Depression; HYP, Hypomania/Mania; CB, Challenging Behaviour; 
SCZ, Schizophrenia; ADHD, Attention Deficit Hyperactivity Disorder; BP, Bipolar Disorder; OCD, Obsessive Compulsive Disorder; AFF, Schizoaffective Disorder; 1 CNVs 
in the same participant; 2 ASD traits only; 3 Confirmed by qPCR  
 
327119 16p11.2 Gain chr16:29,746,320-30,093,460 Female 27 Mild 
ASD, DEP, 
OCD 
DEP, OCD - - - 
White 
(Other) 
327121 16p11.2 Gain chr16:29,746,320-30,093,460 Female 62 Mild 
DEP 
(psychotic) 
PSY - - - 
White 
(British) 




None met - + - 
White 
(British) 
327135 16p11.2 Loss chr16:29,746,320-30,192,560 Male 19 Mild 
None 
recorded 
DEP, ANX, HYP, 
OCD, PSY 
- - + 
White 
(British) 
327130 16p13.11 Gain chr16:14,892,210-16,616,420 Female 45 Moderate CB N/A N/A 
White 
(British) 






Loss chr18:141,489-6,964,200 Male 49 Mild ANX, DEP HYP, PSY, ASD - + + 
White 
(British) 
327129 19q13.32 Loss chr19:45,741,741-47,268,131 Female 58 Mild BP DEP, PSY - + - 
White 
(British) 

























327138 2p16.3 21 Asthma 55.9 169 Abnormal facial shape, dental crowding 
327136 2q13 19 
Recurrent ear infections, urinary reflux, facial nerve 
palsy 
N/A N/A Cranial abnormality 
327134 4p16.3 33 Constipation 59 179 







Bilateral sensorineural hearing impairment, epilepsy, 
psychogenic polydipsia, hypogonadism, arthritis, 
osteoperosis, dysphagia 
56 157 
Facial asymmetry, abnormal facial shape, dental 
crowding, abnormality of the fingers, large ears, 
cranial abnormality 




31 None recorded 64 169 
Hypertelorism, depressed nasal bridge, wide nasal 
bridge, low set ears, microtia 
327125 13q32.3-33.3 21 Epilepsy, shuffling gait, bradykinesia 59 167 Low set ears, abnormality of the hand 
327128 15q11.2 42 Recurrent urinary tract infections 55 N/A 
Abnormality of external nose, abnormalities of the 
fingers 
327127 15q11.2-13.1 33 
Hypotonia (infant), epilepsy (infancy), probable 
diplopia, abnormality on neuroimaging 
53 161 
Upward slanting palpebral fissures, prognathia, 
protruding tongue, hypopigmentation of the skin 
327124 15q11.2-13.1 22 None recorded N/A 182 No gross dysmorphology 
327123 15q12-13.1 28 Epilepsy (grand mal and absence seizures) 55.8 170 Cranial abnormality, facial asymmetry 









327119 16p11.2 27 
Renal problems (childhood), menorrhagia,  anaemia 
(severe), onychogryphosis 
54.2 
161.8 No gross dysmorphology 
327121 16p11.2 
62 
Jaundice (childhood), epilepsy (childhood), type II 
diabetes, constipation, glaucoma 
53.2 172.5 No gross dysmorphology 
327133 16p11.2 
21 
Insulin dependent diabetes, hypercholesterolaemia 
59 188 N/A 
327135 16p11.2 
19 
Seizures (infancy), acne 
59 162 Tapering fingers 
327130 16p13.11 
45 
Hypertension,  type II diabetes, constipation, asthma, 
obesity 
54 147 Abnormal facial shape, microtia 
327132 17q11.2 
57 
Pacemaker in situ (long Q-T syndrome), 
hypothyroidism, hypercholesterolaemia, cataracts 





Bilateral sensorineural hearing impairment, epilepsy, 
psychogenic polydipsia, hypogonadism, arthritis, 
osteoperosis, dysphagia 
56 157 
Facial asymmetry, abnormal facial shape, dental 
crowding, abnormality of the fingers, large ears, 
cranial abnormality 
327129 19q13.32 58 Epilepsy, incontinence, Cataracts, broad based gait 55 148 Short upturned nose 
327139 Xq24-25 57 Shuffling gait, bradykinesia 61 174 
Abnormality of the skull, abnormality of the eyelid, 







Hypertension, hypercholesterolaemia, type I diabetes, 
absent kidney, constipation, cataracts, anaemia, 
asthma, osteoarthritis 
58.5cm 176cm N/A 
Age, age at date of recruitment ; Medical history was collected using a standard pro-forma from informants (family members and/or carers) and medical records where available. 
Dysmorphic features were recorded using a standard pro-forma by researchers carrying out the assessment. Only dysmorphic features obvious on general observation in normal 
clothing were documented no structured physical examination was undertaken. Dysmorphic features were corroborated by examination of accompanying photographs by the 






Table 3-3: Psychiatric phenotype (ICD-10 diagnoses, Mini PAS-ADD thresholds and section history) for pathogenic and benign CNVs 
 
 
a P-Value from binary logistic regression analyses, ICD10  diagnoses - the psychosis group was amalgamated to comprise: F20 schizophrenia, F25 schizoaffective disorder and 
F29 unspecified nonorganic psychosis. Other ICD-10 diagnoses reported independently are: F31 Bipolar disorder, F32 Depressive episode, F41 Other anxiety disorders, F90 
Hyperkinetic disorder, F84 Pervasive developmental disorder. Mini PAS-ADD thresholds - scores were calculated using standard guidelines, Mental Health Act (MHA) section 
– previous history of involuntary admission included previous and current MHA sections and forensic sections, Forensic section - all individuals were on a forensic section at 
the time of recruitment no history of being on a forensic section was identified in any of the other participants. N.B. Several individuals had co-morbid diagnoses and are 
included in more than one category. 
 Total in sample (%) N=202 
Pathogenic CNV group (%) 
n=22 




ICD-10 Diagnosis    
Psychosis 49 (25%) 3 (14%)        46 (26%) -      
Bipolar disorder 23 (11%) 3 (14%)        20 (11%) -   
Depressive episode 62 (31%) 4 (18%)       58 (32% -   
Other anxiety disorders 45 (23%)                     2 (9%)        43 (24%) -   
Hyperkinetic disorder 21 (10%) 3 (14%)        18 (10%) -   
Pervasive developmental disorder 68 (34%) 8 (36%)        60 (33%) -   
Mini PAS-ADD thresholds    
Psychosis 72 (36%) 9 (41%)        63 (35%) 0.63 
Hypomania/Mania 33 (16%) 5 (23%)        28 (16%)   0.41 
Depressive disorder 76 (38%) 5 (23%)        71 (39%)  0.12 
Anxiety disorder 80 (40%) 6 (27%)        74 (41%)   0.84 
Obsessive compulsive 55 (27%) 5 (23%)        50 (28%)   0.59 
Mental Health Act Section History    
Previous history of involuntary admission 45 (22%) 7 (32%)        38 (21%)  0.27 
Forensic section 21 (10%) 6 (27%)      15 (8%)  0.01 
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3.4.3 Recurrent CNVs 
Four of the recurrent pathogenic CNVs were identified at the 16p11.2 locus (4 
duplications, 1 deletion). The 16p11.2 region is associated with increased risk for 
ASD, schizophrenia and MDD, in keeping with the phenotypes observed in this 
cohort153. One CNV duplication was identified at the 16p13.11 locus, which has 
previously been associated as a risk factor for cognitive impairments and behavioral 
abnormalities154. A further five CNVs were identified in the 15q11.2-13.3 region 
(15q11.2 deletion, Angelman syndrome type 2, 15q12-13.1 deletion, 15q11.2-13.1 
duplication, and 15q13.3 deletion) with variable psychiatric phenotypes. The 15q11.2 
deletion, 15q13.3 deletion, 16p11.2 deletion and duplication and 16p13.11 duplication 
can be considered as neurosusceptibility loci. These CNVs have incomplete 
penetrance in that they occur at significantly higher frequencies in disease cohorts, 
however do not inevitably result in a disease phenotype and can sometimes be 
observed in healthy controls150. 
Another region prone to pathogenic recurrent CNV is the 17q11.2 locus, which 
encompasses the neurofibromatosis type 1 (NF1) tumour suppressor gene. A 
participant with a NF1 microdeletion was identified who presented with a clinical 
diagnosis of ASD and challenging behaviours. This supports previous evidence of 
ASD being associated with variants in the NF1 gene mutations155. A deletion at 2q13 
was also detected in a participant with a clinical diagnosis of ASD. Of the 29 patients 
now described with this CNV four are reported to have ASD, although assessment 
information was only available for six participants156. CNVs in this region have also 
been shown to be enriched in schizophrenia cohorts157. The participant also presented 
with sub-clinical features of psychosis in addition to anxiety and behavioural 
problems.  
Finally, a recurrent CNV was identified in the NRXN1 gene. The NRXN1 gene is 
located at 2p16.3, it encodes a cell-surface receptor which is important for 
neurotransmission. Exonic NRXN1 deletions have been associated with increased risk 
for schizophrenia and ASD158. The participant had a deletion of exon 1 of the NRXN1 
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gene, a clinical diagnosis of personality disorder and subclinical symptoms of 
psychosis and stereotyped behaviours. 
3.4.4 Non-recurrent rare CNVs 
One CNV was identified in a known neurodevelopmental gene, GRIN2B. The GRIN2B 
gene is located at 12p13.1 and encodes the NR2 subunit of a N-methyl-D-aspartate 
(NMDA) glutamate receptor heteromer, which mediates excitatory neurotransmission 
and is thought to play an important role in memory and learning. Variants in the 
GRIN2B gene have previously been associated with behavioural problems159. Three 
patients with moderate ID and facial dysmorphisms were initially described by 
Dimassi et al., who had overlapping microdeletions encompassing all or part of the 
GRIN2B gene160. Further CNV deletions were subsequently described in patients with 
ID and macrocephaly161, and DD, autistic features, dysmorphic features and congenital 
abnormalities162. Furthermore, three patients with duplication CNVs encompassing the 
GRIN2B gene were also described, all of whom had DD and dysmorphic features163. 
A duplication affecting exon 9 of the GRIN2B gene was identified in a participant 
displaying self-injurious and aggressive behaviours. This 9kb duplication only 
affected the GRIN2B gene, whereas the CNVs reported in previous literature were 
larger and encompassed multiple additional genes.  
A duplication of the 4p16.3 loci, a region where deletions give rise to the better 
characterised Wolf-Hirschhorn syndrome, was also detected. The CNV identified 
partially overlaps with the CNV reported in a case study of a patient with ADHD164. 
The participant has a clinical diagnosis of ASD and was a forensic in-patient. A 
duplication at Xq24-25 was observed in a participant with aggressive and stereotyped 
behaviours. Abnormal behaviours, primarily hyperactivity, have previously been 
associated with CNVs in this region. This region encompasses the GRIA3 gene, 
encoding glutamate receptor, ionotropic AMPA subunit 3 and the STAG2 gene, which 
encodes a component of the cohesion complex and is essential for chromosome 
segregation in dividing cells. The CNV has been identified as X-linked intellectual 
disability syndrome165. Aggregation of patients with Xq24-25 duplications has enabled 
refinement of the shortest region of CNV overlap, implicating STAG2 as the likely 
causative gene166. 
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A CNV deletion was detected in one participant at 12q21.2-21.31 loci comprising 17 
genes. This region contains the Synaptotagmin-1 (SYT1) gene, which encodes a 
calcium-binding synaptic vesicle membrane protein involved in triggering 
neurotransmitter release at the synapse.  A variant in SYT1, with a dominant negative 
function, has recently been associated with profound cognitive impairment although 
no psychiatric phenotype is described167. Whilst this is a copy number loss and 
different phenotype a low haploinsufficiency score is suggestive of adverse functional 
consequences29. The participant has a clinical diagnosis of paranoid schizophrenia, a 
history of alcohol abuse and was a forensic in-patient.  
Another participant had a duplication at 13q32.3-13q33.3 comprising 33 genes. This 
region contains the D-amino acid oxidase activator (DAOA) gene which indirectly 
affects glutamatergic transmission and dopamine turnover. The DAOA gene has been 
reported to be associated with both schizophrenia and BPAD168. The participant had a 
clinical diagnosis of ASD and ADHD and was a forensic in-patient. Finally a 
participant had a CNV deletion at 19q13.32 comprising 56 genes. This deletion 
partially overlaps with a case reported previously, but does not include any of the 
proposed candidate genes or a psychiatric phenotype169. The participant had a clinical 
diagnosis of depression and BPAD.  
3.4.5 Clinician survey for patients with pathogenic CNVs 
The survey was distributed to 22 psychiatrists, who were the responsible clinicians for 
the participants with pathogenic CNVs, and 13 psychiatrists responded to the survey. 
All psychiatrists reported that they fed back the genetic results to family members, 
whereas 11/13 psychiatrists fed back the genetic result to their patients. One of the 
patients died, so it was not possible to feedback the result, and no reason was provided 
by the other psychiatrist who did not feedback the result. Only 4/13 (31%) of 
psychiatrists referred their patients to clinical genetics for genetic counselling – despite 
this being recommended to all psychiatrists. Three psychiatrists said that the clinical 
genetics service offered helpful advice and support, whereas one psychiatrist received 
no response. The majority of psychiatrists reported the test result to the participant’s 
GP (10/13, 77%). There were no adverse outcomes reported from feedback of the 
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genetic test results. None of the psychiatrists reported clinical management changes as 
a consequence of the genetic diagnosis. One of the psychiatrists commented: 
“A lot of what was known was clarified by result but a lot of work had 
been done already”. 
3.5 Discussion 
The yield of pathogenic CNVs identified in adults accessing ID psychiatry services 
was 11%. Previously, investigations of paediatric DD/ID cohorts have identified a 
yield of pathogenic CNVs ranging between 14-20%25,44. As the cohort was sampled 
from a population of adults with idiopathic ID, it is likely to be depleted of clinically 
recognisable syndromic disorders, which were testable with pre-CMA technologies. 
In support of this, the majority of CNV identified are recurrent CNVs, which have 
been identified via the genotype-first approach and thus named after the chromosomal 
region involved138. Whereas, there were few occurrences of syndromes in which the 
aetiology was identified prior to the application of CMA, with one Angelman’s 
syndrome, one NF1 microdeletion syndrome type 2 and two chromosomal 
abnormalities. 
The yield identified was considerably higher than that found in cohorts recruited on 
the basis of a schizophrenia diagnosis. The yield of pathogenic CNVs in adults with 
schizophrenia is reported to be in the range of 2.5-5%28,62. There have been calls for 
increased clinical use of CMA in patients with schizophrenia, although there is also 
resistance to this given the low diagnostic yields. This study suggests that 
approximately 11% new genetic diagnoses could be made by testing adults accessing 
ID psychiatry services in the UK. The higher diagnostic yield in patients with ID and 
psychiatric co-morbidities argues that this patient group should be a priority for 
consideration of routine CMA in psychiatric practice.  
A recent study by Lowther et al. also advocated for increased CMA testing in the adult 
DD/ID population, particularly for those with a dual diagnosis. The study undertook 
IQ phenotyping in a large community sample of adults with schizophrenia, identifying 
a yield of 24.1% pathogenic CNVs in individuals with co-morbid ID142. There are 
  78 
several reasons why this study may have identified a higher yield of pathogenic CNVs. 
Firstly, the only co-morbid diagnosis included in this study is schizophrenia, and it 
may be that the yield is indeed higher for schizophrenia as compared to psychiatric 
disorders in general. Secondly, the higher yield may have arisen as the authors used a 
less stringent definition of pathogenicity, whereby they considered CNVs classed as 
VOUS likely pathogenic or pathogenic to be pathogenic. Further testing in adult ID 
psychiatry cohorts will be required to clarify the yield of pathogenic CNVs.   
A broad range of psychiatric diagnoses/symptoms were observed across the cohort. 
The pattern of comorbidities, either defined by ICD-10 diagnoses or Mini PAS-ADD 
thresholds, was complex. Inclusion of Mini PAS-ADD thresholds indicated a burden 
of psychopathology not captured by ICD-10 diagnoses. It is of interest that 41% of 
participants with pathogenic CNVs met the Mini PAS-ADD threshold for psychosis, 
whereas based upon ICD-10 criteria this was only 14%, see Table 3-3. Given the 
challenges of diagnosing psychiatric disorders in individuals with ID, particularly as 
the assessments rely on self-reported symptoms, it may be that more individuals have 
a psychotic disorder than those with a formal diagnosis. Equally, it may be that as the 
screening assessments are more challenging in an ID population this figure is falsely 
inflated. 
The frequency of particular psychiatric phenotypes was tested between the pathogenic 
and benign CNV groups. The only significant finding was that there was an excess of 
participants on a forensic section in the pathogenic CNV group in comparison with the 
benign (including VOUS) CNV group. One observation from participant recruitment, 
which may partly explain this finding, is that many of the forensic participants had a 
family history of mental health problems, often on both sides of the family. It may be 
that assortative mating in these families was contributing to a high psychiatric genetic 
loading. Additionally if many of these participant had inherited psychiatric risk CNVs 
the additional impact of the parent also having the CNV could also contribute to the 
severe phenotype. It was also observed that many forensic participants had disruptive 
childhoods and had been put into the care of social services. However, it was not 
possible to determine the significance of these factors as inheritance data was not 
readily available. Also, the significant finding does not survive a Bonferroni multiple 
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testing correction, thus may be a spurious result. No link can be made between specific 
CNVs and offending behaviour, as causality cannot be inferred. This finding warrants 
further investigation in much larger samples.  
The majority of pathogenic CNVs – 64% - were found at recurrent CNV loci. 
Interestingly, the most frequently observed CNV in this study was the 16p11.2 
duplication (4 individuals, 2%). This CNV has been widely reported in other studies, 
with a frequency of ~0.2% in DD/ID,45 ~1% in ASD82 and ~0.3% in schizophrenia62. 
Accepting the small sample size this may suggest a particular enrichment of this 
recurrent CNV in the adult population of ID and co-morbid psychiatric disorders.  
Assessment of adults with ID and formulation of the psychiatric presentation can be 
challenging. The majority of pathogenic CNVs were found at recurrent CNV loci 
where, at least some, information on the associated phenotype is available. Such 
information may aid understanding of the patient’s clinical presentation for both 
clinicians and family members. Furthermore knowledge of associated phenotypes may 
guide psychiatric evaluation. For example, the identification of a 16p11.2 duplication 
would be an indicator to screen for the presence of ASD, psychosis or affective 
disorders153. As part of the feedback process disorder support guides were provided to 
treating psychiatrists. However, survey results from psychiatrists of participants with 
pathogenic CNVs indicate that no clinical management changes were made as a result 
of the genetic diagnosis and one psychiatrist commented that a lot of the work had 
been done already. One potential explanation for this is that the mean age of the sample 
was 37 years, past the typical age for emergence of later-onset psychiatric and medical 
symptomatology. Thus, it is likely that clinical treatment plans have already been put 
in place. Further research in a larger sample, with a diverse range of ages, is required 
to further investigate this finding.  
One of the main limitations of this study is that the recruitment strategy was 
susceptible to ascertainment bias. The recruitment strategy was focused on individuals 
with a more severe psychiatric phenotype, i.e. those presenting to psychiatric services, 
and PIs may have selected patients who they thought most likely to have a genetic 
disorder. However, those with the most severe phenotypes might have been under 
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sampled because of difficulties recruiting this population group to research studies. 
This is supported by the fact that the majority of the pathogenic CNV group had mild 
ID (15/22, 68%). We took steps to facilitate the recruitment of individuals with 
moderate and severe ID by producing Easy read information sheets and consent forms, 
making the study information accessible during the capacity assessment process. 
However, it is still more time consuming to explain the study information via Easy 
read documentation, which may have been a barrier for clinicians to recruiting patients 
with more severe ID. In addition the recruitment process required the availability of a 
family member or carer to provide informant information. It may be that informants 
felt less able to dedicate their time to research if they are already dealing with extreme 
challenging behaviours or psychiatric diagnoses, which require high levels of care. 
Another approach to participant recruitment might be to ask PIs to randomly sample 
participants from their caseload, although this would initially be more labour intensive 
and may have led to delays in meeting the tight recruitment targets. 
Further limitations of this study are that the sample size was modest. Estimates of the 
penetrance of particular phenotypes would require epidemiological based studies.  
Technological limitations of the aCGH platform include; inability to detect balanced 
translocations, single gene disorders and low level mosaicism. Karyotyping enables 
the detection of chromosomal translocations and inversions, however it was not 
possible to undertake karyotyping in this analysis meaning that these genetic variants 
would be largely missed. As the array platform has not utilised in research studies of 
control populations comparisons with other studies is prone to technical confounds.  
3.6 Conclusion 
CNV screening using clinically available CMA offers over one in ten new aetiological 
diagnoses for adults with idiopathic ID presenting to psychiatric services in the UK. 
Clinical and research data on emerging CNV syndromes is strongly biased towards 
paediatric populations. However, the full extent of the phenotype associated with a 
particular CNV may only be realised in adulthood as psychiatric disorders emerge. 
Most pathogenic CNVs in co-morbid NDDs affect established risk loci, with the 
16p11.2 duplication being particularly frequent in this understudied adult population. 
The addition of psychiatric phenotypic information to very rarely observed and novel 
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likely pathogenic CNVs could be beneficial for patient clinical management and 
management of children with new emerging CNVs.   
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Chapter 4 CNV analysis in a European ID psychiatry cohort 
identifies high rates of NDD risk CNVs 
Parts of this chapter have been adapted from the following journal article, which is 
currently in press: 
Thygesen, J.*, Wolfe, K.*, McQuillin, A., Viñas-Jornet, M., Baena, N., Brison, N., 
D'Haenens, G., Esteba-Castillo, S., Gabau, E., Ribas-Vidal, N., Ruiz, A., Vermeesch, 
J., Weyts, E., Novell, R., Van Buggenhout, G., Strydom, A., Bass, N.*, Guitart 
Feliubadaló, M.*, Vogels, A.* (2018) High rates of neurodevelopmental risk CNVs in 
patients with intellectual disabilities and co-morbid psychiatric disorders. The British 
Journal of Psychiatry. In press. *Joint first-authorship 
I undertook and supervised recruitment of the London participants (including 
psychiatric phenotyping), acted as project co-ordinator for the international 
consortium, undertook phenotypic data analysis, and wrote and revised the manuscript 
for publication. Study design and analytical input from: AM, NB, MGF, AV. CNV 
calling and analysis: NB, JV, GVB. Participant recruitment: MVJ, GAH SEC, EG, 
NRV, AR, RN. JT: led quality control, data amalgamation and statistical analyses. 
Critical review of the manuscript was undertaken by all authors.  
4.1 Introduction 
In Chapter 1 of this thesis it was established that a proportion of the risk for NDDs can 
be attributed to CNVs. As previously discussed, the majority of pathogenic CNVs are 
risk factors for multiple disorders. For example, all the CNVs identified as risk factors 
for schizophrenia are also associated with risk for ID97, and the same is true for ASD 
risk CNVs87. Thus, collectively these CNVs can be referred to as NDD risk CNVs. 
Frequency estimates of these CNVs in different populations show a positive 
correlation between the severity of the phenotype and frequency of the CNV. 
Typically, there is an absence, or low frequency of CNVs in controls, whereas and the 
greatest frequency of CNVs is seen in early-onset NDDs97,107. These CNVs confer 
moderate to large risk factors for NDDs (Odds Ratio 1.5->50)97, and therefore have 
important clinical implications for affected individuals and at risk family members. 
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Research to date has primarily focused on researching cohorts from traditional 
diagnostic categories, and there is a lack of research in adults who have multiple co-
morbid NDD diagnoses. 
Building on the work from Chapter 3, a consortium was formed to bring together three 
European samples of adults with idiopathic ID and co-morbid mental disorders with 
available genome-wide CNV and phenotypic data. The frequency of pathogenic CNVs 
and rate of NDD risk CNVs has never previously been investigated in a large cohort 
of adults with co-morbid NDD phenotypes.  
4.2 Aims 
This analysis aimed to determine; (i) the frequency of known NDD risk CNVs as 
compared to large NDD cohorts from the existing literature; (ii) the overall rate of 
pathogenic CNVs; (iii) the relationship between pathogenic CNVs, level of ID and co-
morbid psychiatric diagnoses; and (iv) likely pathogenic CNVs affecting 
neurodevelopmental candidate genes. 
4.3 Methods  
4.3.1 Recruitment criteria and participant recruitment 
The GENMID (GENetics of Mental disorders in Intellectual Disability) consortium 
comprises three primary research groups based in Catalonia, Spain; Leuven, Belgium; 
and England, United Kingdom. All sites recruited adults over the age of 18 years with 
idiopathic ID and one or more co-morbid psychiatric diagnoses and/or significant 
challenging behaviours. In Catalonia participants were identified from the Mental 
Health ID regional community Service Parc Hospitalari Martí i Julià, Girona. In 
Leuven, participants were recruited at the regional inpatient psychiatric unit for adults 
with ID in the St-Camillus Psychiatric Hospital, Bierbeek. Initially, only patients 
diagnosed with psychosis were recruited, but recruitment was later extended to other 
psychiatric phenotypes. In England, participants were recruited by consultant 
psychiatrists in intellectual disabilities in accordance with the methodology described 
in Chapter 3. 
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There were no significant differences in recruitment strategy between sites, all sites 
recruited adults with ID plus either challenging behaviour and/or one or more 
psychiatric diagnosis – as per the methodology in Chapter 3. Participants were 
screened for prior genetic diagnoses. Approximately 10 participants from the Leuven 
cohort were identified as having a diagnosis of Down’s syndrome or fragile X 
syndrome and were excluded from further analyses. 
4.3.2 Phenotypic assessments 
For all sites the ID levels are in accordance with the ICD-10 ranges (<20 profound ID, 
20-34 severe ID, 35-49 moderate ID, 50-69 mild ID, 70-84 borderline ID)39. As 
previous research has proposed that the factors influencing mild ID and IQ in the 
normal range are separate from those influencing severe ID43, we combined the 
categories into two groups for further analyses. The <20-49 ranges were collapsed into 
a severe category and the 50-84 ranges were collapsed into a mild category. All sites 
identified psychiatric diagnoses from medical records and/or informants. Psychiatric 
diagnoses for Catalonia and Leuven were converted from Diagnostic and Statistical 
Manual of Mental Disorders IV170 to ICD-10 criteria (with agreement between two 
psychiatrists). 
4.3.3 Genetic analysis and CNV calling 
DNA was extracted from blood and saliva samples. Samples from Catalonia were 
analysed using the 400K Agilent platform (Agilent Technologies, Santa Clara, 
California, USA) at the Genetics Laboratory, UDIAT-Centre Diagnòstic, Parc Taulí 
Hospital Universitari. Samples from Leuven were analysed on the CytoSure ISCA 
oligoarray set (OGT, Oxford, UK) at the Constitutional Cytogenetics Unit of the 
Center of Human Genetics, University of Leuven. Samples from England were 
analysed on the NimbleGen 135K platform (87%) (Roche NimbleGen, Madison, 
Wisconsin, USA) and the Cytoscan 750K platform (13%) (Affymetrics, Santa Clara, 
California, USA) at the North East Thames Regional Genetics Service Laboratory.  
CNV calling took place at the respective clinical laboratories. There was a two-tier 
variant categorisation process. CNVs were initially reported by the independent 
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clinical laboratories and classified into three categories: pathogenic, VOUS and 
benign. This was in keeping with internal laboratory protocols based on the American 
College of Medical Genetics best guidelines14 or the Association of Clinical Genetic 
Science Best Practice Guidelines149. The Database of Genomic Variants gold standards 
track was used as a control reference database for determining control CNV 
frequencies30, and compared with internal laboratory databases for frequencies in 
patients with severe developmental disorders referred for genetic testing. 
 None of the pathogenic variants identified were required to be homozygous or 
compound heterozygous in order to be classified as pathogenic. Secondly, between 
site discrepancies in CNV pathogenicity were reclassified in accordance with Kearney 
et al.14, see Table 4-1. CNVs designated as uncertain clinical significance were 
reclassified into likely benign or likely pathogenic using this methodology. The 
genome coordinates for all sites are reported according to the National Center for 
Biotechnology Information (NCBI) human genome build 37 (hg19, February 2009). 
Table 4-1: Between site discrepancies in CNV classifications and reclassification rationale 
4.3.4 NDD CNV frequency methodology 
A list of 63 NDD risk CNVs, that were identified from a sample of paediatric patients 
with severe developmental disorders (DD/ID, ASD and MCA)45, and CNVs associated 
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with risk for schizophrenia were derived from Rees et al.97, henceforth referred to as 
NDD CNVs. The NDD CNVs were called in accordance with the criteria outlined in 
Kendall et al.119, also used by Rees et al.97 (personal communication), see Table 4-2. 
CNVs fulfilling these calling criteria were classified as pathogenic and are included in 
the diagnostic yield. Duplications or deletions of the same chromosomal region were 
counted as separate loci (e.g. 22q11.2 deletion and duplication). The patient population 
rates in healthy controls, ID/ASD (the name given by Rees et al. to a severe 
developmental disorders cohort), and schizophrenia were derived from Rees et al., 
where further information can be found about the respective samples97. Non-recurrent 
rare pathogenic CNVs and larger chromosomal abnormalities are not considered in 
this analysis. A rate percentage (rate in the sample divided by the sample size and 
multiplied by 100) was calculated to enable comparisons between different sample 
sizes and chi-square tests were used to determine the population differences. A 
Bonferroni correction was applied and significance was set at p=0.01 to account for 






Table 4-2: Neurodevelopmental risk CNV critical regions and calling criteria 
Locus Name Critical Region Calling Criteria 
1p36 del/dup chr1:0-2500000 Size >50% of critical region, affecting GABRD 
TAR del/dup chr1:145394955-145807817 Size >50% of critical region 
1q21.1 del/dup chr1:146527987-147394444 Size >50% of critical region 
1q24 del chr1:169680333-173303337 Size >50% of critical region 
NRXN1 del chr2:50145643-51259674 Exonic deletions 
2p15-16.1 proximal dup chr2:61245288-61414572 Size >50% of critical region 
2q11.2 del chr2:96742409-97677516 Size >50% of critical region, affecting both LMAN2L and ARID5A 
2q13 del/dup chr2:111394040-112012649 Size >50% of critical region 
2q33.1 (SATB2) del chr2:200134224-200325255 Size >50% of critical region 
2q37 (HDAC4) del chr2:239716679-243199373 Size >50% of critical region, affecting HDAC4 
3p25.3 (JAGN1 to TATDN2) dup chr3:9932271-10322902 Size >50% of critical region 
3p11.2 (CHMP2B to POU1F1) del chr3:87267612-87531631 Size >50% of critical region 
3q13 (GAP43) del chr3:115332334-115504038 Size >50% of critical region 
3q28-29 (FGF12) del chr3:191859728-192126012 Size >50% of critical region 
3q29 del chr3:195720167-197354826 Size >50% of critical region 
Wolf-Hirschhorn del/dup chr4:1552030-2091303 Size >50% of critical region 
4q21 (BMP3) del chr4:81945477-81985327 Size >50% of critical region 
5q14 (MEF2C) del chr5:88011654-88200703 Size >50% of critical region 
Sotos syndrome del chr5:175720924-177052594 Size >50% of critical region 
Williams-Beuren syndrome del chr7:72744915-74142892 Size >50% of critical region 
WBS dup chr7:72744915-74142892 Size >50% of critical region 
8p23.1 del/dup chr8:8098990-11872558 Size >26.5% of critical region (equal to min 1Mb affected) 
9p13 dup chr9:32648800-38808255 Size >50% of critical region 
9q34 dup chr9:138460697-141036426 Size >38.8% of critical region (equal to min 1Mb affected) 
10q11.21q11.23 dup chr10:49390199-51058796 Size >50% of critical region 
10q23 del chr10:82045472-88931651 Size > 14.5% of critical region (equal to min 1Mb affected), including 
NRG3 and GRID1 
Potocki-Shaffer syndrome del chr11:43940000-46020000 Size >50% of critical region, including EXT2 
12p13 dup chr12:6471959-6825955 Size >50% of critical region 
PWS/AS del/dup chr15:22805313-28390339 Size > 71.6% of critical region (equal to min 4Mb affected) 





15q13.3 del chr15:31080645-32462776 Size >50% of critical region 
15q24 del/dup chr15:72900171-78151253 Size >50% of critical region 
15q25 del chr15:85139815-85716624 Size >50% of critical region 
16p13.11 del/dup chr16:15511655-16293689 Size >50% of critical region 
16p12.1 del chr16:21950135-22431889 Size >50% of critical region 
16p11.2 distal del/dup chr16:28823196-29046783 Size >50% of critical region 
16p11.2 del/dup chr16:29650840-30200773 Size >50% of critical region 
17p13.3 del/dup chr17:1247834-2588909 Exonic deletions; whole gene duplications 
Smith-Magenis syndrome del chr17:16812771-20211017 Size >50% of critical region 
Potocki-Lupski syndrome dup chr17:16812771-20211017 Size >50% of critical region 
17q11.2 del/dup chr17:29107491-30265075 Size >50% of critical region, affecting NF1 
17q12 del/dup chr17:34815904-36217432 Size >50% of critical region 
17q21.31 del chr17:43705356-44164691 Size >50% of critical region 
22q11.2 del/dup chr22:19037332-21466726 Size >50% of critical region 
distal 22q11.2 del/dup chr22:21920127-23653646 Size >50% of critical region 
Phelan-McDermid syndrome del/dup chr22:51113070-51171640 Size >50% of critical region 
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To determine the CMA yield each individual was grouped by the most pathogenic 
CNV detected. We also examined all likely pathogenic CNVs for recurrence in the 
cohort. Regions that have been previously implicated in NDD risk in the existing 
literature which reoccur in this cohort are further described. Finally, chi-square tests 
(or Fisher's exact tests were there were five or less individuals) were undertaken to 
examine the differences between psychiatric diagnoses, ID level and CNV 
pathogenicity. Since many of the co-morbid diagnoses are correlated and thus are non-
independent, correction of p-values through Bonferroni or other methods was deemed 
too stringent. Thus, all p-values are presented uncorrected for multiple testing as 
recommended by several authors171,172. The statistical analyses were undertaken in R 
version 3.3.1173. 
4.4 Results 
There were 599 adults (Catalonia (n=80), Leuven (n=272) and England (n=247)) with 
ID and one or more co-morbid psychiatric diagnoses/challenging behaviours recruited 
to the study (376 (62.8%) male, mean age 43.2). Just over half of the sample (50.8%) 
had severe ID and the remainder had mild ID. Each participant had, on average, 1.6 
co-morbid psychiatric diagnoses, with pervasive developmental disorders being the 
most frequent diagnosis (25%), followed by unspecified non-organic psychosis (20%), 
see Table 4-3. The average number of CNVs per participant was 12.5 (7.4 deletions 
and 5.5 duplications).  
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Table 4-3: Full descriptive summary of the GENMID cohort 
 
GENMID Catalonia Leuven England 
Demographics     
N 599 80 272 247 








Mean age (std.dev) 43.2 (14.1) 37.1 (9.8) 46.2 (14.5) 41.9 (14.1) 
ID Level     
Mild 49.2% 63.7% 66.9% 25.1% 
Severe 50.8% 36.2% 33.1% 74.9% 
Psychiatric diagnoses     
Average number of co-morbid diagnoses 
(range) 
1.6 (1-5) 1.8 (1-3) 1.4 (1-4) 1.7 (1-5) 
F84 Pervasive developmental disorders 148 (25%) 9% 22% 32% 
F29 Unspecified nonorganic psychosis 121 (20%) 12% 30% 12% 
F61 Mixed and other personality disorders 108 (18%) 0% 36% 4% 
Challenging behaviours 95 (16%) 62% 1% 17% 
F32 Depressive episode 86 (14%) 4% 3% 30% 
F41 Other anxiety disorders 60 (10%) 6% 1% 21% 
F20 Schizophrenia 49 (8%) 4% 8% 9% 
F31 Bipolar affective disorder 47 (8%) 2% 7% 11% 
F90 Hyperkinetic disorders 41 (7%) 6% 4% 10% 
F42 Obsessive-compulsive disorder 37 (6%) 16% 1% 9% 
F43 Reaction to severe stress and 
adjustment disorders 
27 (5%) 19% 4% 0% 
F39 Unspecified mood disorder 25 (4%) 0% 9% 0% 
N.B. Only psychiatric diagnoses found in ten or more individuals are listed in the table 
4.4.1 NDD CNV frequency analysis 
CNVs were identified in 23 of the 63 NDD loci described by Rees et al.97. At these 23 
loci 58 CNV carriers were identified, with two subjects carrying two risk CNVs. The 
rate percentage (rate of participants with a NDD CNV) is 10.0%, while the rate 
percentage, determined from the data presented in Rees et al, is 6.5% in ID/ASD, 3.1% 
in schizophrenia and 1.2% in healthy control populations97, see Table 4-4. The NDD 
loci frequencies are most comparable with the ID/ASD population, a sample which 
consisted mainly of children with DD/ID and/or ASD46. However, we still observe a 
significantly higher proportion of NDD CNVs in our ID and co-morbid psychiatric 
diagnosis sample, 3.5% higher (95% CI = 1-6, P = 0.00084). 
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Table 4-4: Rate percentage of CNVs at 63 NDD risk loci compared with populations rates 








Healthy control 26628 1.2 8.8 (6.3-11) 2.8e-72 
Schizophrenia 20403 3.1 7 (4.5-9.5) 9.7e-21 
ID/ASD 29085 6.5 3.5 (1-6) 8.4e-04 
GENMID 599 10.0 - - 
Rate percentage differences, 95% confidence intervals (CI) and p-values for rate comparisons are 
indicated. 
 
The frequencies of the 23 NDD CNVs identified in the dataset are shown in Figure 
4-1. The carrier frequency at each loci was the highest in our sample of ID and co-
morbid mental disorders, with the exception of four loci for which we see comparable 
frequencies to the ID/ASD cohort. The five most frequent NDD CNVs in the GENMID 
cohort, in order of frequency, are: 22q11.2 deletion (n=7, 1.2%), 15q11.2 PWS/AS 
duplication (n=6, 1%), 16p11.2 duplication (n=5, 0.8%), 15q13.3 deletion (n=5, 0.8%) 
and 16p12.1 deletion (n=4, 0.7%). A description of all CNV loci and the carrier 
phenotypes can be found in Table 4-5. 
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Figure 4-1: NDD CNV frequencies in the GENMID sample compared to frequencies in healthy 
controls (N = 26628), ID/ASD (N = 29085) and schizophrenia (N = 20403) cohorts 
 
Y axis: Rate percentage. This enables comparisons between different sample sizes, and is calculated 
by dividing the number of CNVs detected at each loci by the sample size and multiplying by 100, X 
axis: CNV region followed by the name of the associated syndrome and/or relevant genes. CNV 


















22q11.2 del 7 3.8 1.2 0.629 Severe (4), 
Mild (3) 
2p16.3 del (1) F29 Unspecified nonorganic psychosis (3), F61 Mixed and other 
personality disorders (3), F31 Bipolar affective disorder (2), F39 
Unspecified mood disorder (1) 
15q11.2 
PWS/AS dup 
6 0.7 1.0 0.122 Mild (5), 
Severe (1) 
 F84 Pervasive developmental disorders (3), Challenging behaviours (2), 
F29 Unspecified nonorganic psychosis (1), F31 Bipolar affective disorder 
(1), F39 Unspecified mood disorder (1), F40 Phobic anxiety disorders (1), 
F61 Mixed and other personality disorders (1), F91 Conduct disorder (1) 
15q13.3 del 5 1.3 0.8 0.218 Mild (4), 
Severe (1) 
 F32 Depressive episode (2), F41 Other anxiety disorders (2), Challenging 
behaviours (1), F29 Unspecified nonorganic psychosis (1), F31 Bipolar 
affective disorder (1), F84 Pervasive developmental disorders (1), F94 
Disorders of social functioning with onset specific to childhood and 
adolescence (1) 
16p11.2 dup 5 1.4 0.8 0.236 Severe (5)  F84 Pervasive developmental disorders (3), F32 Depressive episode (2), 
F25 Schizoaffective disorder (1), F29 Unspecified nonorganic psychosis 




4 0.6 0.7 0.103 Mild (2), 
Severe (2) 
22q11.21 del (1) F31 Bipolar affective disorder (2), Challenging behaviours (1), F22 
Delusional disorder (1), F29 Unspecified nonorganic psychosis (1), F61 
Mixed and other personality disorders (1) 
15q11.2 BP1-
BP2 del 
4 3.7 0.7 0.625 Mild (2), 
Severe (2) 
Xp22.31 del (1) F29 Unspecified nonorganic psychosis (1), F31 Bipolar affective disorder 
(1), F41 Other anxiety disorders (1), F61 Mixed and other personality 
disorders (1) 
16p12.1 del 4 0.7 0.7 0.124 Mild (3), 
Severe (1) 
 F20 Schizophrenia (1), F23 Acute and transient psychotic disorders (1), 
F29 Unspecified nonorganic psychosis (1), F43 Reaction to severe stress 
and adjustment disorders (1), F61 Mixed and other personality disorders 




3 0.9 0.5 0.148 Severe (3)  F84 Pervasive developmental disorders (2), Challenging behaviours (1), 






1q21.1 TAR dup 2 0.9 0.3 0.155 Mild (1), 
Severe (1) 
 F20 Schizophrenia (1), F43 Reaction to severe stress and adjustment 
disorders (1), F84 Pervasive developmental disorders (1), F90 
Hyperkinetic disorders (1) 
4p16.3 Wolf-
Hirschhorn dup 








2 0.5 0.3 0.076 Mild (2)  F39 Unspecified mood disorder (1), F61 Mixed and other personality 
disorders (1), F90 Hyperkinetic disorders (1) 
16p13.11 dup 2 1.6 0.3 0.275 Mild (1), 
Severe (1) 
 Challenging behaviours (1), F29 Unspecified nonorganic psychosis (1) 
16p11.2 distal 
del 
2 0.6 0.3 0.094 Mild (1), 
Severe (1) 
 F23 Acute and transient psychotic disorders (1), F29 Unspecified 
nonorganic psychosis (1) 
16p11.2 del 2 2.1 0.3 0.347 Severe (2)  F29 Unspecified nonorganic psychosis (1), F41 Other anxiety disorders 
(1) 
22q11.2 dup 2 1.6 0.3 0.260 Mild (1), 
Severe (1) 
 F20 Schizophrenia (1), F29 Unspecified nonorganic psychosis (1) 
1q21.1 del 1 1.2 0.2 0.201 Mild (1)  F32 Depressive episode (1), F41 Other anxiety disorders (1) 
2q13 del 1 0.3 0.2 0.057 Mild (1)  F84 Pervasive developmental disorders (1) 




1 1.2 0.2 0.197 Severe (1)  F41 Other anxiety disorders (1) 
16p13.11 del 1 0.9 0.2 0.142 Mild (1)  F61 Mixed and other personality disorders (1) 
16p11.2 distal 
dup 




1 0.3 0.2 0.055 Mild (1)  F61 Mixed and other personality disorders (1) 
17q11.2 NF1 del 1 0.2 0.2 0.039 Severe (1)  Challenging behaviours (1), F84 Pervasive developmental disorders (1) 
Total 60 38.8 10.0 6.512    
N Expected, number of carriers we would expect based on ID/ASD frequencies (Rees et al. 2016) of the loci and our sample size of 599 participants, Rate(%) in GENMID and 
ID/ASD samples, ID level, other identified pathogenic CNVs and psychiatric diagnosis of the GENMID carriers.  
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4.4.2 Yield of pathogenic CNVs 
At least one pathogenic CNV was identified in 78 participants (13.0%, 95% CI 10.5-
16.0), with similar yields found at all research sites (Catalonia: 13.8%, Leuven: 14.0%, 
and England: 11.7%). Pathogenic CNVs comprised those identified at the NDD loci 
previously described and a further 25 CNVs reported as pathogenic by the clinical 
laboratory services. The pathogenic CNVs were predominantly deletions (59.5%). A 
rate of 11% pathogenic CNVs has previously been was reported in a subset of 202 of 
the 247 participants from the England sample174. Removing these 202 individuals from 
the GENMID sample still provides a diagnostic yield of 13.9%, thus indicating that 
the yield of undiagnosed pathogenic CNVs in adults with co-morbid NDDs is in the 
range of 11-14%. 
4.4.3 ID level, psychiatric diagnoses and CNV pathogenicity 
Group differences between CNV pathogenicity, psychiatric diagnoses and level of ID 
were examined. There were some differences in the proportions of level of ID and 
psychiatric diagnoses between the CNV pathogenicity groups (pathogenic, likely 
pathogenic, likely benign and benign), see Figure 4-2. However, no simple 
unidirectional relationships were observed. Equally, minor differences in the severity 
of ID were found between CNV pathogenicity groups, but no overall unidirectional 
relationship was observed. 
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Figure 4-2: Association between CNV pathogenicity, diagnostic groups and ID severity 
 
Bars 1-4 show the diagnostic rates of all diagnoses with 10 or more affected, for carriers with benign, 
variant of unknown significance likely benign (VOUS B), VOUS likely pathogenic (VOUS P) and 
pathogenic CNVs. Bars 5-8 show the frequency of mild and severe ID for individuals with benign, 
VOUS B, VOUS P and pathogenic CNVs. Lines indicate nominal statistical difference between 
groups P-value <0.05 only adjacent groups within bars 1-4 and 5-8 have been tested.  
4.4.4 Likely pathogenic CNVs  
The yield of likely pathogenic CNVs in the sample was 21.5% (95% CI 18.4-25.1). 
Investigation of recurrent likely pathogenic CNVs revealed 34 CNVs in 16 regions. 
Four recurrent CNVs identified corroborate existing evidence for the involvement of 




Figure 4-3: Chromosomal locations of four overlapping likely pathogenic CNVs  
 
The top image shows the chromosomal location of the CNV, with the region highlighted by a red box, CNV deletions are shown in red and CNV duplications are 
shown in green, UCSC genes included in the CNV are shown, the image was exported from UCSC in chromosomal build GRCh37/hg19. 
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First, we identified two carriers of exonic duplications in the CNTN6 gene at 3p26.3. 
The CNTN proteins belong to a immunoglobulin super family of cell adhesion 
molecules and have an important role in neurodevelopmental processes175. CNTN6 
duplications were first identified in patients with ASD86,176 and later in a patient with 
ID and facial dysmorphisms177. A review of 14 patients with CNTN6 CNVs revealed 
that both CNV deletions and duplications affecting CNTN6 are thought to be involved 
in variable neuropsychiatric phenotypes178. The participants with CNTN6 duplication 
CNVs both presented with mild ID. One had schizophrenia and personality disorder, 
and one had challenging behaviours and had been convicted of a serious criminal 
offence. Interestingly, the participant with schizophrenia and personality disorder also 
had a duplication in the CNTN4 gene. CNVs affecting CNTN4 are also thought to 
confer risk for various NDDs179. As CNTN4 is an important paralog of CNTN6, it may 
be that a double hit in both of these genes results in a more severe phenotype as 
multiple genes are affected in the same pathway. 
Second, two participants with CNV duplications at the 9q21.32q21.33 locus were 
identified encompassing the SLC28A3 and NTRK2 genes. SLC28A3 is a nucleoside 
transporter involved in the regulation of multiple processes, including 
neurotransmission; however, there are no prior reports of its role in psychiatric risk. 
NTRK2 is a receptor tyrosine kinase with numerous neurodevelopmental functions, 
including synapse formation and plasticity. Altered NTRK2 expression has been 
identified in the brains of patients with schizophrenia180. One participant had severe 
ID and BPAD, and the other had mild ID and unspecified non-organic psychosis. 
Third, five participants with exonic CNVs in the CHD gene family were identified. 
The CHD proteins are involved in chromatin structure remodeling and the epigenetic 
regulation of transcription. Three of the participants had exonic CNVs (2 duplications, 
1 deletion) in the CHD8 gene at 14q11.2, which also encompass SUPT16H. The 
protein encoded by the SUPT16H gene is thought to be involved in DNA replication 
and repair. CNV deletions affecting CHD8 and SUPT16H were initially described in 
children with DD and dysmorphic features181. Variants in the CHD8 gene are thought 
to confer a phenotypic subtype of ASD, comprising macrocephaly, facial 
dysmorphologies and gastrointestinal abnormalities182. Both deletions183 and 
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duplications184,185 affecting CHD8 and SUPT16H have been described with variable 
neurodevelopmental phenotypes. The two participants with CNV duplications both 
had severe ID, one was diagnosed with schizophrenia and the other with BPAD. The 
participant with the CNV deletion also had severe ID and ASD. 
Finally, two participants with exonic CNVs in the CHD2 gene at 15q26.1 (one deletion 
and one duplication) were identified. Several patients have been described with CHD2 
deletions; with a common phenotype of ID, epilepsy, and aggressive challenging 
behaviours186,187. To our knowledge, a CNV duplication in CHD2 has not previously 
been described in the literature. The deletion carrier had severe ID and schizoaffective 
disorder, and the duplication carrier had challenging behaviours and BPAD. Both 
patients also had an epilepsy phenotype. 
4.5 Discussion 
Previous investigations in this novel patient group of adults with co-morbid ID and 
psychiatric disorders identified a diagnostic yield of 11% pathogenic CNVs174. 
Combining this with data from two additional European research sites, this finding is 
replicated with a higher yield of 13% pathogenic CNVs in 599 participants (or 13.9% 
with the previously reported cases removed). There were similar rates of pathogenic 
CNVs across the separate research sites, making this a relatively robust finding of a 
high diagnostic yield in this patient group.  
In the study described in Chapter 3 the majority of pathogenic CNVs were found to 
occur at recurrent loci, which have been independently implicated in risk for various 
NDDs. This pattern was also seen in the GENMID consortium study, with 70% of 
pathogenic CNVs being identified at NDD risk loci. Out of 63 NDD risk loci, 
described by Rees et al., carriers were identified at 23 of the loci. It is unsurprising that 
no carriers were identified in the remaining 40 loci, as these CNVs are very rare with 
reported frequencies in ID between 0.01-0.26% (mean = 0.06%)97. Presuming that 
there is an additive effect of having both ID and a co-morbid psychiatric disorder, then 
one would expect to see an increased frequency of the 63 NDD CNVs. Indeed, the 
cumulative frequency was significantly higher, as compared to both ID/ASD 
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populations not selected for psychiatric co-morbidity and individuals with 
schizophrenia.  
One complication in interpreting these findings is that the ID/ASD population is poorly 
phenotyped. For example, the phenotypic information from Coe et al.46, from which 
many of these participants were derived, states that 73% of the cases suffer from ID, 
DD and/or ASD, with the remaining cases either having congenital abnormalities or 
not being annotated. Firstly not all of the individuals had ID, and secondly it is unclear 
what proportion of the cohort have an ASD diagnosis. All participants in the GENMID 
cohort had ID plus challenging behaviour and/or one or more psychiatric diagnoses, 
so overall the participants will be more severely affected. However the exact 
differences between the cohort is unknown, particularly as the ID/ASD sample was 
derived from paediatric cases and many patients may have gone on to develop later-
onset psychiatric diagnoses. 
The phenotypic presentation of the majority of NDD CNV carriers is highly variable, 
both in terms of the level of ID and the psychiatric diagnoses. This indicates a broader 
role for genes within NDD CNV loci in conferring general, as opposed to disorder 
specific, psychiatric risk. Although, previous research has highlighted that NDD loci 
can show a complex pattern of both shared and distinct risk for NDDs108. Extremely 
large sample sizes will be required to further delineate these loci specific associations. 
Interestingly, at least one CNV carrier at each of the five most frequent loci has a 
psychosis phenotype. Of particular interest are the four carriers of the 16p12.1 
deletion, which was significantly associated with risk for schizophrenia by Rees et 
al.97. The rate in the schizophrenia cohort was found to be 0.16% (33/20403), whereas 
we identified a higher rate of 0.67% (4/599) in the GENMID cohort. Three of the four 
carriers had a psychosis phenotype, offering further support for this locus as a risk 
factor for both ID and psychotic disorders. Previously, in Chapter 3, an enrichment of 
the 16p11.2 duplication (2%) was identified as compared to the frequencies reported 
in other studies. Analysis of this CNV in a larger cohort has identified a lower overall 
frequency (0.8%), although it still remains one of the most frequent CNVs identified 
in adults with co-morbid NDDs. 
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In addition to the CNVs identified at known NDD loci, a further 26 CNVs were 
reported as pathogenic by the clinical genetic services. The majority of these were 
large deletion CNVs (1.7Mb-13.2Mb), which overlapped CNVs described in single 
case reports in the existing literature. This group of CNVs are likely to be extremely 
rare and thus would not be observed at high enough frequencies in existing case-
control studies. A clear unidirectional relationship between psychiatric diagnoses, 
level of ID and CNV pathogenicity could not be identified. It is possible that this partly 
reflects the difficulty of diagnosing psychiatric disorders and assessing ID severity in 
individuals with ID and delineation of this relationship requires larger sample sizes.  
Following a literature review of likely pathogenic CNVs that recur, support is provided 
for neurodevelopmental candidate genes which have been implicated in previous 
literature. Unlike the pathogenic CNVs, the likely pathogenic CNVs supporting 
existing NDD candidate loci were small (<1Mb) and affected only a small number of 
genes. There is a growing body of literature for the role of the CNTN and CHD gene 
families in risk for ID and co-morbid psychiatric disorders. Again, there appears to be 
a highly variable phenotype associated with CNVs affecting these genes. Further 
research will be required to consider the clinical implications of these CNVs, which 
were not reported as pathogenic by the clinical genetics services. 
One of the limitations of this study is that there were some differences between the  
recruitment strategies at the different sites, for example participants were recruited 
from in-patient psychiatric services in Leuven and primarily outpatient services in 
Catalonia and England. Most individuals lacked inheritance data, which is a valuable 
aid in categorisation of rare variants and may have led to an underestimate of the 
diagnostic yield. Different array CGH platforms were utilised to detect the CNVs at 
the different sites; however, as all the platforms used were high resolution this is 
unlikely to have major effects. For the phenotype analysis the ID levels were 
categorised into two broader groups, which resulted in participants with different 
levels of ID being classified together. Finally, further characterisation of the 
relationship between NDD risk CNVs and associated phenotypes would require much 
larger case-control samples or epidemiological based studies. 
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4.6 Conclusion 
A 13% rate of undiagnosed pathogenic CNVs was detected in adults with idiopathic 
ID and co-morbid psychiatric disorders, which is much higher than in studies of 
schizophrenia alone. Consistent with the findings of Chapter 3, this suggests that if 
CMA is going to be offered more widely in psychiatric practice, ID psychiatry services 
should be a priority for increased testing. Replicating the findings of Chapter 3, the 
majority of CNVs were identified at recurrent loci – with 70% of pathogenic CNVs 
being identified at established NDD risk loci. The high rates of CNVs at established 
NDD loci support a model whereby the frequency of NDD CNVs increases with the 
severity of the phenotype. Studying this adult population also facilitates description of 
psychiatric and medical associations across the life course, for both pathogenic CNVs 
and likely pathogenic candidate loci.    
  103 
Chapter 5 Delineating the psychiatric and behavioural phenotype 
of recurrent 2q13 deletions and duplications 
Parts of this chapter have been adapted from the following published journal article:  
Wolfe, K., McQuillin, A., Alesi, V., Boudry Labis, E., Cutajar, P., Dallapiccola, B., 
Dentici, M.L., Dieux-Coeslier, A., Duban-Bedu, B., Duelund Hjortshøj, T., Goel, H., 
Loddo, S., Morrogh, D., Mosca-Boidron, A.L., Novelli, A., Olivier-Faivre, L., Parker, 
J., Parker, M.J., Patch, C., Pelling, A.L., Smol, T., Tümer, Z., Vanakker, O., 
Haeringen, A.V., Vanlerberghe, C., Strydom, A., Skuse, D., Bass, N. (2018) 
Delineating the psychiatric and behavioural phenotype of recurrent 2q13 deletions and 
duplications. American Journal of Medical Genetics Part B: Neuropsychiatric 
Genetics. PMID 29603867. 
I designed the study, undertook participant recruitment, data analysis and wrote the 
manuscript. Support with recruitment and participant phenotyping: AV, E. BL, PC, 
BD, M.L D, A D-C, B D-B, T. DH, HG, SL, DM, A.L M-B, AN, L O-F, JP, M.J P, 
CP, A.L P, TS, ZT, OV, A.V. H, CV, Support with study design and data analysis: 
AM, AS, DS, NB. Critical review of the manuscript was undertaken by all authors. 
5.1 Introduction 
In Chapter 3 an individual with a recurrent CNV at chromosome locus 2q13 was 
identified. Whilst this is classed as a recurrent CNV, in that it is flanked by LCRs and 
thus the same CNV has arisen at 2q13 in multiple independent individuals, very few 
patients with this CNV have been described in published studies. For example, the 
latest large study of 2q13 deletions presented a summary of 29 patients from all 
previous published studies156, and even fewer published case series of 2q13 
duplication patients exist. The addition of detailed phenotypic information to very 
rarely observed CNVs could be beneficial for patient clinical management. It is 
particularly pertinent to study psychiatric and behavioural phenotypes, which have 
been less well explored in the existing literature. 
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Investigation of chromosomal rearrangements in regions of LCRs, identified 2q13 
CNVs in patients with developmental disorders188. However, the pathogenicity of 
these CNVs was initially described as of uncertain significance. This was due to a 2q13 
duplication also being found in a healthy control188 and the findings from a previous 
study that the same 2q13 deletion in two siblings with developmental problems had 
been inherited from an unaffected parent189.  
Analysis of larger samples revealed that 2q13 CNVs are associated with an increased 
risk of DD and ID. Cooper et al. reported 12 deletions and 9 duplications in cases 
(N=15,767) and observed 1 deletion and 0 duplications in controls (N=8,329). They 
found an enrichment of the deletion (P=0.032) and duplication (P=0.022) in cases, as 
compared to controls. The deletion was associated with cardiovascular disorders, 
whereas the duplication was associated with craniofacial features45. Yu et al. described 
the phenotype of five 2q13 patients alongside 14 additional cases from a literature 
review, concluding that 93% of individuals had impaired development and 63% had 
facial dysmorphisms190. Some of these patients had a diagnosis of ASD or ADHD, 
although many were too young for clinical assessment, or it was unclear whether 
assessments had taken place.  
Costain et al. found 2q13 CNVs to be significantly associated with schizophrenia 
(P=0.0002) in a community-based schizophrenia cohort (N=459), as compared to a 
large population-based control sample (N=23,838)157. They identified three 2q13 CNV 
carriers (one deletion, two duplications) in cases and four CNV carriers (one deletion, 
three duplications) in controls. However, subsequent case-control studies in larger 
schizophrenia patient cohorts have failed to find a significant association at the 2q13 
locus 59,97. In a follow up study Costain et al. (2014) undertook detailed phenotyping 
with two unrelated 2q13 duplication carriers and their families, identified in the 2013 
study. Four family members, from one patient pedigree, also carried the duplication 
and this co-segregated with a neuropsychiatric phenotype. There was a variable 
psychiatric phenotype, with one psychotic disorder, two major mood and/or anxiety 
disorders, and one mood and/or anxiety disorder and obsessive compulsive disorder 
(OCD). The original patient with schizophrenia also had OCD. None of these 
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individuals had significant DD, ASD or facial dysmorphisms, although three of the 
family members and one patient had learning difficulties191. 
Riley et al. identified three 2q13 deletion carriers and one 2q13 duplication carrier, 
and compared the phenotype with previous published cases. They concluded that 
congenital heart defects, hypotonia, dysmorphic features, and abnormal head size are 
common in deletion carriers and developmental delay, dysmorphic features and 
abnormal head size are common in duplication carriers. No ASD or psychiatric 
phenotype was described in these patients, likely because they were too young for 
clinical assessment192. Finally, Hladilkova et al. described two additional 2q13 
deletion patients, one of whom has ASD and ADHD156. 
A large study of rare CNVs estimated the rate of occurrence of 2q13 deletions and 
duplications in healthy controls (0.004% deletions, 0.015% duplications), 
schizophrenia (0.015% deletions, 0.02% duplications) and a mixed developmental 
disorders (predominantly DD/ID and ASD) cohort (0.057% deletions, 0.022%, 
duplications)97. This suggests that 2q13 CNVs can be observed in healthy controls, but 
are more common in psychiatric and DD/ID cohorts. The 2q13 CNV is now 
understood to be a susceptibility locus, which describes a CNV that can be inherited 
from a healthy or mildly affected parent, but is enriched in individuals with various 
developmental disorders35.  
A limitation of current 2q13 CNV literature is that few studies have undertaken 
comprehensive behavioural and psychiatric phenotyping, so the full extent of the 
neuropsychiatric risk associated with these CNVs remains unclear.  
5.2 Aims 
This investigation aims to further delineate the 2q13 CNV profile by undertaking deep 
phenotyping comprising: developmental, medical, dysmorphic, behavioural and 
psychiatric features. 
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5.3 Methods 
5.3.1 Participant recruitment 
In order to maximise recruitment of patients with this rare CNV a multi-faceted 
approach to recruitment was employed. Unique is a UK-based support group, working 
internationally to inform and support anyone affected by a rare chromosome or single 
gene disorder and with professionals involved in their care193. The Unique Information 
Officer identified and emailed registered contacts of Unique members with 2q13 
CNVs. Information was provided about the study, and contacts were encouraged to 
contact the study team if they wanted to participate. Patients with 2q13 deletions were 
also identified via two NHS RGCs – the North East and South East Thames RGCs 
(Great Ormond Street Hospital for Children NHS Trust and Guy's and St Thomas' 
NHS Foundation Trust respectively). Clinicians were approached in the first instance 
and where appropriate invitations to participate in the study were sent to the patient 
contact via letter. All participants recruited by KW either lacked capacity to consent 
to the research, or were deemed too young to provide consent, and consent was 
provided by a parent for participation in the study. Additionally, patients with 2q13 
CNVs on the DECIPHER database were identified and further phenotypic information 
was sought from responsible clinicians152. One participant was included from a 
previous investigation of CNV in adults recruited from ID psychiatry services174. 
Ethical approval for the study was attained from the North Wales Research Ethics 
Committee West, reference 11/WA/0370.  
5.3.2 Phenotyping and analysis protocol 
All participants recruited through Unique and NHS RGCs underwent detailed 
phenotyping (n=10), whereby clinical data, including medical and psychiatric history, 
was collected from a parent in a face-to-face interview. This was conducted by KW 
and interviews were undertaken in person for UK recruits and via Skype for overseas 
recruits. Responsible DECIPHER contacts were contacted via email to provide further 
phenotypic data about their patients and anonymised data was collected via the UCL 
web-based survey tool Opinio (n=15).  
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All phenotypes were converted to Human Phenotype Ontology (HPO) terms for 
presentation in the manuscript194. The level of ID was taken from available medical 
records or reported by clinicians and was categorised in accordance with the HPO 
criteria: borderline intellectual disability (IQ 70-79); mild intellectual disability (IQ 
50-69); moderate intellectual disability (IQ 35-49); severe intellectual disability (IQ 
20-34).  
Psychiatric phenotyping was undertaken using the Mini PAS-ADD for participants 
over 18 years of age, and the Child and Adolescent Psychiatric Assessment Schedule 
(ChA-PAS) for those under 18. These assessments provide threshold scores for 
psychiatric symptoms that are likely to warrant a diagnosis in conjunction with a 
clinical psychiatric assessment147. The Mini PAS-ADD includes ASD screening, but 
does not include an ADHD assessment. The ADHD section of the CHA-PAS requires 
a second informant, who is familiar with the individual in other contexts (typically a 
teacher). It was not possible to interview a second informant for the ChA-PAS, so both 
sections were completed by the primary informant.  
Behavioural phenotyping was undertaken using the Behaviour Problems Inventory - 
Short Form (BPI-S). The BPI-S provides frequency scores of self-injurious and 
aggressive/destructive behaviours195. Behaviours were reported as present if they were 
scored at a minimum of a weekly frequency on the BPI-S measure or were documented 
in the medical history. General observations for dysmorphic features were also made 
and photographs taken where consent given. Dysmorphic features were independently 
verified by a second investigator (NB, Consultant Psychiatrist).  
Analyses and data visualisation were undertaken using R version 3.4.2 and the ggplot2, 
Rcmdr and ontologyX packages173,196–198. For the breakdown of CNV carriers for each 
phenotype, deletion and duplication will be abbreviated to del and dup. 
5.4 Results 
5.4.1 Sample description 
A total of 25 participants were recruited to the study, 10 from the Unique and NHS 
RGCs group and 15 from the Decipher group (64% male). The participants are 
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predominantly children (23/25 <18 years of age, median age 9 years, range 4-42 years). 
The dataset comprises 21 deletion and 4 duplication carriers. The CNVs ranged in size 
from 1.4Mb to 2.1Mb with a 1.3Mb region of overlap between all CNVs, see Figure 
5-1. One family with an inherited 2q13 deletion is included in the case series, a father 
and two children, as removing the family did not change the results they are presented 
together with the rest of the cohort.  
Figure 5-1: Chromosomal location of the CNV breakpoints for 2q13 CNV carriers  
 
The top image shows the chromosomal location of the CNV, with the region highlighted by a red box, 
CNV deletions are shown in red and CNV duplications are shown in green, UCSC genes included in 
the CNV are shown, the blue highlighted region shows the 1.3Mb region of overlap between CNVs, the 
image was exported from UCSC in chromosomal build GRCh37/hg19. 
 
5.4.2 Inheritance status 
For 32% of participants the inheritance status was unknown (9 del, 1 dup). These were 
all participants from the DECIPHER group, where inheritance information was 
unavailable to responsible clinicians. A further 20% (5 del) had de novo CNVs, 12% 
(2 del, 1 dup) had a maternally inherited CNV, 28% (5 del, 2 dup) had a paternally 
inherited CNV, and finally 8% had inherited CNVs but the parental origin was 
unknown. Focusing on the 12 individuals with inherited 2q13 CNVs, 4 (34%, 2 del, 2 
dup) had no family history of ID or mental health problems, 5 had a family history of 
ID and/or mental health problems (42%, 5 del), and 3 (25%, 2 del, 1 dup) had a family 
history of ID and/or mental health problems only on the side of the family from which 
the 2q13 CNV was not transmitted. 
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5.4.3 Intellectual and learning difficulties 
Overall 76% of participants had DD (15 del, 4 dup). Just over half the participants had 
an IQ in the borderline or average range (52%, 10 del, 3 dup), and (32%, 8 del) had 
mild ID. There were no individuals with moderate ID and 12% had severe ID (2 del, 
1 dup). We also asked informants or clinicians whether the participants had any other 
specific learning difficulties, 4 participants (16%) had dyslexia, 2 participants (8%) 
had dyscalculia, and 2 participants (8%) had an auditory processing disorder (all these 
were identified in del carriers only). 
5.4.4 Psychiatric disorders and challenging behaviours 
In total 64% of participants had a formal psychiatric diagnosis, amongst these 44% (9 
del, 2 dup) had one diagnosis and 20% (4 del, 1 dup) had two. The most frequently 
diagnosed psychiatric disorder was ADHD (44%, 9 del, 2 dup), followed by ASD 
(24%, 5 del, 1 dup) and anxiety disorders (12%, 2 del, 1 dup). Both aggressive and 
self-injurious behaviours were also identified in the participants, 8 had aggressive 
behaviours (32%, all del) and 8 had self-injurious behaviours (32%, 7 del, 1 dup), for 
an overview see Figure 5-2. 
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Figure 5-2: Clinically diagnosed psychiatric disorders and behavioural phenotype in 2q13 
deletion (n=21) and duplication (n=4) carriers 
 
Y axis: count - the number of participants with the diagnosis or behaviour; X axis: ADHD, attention 
deficit hyperactivity disorder, Aggressive, aggressive behaviours, Anxiety, anxiety disorder, Autism, 
autism spectrum disorder, Mood disorder, ODD, oppositional defiant disorder, Self-injurious, self-
injurious behaviours.  
 
Of the detailed phenotyping group (n=10), 5 had no clinical psychiatric diagnosis. For 
two of these participants, both aged 6, ADHD was suspected, but the families were 
awaiting formal clinical assessment. Additionally, ASD was suspected for one of these 
participants. Taking into account the PAS-ADD thresholds, 9/10 individuals reached 
one or more PAS-ADD thresholds. The most frequent thresholds met were anxiety 
disorder (60%, all del) and manic episode (60%, 5 del, 1 dup) followed by 20% each 
for ADHD, depressive disorder and psychosis (all del), see Figure 5-3. 
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Figure 5-3: PAS-ADD thresholds met in the 10 participants in the detailed phenotyping group (9 
deletion and 1 duplication carrier) 
     
Y axis: totals - number of participants with the diagnosis or behaviour, X axis: Thresholds on the 
PAS-ADD or CHA-PAS assessments, ADHD, attention deficit hyperactivity disorder, ASD, autism 
spectrum disorder, OCD, obsessive compulsive disorder.  
5.4.5 Medical phenotype 
The most commonly observed phenotypes were; glue ear (40%, 9 del, 1 dup), followed 
by muscular hypotonia (32%, 7 del, 1 dup), sleep disturbances (28%, 6 del, 1 dup), 
arthralgia (24%, 6 del), recurrent infections of the middle ear (20%, 4 del, 1 dup), joint 
hypermobility (20%, 5 del), and gastroesophageal reflux (16%, 4 del). See Figure 5-4 
for an overview of the systems affected.  
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Figure 5-4: Human Phenotype Ontology tree plot with ancestral ontologies for the medical 
phenotypes occurring in more than three participants 
 
5.4.6 Dysmorphology phenotype 
The most commonly observed phenotypes were: macrotia (32%, 8 del), abnormality 
of the skull (28%, 4 del, 3 dup), macrocephaly (16%, 4 del), upslanted palpebral fissure 
(16%, 3 del, 1 dup), hypertelorism (16%, 4 del), strabismus (16%, 2 del, 2 dup), and 
depressed nasal bridge (16%, 4 del). See Figure 5-5 for an overview of the systems 
affected.  
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Figure 5-5: Human Phenotype Ontology tree plot with ancestral ontologies for the 
dysmorphology phenotypes occurring in more than three participants 
 
5.4.7 Comparison with previous literature  
To combine phenotypic data for all published 2q13 CNV carriers the dataset initially 
presented by Hladilkova et al. has been adapted (permission via personal 
correspondence)156. All the patients presented are derived from patient case studies, as 
equivalent phenotypic data was not available for healthy controls carrying these 
CNVs. For deletion carriers, the cases presented by Hladilkova et al. have been added 
together with new cases from subsequent literature and the cases presented in this 
study. An equivalent version of the dataset has also been compiled for 2q13 duplication 
carriers. Table 5-1 presents an overview of all known 2q13 deletion and duplications 
carriers to date and the phenotypes observed, note the denominator differs due to the 
varying availability of phenotypic information in published case studies.
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Table 5-1: Summary of phenotypic observations in 2q13 participants in conjunction with 
patient phenotypes presented in previous published studies 
 2q13 deletions 2q13 duplications 
DD/ID 30/38 (79%) 14/20 (70%) 
ASDs 9/27 (33%) 2/12 (17%) 
ADHD/ADD 12/25 (48%) 3/5 (60%) 
Dysmorphic features 34/40 (85%) 9/10 (90%) 
Heart defect 9/34 (26%) 0/5 (0%) 
Hypotonia 16/34 (47%) 3/7 (43%) 
Seizures 9/31 (29%) 0/10 (0%) 
Macrocephaly 10/34 (29%) 1/7 (14%) 
Microcephaly 7/34 (21%) 2/7 (29%) 
DD, developmental delay, ID, intellectual disabilities, ASDs, autism spectrum disorders, ADHD, 
attention deficit hyperactivity disorder. 
5.5 Discussion 
CNVs at the 2q13 locus are rare in the population, can be observed in healthy controls 
and transmitted from unaffected parents. Despite this, multiple studies have now 
shown that CNVs at 2q13 are risk factors for DD and dysmorphisms. This study 
represents the largest ever case series of 2q13 patients, comprising detailed phenotypic 
data for 25 new cases and combined analysis in 77 individuals, refining our 
understanding of the phenotypic associations of CNVs at the 2q13 locus. 
DD was identified in 76% of participants in this study. Combined with all available 
data from existing literature 79% of deletion carriers and 70% of duplication carriers 
have DD/ID. This phenotype has been further delineated by investigating the level of 
ID, which revealed that the intellectual impairment is generally mild with 52% of 
participants having IQ in the borderline or average range. Only 12% of participants 
had severe ID, and data available for two of these participants in the detailed 
phenotyping group revealed that both were referred for further exome sequencing 
investigations, due to the 2q13 CNV not being thought to fully explain their phenotype.  
Combined analysis reveals that 80% of 2q13 deletion carriers and 90% of 2q13 
duplication carriers have dysmorphic features. Deep phenotyping in the new cases 
showed that macrotia, abnormalities of the skull, macrocephaly, upslanted palpebral 
fissures, hypertelorism, strabismus, and depressed nasal bridge were common in 
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deletion carriers. In duplication carriers, abnormalities of the skull and strabismus were 
observed. No other features achieved more than a single occurrence, however there 
were only 4 individuals who had 2q13 duplications. Combined analysis identified 29% 
of deletion carriers and 14% of duplication carriers as having macrocephaly and 23% 
of deletion carriers and 29% of duplication carriers as having microcephaly. 
Previous 2q13 CNV literature has described congenital heart defects, hypotonia and 
seizures as associated medical phenotypes. Combined analysis found that 31% of 
deletion carriers had heart defects, and this phenotype was not observed in duplication 
carriers. Combined analysis identified 44% of deletion carriers and 43% of duplication 
carriers as having hypotonia, supporting previous results on the association of the 2q13 
deletion with this feature and extending this to also affect duplication carriers. Seizures 
were only observed in deletion carriers at a frequency of 26%. Deep phenotyping in 
this study also associated novel medical phenotypes with 2q13 CNVs, including: glue 
ear, sleep disturbances and recurrent infections of the middle ear, both in deletion and 
duplication carriers, and arthralgia, joint hypermobility and gastroesophageal reflux in 
deletion carriers only. 
A limitation of published 2q13 case reports is that many are in young children, who 
are below the typical assessment age for various psychiatric disorders. Also, it is 
unclear in some studies whether comprehensive behavioural and mental health 
assessments have taken place. The new cases presented in this study had a median age 
of 9 years, and 64% already had a clinical psychiatric diagnosis. Some of the remaining 
participant either had suspected psychiatric disorders, which had yet to be formally 
tested, or met PAS-ADD thresholds, indicating that this figure could be even higher. 
To our knowledge, challenging behaviours have never previously been assessed in 
2q13 CNV carriers and we found both aggressive and self-injurious behaviours to be 
present in deletion carriers and self-injurious behaviours in one duplication carrier. 
Despite the aforementioned limitations, previous case reports of individuals with 2q13 
CNVs have reported both ASD and ADHD diagnoses. Combining analysis identified 
48% of deletion carriers and 60% of duplication carriers as having an ADHD 
diagnosis, and 33% of deletion carriers and 17% of duplication carriers as having an 
ASD diagnosis. Both 2q13 deletions and duplications have also been identified in 
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schizophrenia patients. We did not identify any participants with schizophrenia, 
although only three individuals were over the age of 16, so the typical age of onset was 
not reached in most individuals. Our study identifies a strikingly high incidence of 
ADHD in 2q13 CNV carriers. A literature review of genes in the 2q13 region was 
undertaken and no prior association of genes in this region with risk for ADHD was 
identified, although postulations have been made about the involvement of genes in 
the region in other neuropsychiatric phenotypes. 
A 1.3Mb common region of overlap was identified in CNV carriers, disrupting four 
genes: ACOXL, BCL2L11, ANAPC1 and MERTK. It has been suggested that disruption 
of the ACOXL and BCL2L11 genes may contribute to neurodevelopmental and ASD 
phenotypes190. The ACOXL gene encodes a protein responsible for fatty acid 
oxidisation, alterations in fatty acid metabolism have been proposed to play a role in 
the pathogenesis of ASD199. BCL2L11 encodes a neuronal apoptosis regulator and 
previous research has found decreased expression of this gene in the frontal cortex and 
cerebellum of autistic subjects. It has been hypothesised that an increase in apoptosis 
in these regions may contribute to the pathogenicity of autism200. ANAPC1, a 
neurodevelopmental facilitator, and MERTK, a TAM receptor and multiple sclerosis 
risk gene, have also been proposed as candidate genes for the psychosis phenotype of 
2q13 CNV carriers157. All but one participant had CNVs which extend distally to 
include FBLN7 and TMEM87B. Russell et al. undertook a functional analysis of 
candidate genes in the 2q13 region using zebrafish morpholino knockdowns. They 
found that depletion of FBLN7 and TMEM87B orthologues resulted in cardiac 
hypoplasia and FBLN7 additionally was associated with craniofacial abnormalities201. 
One theory as to why some CNVs show incomplete penetrance is that a second genetic 
hit is required to unmask the predisposition to a neuropsychiatric phenotype202. None 
of the participants in this study had another CNV that had been classified as 
pathogenic. However, as sequencing data was not available for analysis, it cannot be 
ruled out that the participants had another genetic variant contributing to their 
phenotype. Yu et al. recently identified a paternally inherited variant in the TMEM87B 
gene, one of the genes in the 2q13 region associated with the cardiac phenotype201, in 
a patient with a severe cardiac phenotype who also had a maternal 2q13 deletion. It is 
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thought that the unmasking of this homozygous variant by the maternal deletion acted 
as a second genetic hit, resulting in the severe phenotype 203. The inheritance pattern 
of CNVs was mixed, as was the family history of ID and mental health problems. It is 
of interest that 25% of participants had a family history of ID and mental health 
problems on the other side of the family from which the variant was transmitted. This 
could provide support to the second-hit hypothesis, but further genetic investigations 
would be required.  
One of the benefits of receiving a genetic diagnosis for patients and their families is 
the ability to access diagnosis specific information, which could be used to facilitate 
early intervention screening for associated medical and psychiatric phenotypes. 
Disorder guides, written for both professionals and families, are available for 2q13 
CNVs from the patient support group unique135. The findings from combined analyses 
in this study could also guide clinical management of individuals with newly 
diagnosed 2q13 CNVs, for example screening for ADHD might be considered. 
However, it must be acknowledged that whilst we find some phenotypes to occur more 
frequently, 2q13 CNV carriers still display variable phenotypic outcomes – posing 
challenges for genetic counselling of patients and their families.  
Many studies of rare CNVs have been undertaken in paediatric cohorts, and 
comprehensive psychiatric and behavioural phenotyping has not been carried out. The 
degree to which neuropsychiatric phenotypes are common in rare CNV carriers has, 
therefore, yet to be established – making it difficult to find an appropriate comparison 
group for the frequency of psychiatric diagnoses. The medical and dysmorphology 
phenotypes described are also diverse, and it is difficult to ascertain ‘core symptoms’ 
of the disorder which could be an indicator for genetic testing for 2q13 imbalances. 
However, this study had a comprehensive phenotyping protocol and it may be that a 
similar pattern of diverse phenotypes would be observed if comparable phenotyping 
approaches were to be used in other studies investigating rare neurosusceptability 
CNVs. One unusual finding is that both micro and macrocephaly were present in both 
deletion and duplication carriers, whereas in other CNVs (such as 16p11.2) it is more 
typical to find an excess of one of the phenotypes segregating with the CNV type. 
There is natural variation in head size in the general population and the ideal method 
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of measurement would be deviation from parental means, however it was not possible 
to collect parental measurement in this analysis. It may be that the observations have 
arisen from normal variation, rather than being associated with the 2q13 CNVs. 
Increasing the depth of phenotyping in rare CNV studies is an important avenue for 
future research, as well as conducting ongoing mental health assessments in 2q13 
carriers to elucidate associations with psychiatric disorders across the life course. 
Additionally, further studies of the unaffected parents and healthy controls with 2q13 
CNVs will be important to elucidate potential protective factors. 
The limitations of this study are that observations are being made in participants who 
have presented to clinical services. This may create an ascertainment bias, whereby 
the most severe cases are described. However, the accumulation of cases from a wide 
range of sources attempted to ensure as representative a sample as possible. The 
assessments of dysmorphology were not conducted by a clinical dysmorphology 
expert, although we utilised a second rater to improve the reliability of the 
observations. The PAS-ADD and ChA-PAS schedules were completed by a 
researcher, and clinical verification by a trained psychiatrist did not take place. Some 
of the participants were as young as four, meaning some of the later-onset phenotypes 
could not be accurately measured at this age. However, if anything this would have 
led to an under estimation of the phenotype frequencies.  
5.6 Conclusion 
In the largest study of 2q13 CNVs to date, we present detailed phenotypic data for 25 
new 2q13 deletion and duplication carriers. Combining this with previous literature 
yields a total of 54 deletion and 23 duplication carriers, enabling a refined 
understanding of the phenotypic associations of CNVs at the 2q13 locus. Combined 
analysis predominantly supports existing literature on an increased rate of 
developmental, medical and dysmorphic phenotypes. Psychiatric investigations reveal 
that the majority of deletion and duplication carriers have been clinically diagnosed 
with a psychiatric disorder, with a particularly high incidence of ADHD. This could 
have important implications for psychiatric screening upon clinical diagnosis of 2q13 
CNVs, and further investigation of this region may have some relevance to 
understanding the neurobiology of ADHD.   
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Chapter 6 Relative burden of rare CNVs in different 
neurodevelopmental cohorts 
6.1 Introduction 
The previous chapters have focused on the analysis of CNVs that have already been 
classified (as pathogenic, VOUS and benign) using clinical laboratory protocols for 
variant categorisation. As discussed previously, there are many factors involved in this 
variant classification process. For example, classification parameters include: the size 
and genic content of the CNV, the inheritance status, and population frequencies in 
reference disease and control cohorts. Another methodology used in the research 
literature to test the association of a class of genetic variants is a burden analysis. 
Burden analyses compare the collective frequency of variants in two groups, typically 
cases and controls. Typically, in CNV burden analyses, common CNVs are filtered 
out and the analysis is undertaken on the rare CNVs that are most likely to be 
implicated in disease pathology (<1% population frequency),.  
There are some advantages to undertaking CNV burden analyses for testing the 
differences between groups. Many CNVs are individually rare and evolutionarily 
selected against.  This means that extremely large sample sizes are required to detect 
statistically significant differences in CNV frequencies. Whereas, CNV burden 
analyses enable comparisons of rare CNVs beyond those that are currently deemed 
pathogenic, working under the general assumption that a greater CNV burden is likely 
to be associated with a greater propensity to disease142. 
One of the earliest schizophrenia CNV burden analyses was undertaken by the 
International Schizophrenia Consortium in 2008, comprising 3,391 patients and 3,181 
controls. The analysis focused on rare CNVs (<1% frequency) >100kb in size. 
Controls on average had 0.99 CNVs per person and the rate was increased 1.15-fold 
in patients with schizophrenia to 1.14 CNVs per person. When stratifying by size of 
event, larger (>500kb) deletions were enriched, whilst the opposite was true for 
duplications – with shorter duplications showing a stronger association with disease204. 
Analysis of genome-wide data from case-control studies of DD/ID have also revealed 
an increased CNV burden in DD/ID cases. As discussed previously Coe et al. analysed 
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data from 15,767 children with developmental disorders and 8,329 unaffected adult 
controls. An excess of large CNVs was identified in cases and the effect was more 
pronounced with increasing CNV size. At a threshold of 400kb ~25.7% (4,047 cases), 
compared to 11.5% of the controls harboured a CNV event of this size45.  
Girirajan et al. assessed the relative contribution of CNV burden by undertaking 
analyses in three distinct NDDs – ID, ASD and dyslexia – comprising 1,227 cases and 
337 controls. ID was most associated with a greater CNV burden. The three NDD 
groups were further characterised, as to their phenotypic severity, and it was identified 
that the most severe phenotype is correlated with a greater size of CNV and a greater 
gene density of genes affected by the CNV. The phenotype groups in order of severity 
are: ID with MCA, idiopathic ID, ID with ASD, ASD without ID, dyslexia, controls. 
No differences were identified when segregating by CNV type (deletion and 
duplication), although analysis of inheritance status revealed a trend of increased de 
novo CNVs with increased severity of the disorder140.  
CNV burden has also been investigated in patients with ID and co-morbid 
schizophrenia. Derks et al. studied patients with ID only (n=66), versus patients with 
ID and schizophrenia (n=64). No differences were found in the burden of CNV 
deletions and duplications >100kb in patients with ID only versus patients with ID and 
co-morbid schizophrenia. However, a higher burden of duplications larger than 1Mb 
was identified in patients with ID and schizophrenia. This was largely driven by 
duplications at the 15q11.2 region141. Lowther et al. also investigated CNV burden in 
546 schizophrenia patients who were segregated into various IQ groups, ranging from 
low (< 85) to average (≥ 85) IQ. They identified a significantly (p=0.002) increased 
burden of rare genic duplications in individuals in the low IQ schizophrenia group. 
This higher burden persisted even after excluding individuals with a pathogenic CNV. 
142.  
CNV burden analyses have also been undertaken in  patients with BPAD, however the 
results do not follow the expected trend of an increased CNV burden with increased 
phenotypic severity. In fact, multiple studies have shown that there is actually a 
reduced burden of rare large CNVs in BPAD patients as compared to controls205–207. 
One study by Malhotra et al. investigated parent proband trios with BPAD (n=185) 
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and healthy controls (n=426) and found an increased frequency of large de novo CNVs 
in BPAD patients. However, this effect only remained significant when considering 
BPAD cases with an age of onset below 18 years of age208. Noor et al. also found no 
increased burden of CNVs in BPAD cases as compared to controls209.  
Marshall et al. conducted the largest genome-wide CNV burden analysis for any 
psychiatric disorder to date, comprising 21,094 schizophrenia cases and 20,227 
controls. Several parameters were significantly greater in schizophrenia cases, as 
compared to controls, including: total CNV distance (kb) covered, number of genes 
affected by CNVs and the number of CNVs. When split by CNV type, the effect size 
for CNV deletions was greater than for CNV duplications. Interestingly, this 
enrichment in CNV burden persisted even after exclusion of CNV loci implicated as 
schizophrenia risk factors in previous studies. Furthermore, CNV burden was enriched 
for  genes associated with synaptic function and neurobehavioral phenotypes in mice59. 
There are now several lines of evidence to support the theory that there is an increased 
CNV burden as the severity of the NDD phenotype increases. ID is generally the most 
severe phenotype observed – although ID with MCA or ID with co-morbid 
schizophrenia are more severe phenotypes associated with a greater CNV burden. 
BPAD is the only psychiatric phenotype, that has been systematically investigated, 
which does not have an increased CNV burden as compared to controls. It is also 
towards the milder end of the spectrum of developmental and psychiatric disorders 
investigated. Some studies only find this increased CNV burden to be true for certain 
types of CNV and for CNVs of particular size. For example, in ID patients with co-
morbid schizophrenia CNV duplications appear to be driving the significant 
differences in CNV burden. In one study, the significant difference was further limited 
duplications larger than 1Mb. To the best of my knowledge, no previously published 
study has compared the CNV burden between ID plus co-morbid mental disorders and 
schizophrenia.  
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6.2 Aims 
The aim of this analysis is to compare CNV burden in a cohort of patients with ID plus 
co-morbid psychiatric disorders (ID+) with CNV burden in schizophrenia patients and 
healthy controls. The impact of CNV size and type will also be considered. 
6.3 Methods 
6.3.1 Sample collection and DNA preparation 
The samples analysed in this section comprise participants from the DNA variation in 
adults with learning disability sample, described in Chapter 3 and Chapter 4, for which 
genomic DNA was available for analysis (n=228 out of N=248). Participants with 
large-scale chromosomal abnormalities were excluded from the analysis. Sample 
collection for this dataset has been described in Chapter 3. The UCL schizophrenia 
and control samples were derived from the DNA polymorphisms in Mental Illness 
(DPIM) study have been described elsewhere210. Briefly, patients with a clinical ICD-
10 diagnosis of schizophrenia were recruited through NHS services. Diagnoses were 
confirmed and additional phenotypic data collected with the Schizophrenia and 
Affective Disorders Schedule (SADS-L)211. Controls were recruited with an absence 
of personal history of mental illness as well as an absence of mental illness in first-
degree relatives. Data from a subset of the schizophrenia (N=1529), BPAD (N=1445) 
and control (N=1285) cohorts were used in this analysis. For the ID+ sample 17% of 
the sample (38/228) were of non-European ancestry, all of the DPIM participants were 
of European ancestry. DNA extraction for the ID+ study was undertaken at the North 
East Thames Regional Genetics Service Laboratory and for the DPIM sample DNA 
was extracted in-house. DNA quantifications were undertaken using the Qubit 
quantification protocol212. A number of students and Post-Doctoral researchers 
quantified the DNA samples from the DPIM study, I personally quantified all the 
samples for the ID+ study.  
6.3.2 Genotyping and Quality Control 
The PsychChip, also known as the PsychArray, is a high density (>500,000 markers) 
customised microarray chip containing 265,000 proven tag SNPs found on the 
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Infinium Core-24 BeadChip, 245,000 markers from the Infinium Exome-24 
BeadChip, and 50,000 markers known to be associated with psychiatric disorders213. 
For the DPIM samples genotyping was performed at the Broad Institute of MIT and 
Harvard and the ID samples were genotyped at the University of Bonn.  
Quality control of the data was undertaken in PLINK214. Samples were excluded if 
they: did not match the SNP sex, if they had excessive heterozygosity (more than 5 SD 
above the mean, measured using common SNPs, MAF>0.05), if more than 5% of the 
SNPs genotyped had missing information, and SNPs failing Hardy-Weinberg 
equilibrium (HWE), a test which measures if the observed allelic distribution fits 
within the expected distribution. This is in line with quality control protocols described 
in relevant literature215. 
For the ID+ dataset the PsychChip raw intensity files, (*.idat), were converted into 
*.gtc files via Illumina’s GenomeStudio software216, *.gtc files were supplied by the 
Broad Institute for the DPIM samples. The signal intensity file was exported from 
GenomeStudio containing, SNP information, B allele frequency (BAF) and log R ratio 
(LRR). The BAF is a normalised representation of how often the B allele is called. A 
normal BAF plot has three distinct bands, with homozygous calls at the top and bottom 
and heterozygous in the middle. Absence of the middle band could be indicative of a 
CNV deletion, whereas the presence of extra bands could be indicative of a CNV 
duplication. LRR is a metric that normalises signal intensity for CNV analysis, when 
the fluorescence values are above 0 this might indicate a CNV duplication and 
florescence below 0 could indicate a CNV deletion. See Figure 6-1 for an example of 
the BAF and LRR plots exported from GenomeStudio for an individual from the ID+ 
sample. Data was exported from GenomeStudio for the ID+ sample in accordance with 
the methods described on the PennCNV website217. 
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Figure 6-1: CNV plots for a participant with a CNV deletion on chromosome 5 
 
 
Plots exported from GenomeStudio, The top image shows the log R ratio (LRR) and B allele 
frequency (BAF) of each marker, with the CNV deletion region highlighted, below is the region of 
chromosome 5 that is affected and the implicated genes, the bottom image has the same content as the 
top but the perspective is zoomed out to show the whole of chromosome 5. 
6.3.3 CNV calling in PennCNV 
Postdoctoral Researcher Dr Johan Thygesen wrote the scripts ‘prep_calling.sh’, 
‘call_cnvs_array.sh’, and ‘post_calling.sh’, to call the CNVs via PennCNV for the 
DPIM dataset. I ran these scripts to call the CNVs for the ID+ dataset to ensure 
methodological consistency. The script ‘prep_calling.sh’ modifies the signal intensity 
file to the format which is accepted by PennCNV. The script ‘call_cnvs_array.sh’ calls 
CNVs from the signal intensity data using the PennCNV algorithm. Finally, the 
‘post_calling.sh’ script performs post calling quality control checks. These scripts 
were created in accordance with the CNV calling guidelines on the PennCNV 
website218. Samples with more than 300 CNVs, with a BAF drift bigger than 0.01 and 
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with a LRR SD bigger than 0.5 were removed. Copies of these scripts are available in 
the appendix. Both autosomal and X chromosome CNVs were called. The X 
chromosome is of particular interest to the ID phenotype, given that 5-10% of ID in 
males is caused by genetic variants on the X chromosome and over 150 X linked ID 
syndromes have been identified219. It is typical to undertake X chromosome burden 
analyses separately for males and females, given the sex differences in the number of 
X chromosomes. The participants in the ID+, schizophrenia, and healthy control 
groups with CNVs called on the X chromosome were separated by sex, see Table 6-1. 
It was not possible to undertake the X chromosome analysis segregated by sex given 
the low number of females in the ID+ group. The analysis protocol will therefore focus 
on autosomal CNVs. 
Table 6-1 The number of males and females with X chromosome CNV calls in the three 
participants groups 
  Female (%) Male (%) 
Controls 266 (20.7) 347 (27.0) 
Schizophrenia 65 (4.3) 765 (50) 
ID+ 20 (8.8) 89 (39.0) 
6.3.4 CNV burden analysis – PLINK 
The PennCNV output files were converted to the PLINK format. As the focus of the 
CNV burden analysis was rare autosomal CNVs, a new CNV file was created on a 
filtered subset of the data. It is typical to use a frequency cut off of <1% for rare 
CNVs59,204, therefore CNVs were excluded that were present in >1% of the dataset. 
This frequency filter removed 74,112 CNVs from further analyses. CNV segments 
were considered to cover the same region if the minimum reciprocal breakpoint 
overlap was at least 50%. For the remaining CNVs the number of CNVs per individual 
was plotted to investigate individuals with a greater than expected number of CNVs. 
Taking a cut off of greater than 30 CNVs per individual, a histogram was plotted using 
IBM SPSS Statistics for Windows, Version 24.0 (IBM Corp, Armonk, NY, USA), see 
Figure 6-2. Furthermore, we decided to reduce the exclusion cut off of number of 
CNVs per individual from 300 to 100 to ensure a conservative cut off for possible 
falsely called CNVs. This resulted in 17 participants being excluded from further 
analyses. The BPAD cases were included for the frequency filter, to increase the 
sample size and reliability of the filter, however are not included in further analyses as 
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research has shown that there patients with BPAD have a lower burden of large rare 
CNVs than controls..  
Figure 6-2: Histogram of number of CNV segments per person in individuals with 30 or more 
CNVs 
Y axis: frequency, the number of individuals, X axis: NSEG, number of CNVs (or segments – the term 
used in the PLINK software), participants to the right of the vertical line (>100 CNVs per individual) 
were excluded from further analyses.  
A MAP file was then created, which maps the start and stop of CNV segments 
facilitating subsequent CNV parsing and analysis. Burden analyses of segmental CNV 
data were undertaken, which compares the metrics of cases versus controls evaluated 
by permutation. A phenotype file was included to enable separate comparisons: ID+ 
versus controls, schizophrenia versus controls and ID+ versus schizophrenia. In 
accordance with previous literature CNVs >100kb were analysed204, as calling of 
smaller CNVs can be less reliable and the primary interest is the role of rare and large 
CNVs in disease pathology. Additional size cut offs, >200kb and >400kb, were also 
considered. Furthermore, the role of CNV type, deletion or duplication, was also 
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considered. The script for this analysis was written by myself in accordance with the 
protocols described on the PLINK website220. An excerpt from this script for the ID 
versus controls analysis at a 100kb cut off for all CNVs, CNV deletions only, and CNV 
duplications only is detailed below. 
6.3.5 CNV analysis script 
#Creating a new CNV file on a filtered subset - excludes CNVs present more than 45 
times (1% frequency in a 4,487 sample size) with a minimum reciprocal overlap of 
50% 
./plink1 --noweb --cnv-list pchip_comorbid_auto_over100rem.cnv --fam 
pchip_comorbid.fam --map plink.cnv.map --cnv-freq-exclude-above 45 --cnv-overlap 
0.5 --cnv-write --out rarecnvless1per 
./plink1 --noweb --cnv-list rarecnvless1per.cnv --cnv-make-map --out rarecnvless1per 
 
#id versus controls all CNVs over 100kb in size 
./plink1 --noweb --map rarecnvless1per.cnv.map --cnv-list rarecnvless1per.cnv --fam 
rarecnvless1per.fam \ 
--cnv-indiv-perm --mperm 10000 \ 
--cnv-kb 100 \ 
--pheno pchip_comorbid.pheno --pheno-name $pheno \ 
--out $pheno.allover100kb 
 
#id versus controls CNV del over 100kb in size 
./plink1 --noweb --map rarecnvless1per.cnv.map --cnv-list rarecnvless1per.cnv --fam 
rarecnvless1per.fam \ 
--cnv-indiv-perm --mperm 10000 \ 
--cnv-kb 100 \ 
--cnv-del \ 
--pheno pchip_comorbid.pheno --pheno-name $pheno \ 
--out $pheno.100kbdel 
 
#id versus controls CNV dup over 100kb in size 
./plink1 --noweb --map rarecnvless1per.cnv.map --cnv-list rarecnvless1per.cnv --fam 
rarecnvless1per.fam \ 
--cnv-indiv-perm --mperm 10000 \ 
--cnv-kb 100 \ 
--cnv-dup \ 
--pheno pchip_comorbid.pheno --pheno-name $pheno \ 
--out $pheno.100kbdup 
6.4 Results 
The PLINK burden analysis of segmental CNVs reports four comparisons between 
cases and controls. The rate test compares the rate (number of segments or CNVs) per 
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person, the prop test compares the proportion of cases/controls to have at least one 
event, Totkb compares the total distance spanned by segments or CNVs per person, 
and the Avgkb compares the average segments or CNV event size per person. Results 
are presented uncorrected for multiple testing, in accordance with equivalent literature, 
where multiple testing corrections are only applied to breakpoint and gene-based 
association tests59. As the ID+ sample comprised participants with non-European 
ancestry (38/228), post-hoc analyses were also undertaken with these individuals 
removed. Where this changed the significance of the results this has been indicated.  
6.4.1 ID plus mental illness versus controls 
The results from the ID plus co-morbid mental disorders (ID+) versus control 
comparisons can be seen in Table 6-2. ID+ cases have a significantly increased rate of 
CNVs per person, as compared to controls. When filtering on CNV type this only 
remains significant for deletion CNVs and this remains significant at all size cut offs. 
The proportion of ID+ cases versus controls to have at least one event is only 
significant when considering CNVs >200 and >400kb, again filtering by CNV type 
this only remains significant for deletion CNVs. The total kb spanned by CNVs is 
significantly different between ID+ cases and controls except for at the 400kb cut off, 
again this only remains significant for deletion CNVs. For the average kb, or CNV 
event size per person, there is only a significant difference at the >100kb cut off and 
this is only significant when including both deletion and duplication CNVs. This result 
no longer remains significant when removing individuals with non-European ancestry. 
To further investigate the distribution of average CNV kb per individual a histogram 
was plotted, see Figure 6-3, and it appears that the significant difference between cases 
and controls is being driven by a small number of individuals who have high average 
CNV size in the ID+ group. 
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Table 6-2: CNV burden permutation test results for ID+ versus controls 
ID+ (n=228) versus controls (n=1285) 





CNV type (kb) (n) (n) Rate Prop TotKb AvgKb 
Del+Dup >100 818 1277 1.00E-04 0.082892 1.00E-04 0.0046 
  >200 294 437 1.00E-04 0.0009 1.00E-04 0.067993 
  >400 75 140 1.00E-04 1.00E-04 0.044296 0.209179 
Del >100 695 697 1.00E-04 0.017598 1.00E-04 0.013899 
  >200 236 180 1.00E-04 1.00E-04 0.0014 0.190981 
  >400 49 46 1.00E-04 1.00E-04 0.140486 0.294671 
Dup >100 123 580 0.19678 0.39836 0.112189 0.368063 
  >200 58 257 0.159784 0.59644 0.082392 0.283572 
  >400 26 94 0.094991 0.344966 0.10179 0.432957 
Key: Rate = Number of segments, Prop = Proportion of sample with one or more segment, Totkb = 
Total kb length spanned, Avgkb = Average segment size, Del = deletion, Dup = duplication, Bold = 
results that are significant at a significance threshold of P <0.05 
 
 
Figure 6-3 The average kb of CNVs for individuals from the ID+ group (N=228) 
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6.4.2 Schizophrenia versus controls 
There were no significant differences identified in CNV burden between schizophrenia 
cases and controls, see results in Table 6-3. 
Table 6-3: CNV burden permutation test results for schizophrenia versus controls 
Schizophrenia (n=1529) versus controls (n=1285) 







(kb) (n) (n) Rate Prop TotKb AvgKb 
Del+Dup >100 1241 1277 0.674633 0.40256 0.654835 0.09669 
 >200 460 437 0.371663 0.446955 0.534847 0.560644 
 >400 150 140 0.343666 0.359264 0.707929 0.687031 
Del >100 733 697 0.394561 0.418458 0.465653 0.290071 
 >200 203 180 0.323468 0.231577 0.627637 0.735226 
 >400 44 46 0.647135 0.70213 0.456454 0.487551 
Dup >100 508 580 0.906309 0.487951 0.79732 0.053495 
 >200 257 257 0.565943 0.257374 0.811919 0.305869 
 >400 106 94 0.171983 0.161484 0.534647 0.728327 
Key: Rate = Number of segments, Prop = Proportion of sample with one or more segment, Totkb = 
Total kb length spanned, Avgkb = Average segment size, Del = deletion, Dup = duplication, Bold = 
results that are significant at a significance threshold of P <0.05 
6.4.3 ID+ versus schizophrenia 
ID+ cases have a significantly increased rate of CNVs per person compared to 
schizophrenia only cases, see Table 6-4. When filtering on CNV type this only remains 
significant for deletion CNVs and this remains significant at all size cut offs. The 
proportion of ID+ cases versus schizophrenia to have at least one event is only 
significant when considering CNVs >200 and >400kb, again filtering by CNV type 
this only remains significant for deletion CNVs. The total kb spanned by CNVs is 
significantly different between ID+ and schizophrenia cases except for at the 400kb 
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Table 6-4: Permutation results for ID+ versus schizophrenia 
ID+ (n=228) versus schizophrenia only (n=1529) 







(kb) (n) (n) Rate Prop TotKb AvgKb 
Del+Dup >100 818 1241 1.00E-04 0.10159 1.00E-04 0.011499 
 >200 294 460 1.00E-04 0.0007 1.00E-04 0.051395 
 >400 75 150 1.00E-04 1.00E-04 0.023498 0.144386 
Del >100 695 733 1.00E-04 0.019898 1.00E-04 0.020398 
 >200 236 203 1.00E-04 1.00E-04 0.0004 0.123188 
 >400 49 44 1.00E-04 1.00E-04 0.142086 0.282772 
Dup >100 123 508 0.071693 0.39796 0.093291 0.674033 
 >200 58 257 0.132287 0.742826 0.046795 0.380462 
 >400 26 106 0.134087 0.573343 0.057694 0.283672 
Key: Rate = Number of segments, Prop = Proportion of sample with one or more segment, Totkb = 
Total kb length spanned, Avgkb = Average segment size, Del = deletion, Dup = duplication, Bold = 
results that are significant at a significance threshold of P <0.05 
6.5 Discussion 
A greater burden of large CNVs was identified in ID+ individuals, as compared to 
controls. Also a higher proportion of individuals with ID+ have at least one CNV 
event, as compared to controls, for CNVs >200 and >400kb. Whilst there has been no 
previous burden analysis in an ID+ cohort, analyses in paediatric cohorts with severe 
developmental disorders support this trend of greater CNV burden for individuals with 
ID and co-morbidities45. When segregating by CNV type, the association only 
remained significant for CNV deletions. Previous literature has been mixed as to the 
effect of CNV type on CNV burden. Research in severe developmental disorders found 
deletions to be twice as common as duplications45, a study investigating a range of 
NDD phenotypes found no bias towards deletions or duplications140, whereas a study 
of ID with and without schizophrenia only identified a significant difference between 
the groups for large CNV duplications141. It is unclear why these inconsistencies 
between studies exist. All of these studies have a slightly different ascertainment focus 
for their case samples, so it may be that the relationship with CNV type differs with 
the NDD under investigation.    
For the size analyses the total kb of CNVs per person was found to be larger for ID+ 
cases versus controls, however this does not remain significant when filtering by 
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CNVs >400kb. This is surprising given that individuals with ID+ were already found 
to have a significantly greater number and proportion of CNVs >400kb as compared 
to controls. Potentially this is due to that fact that CNV >400kb are rarer and there are 
fewer CNVs contributing to the total kb metric (75 CNVs in cases and 140 CNVs in 
controls). There are only significant differences between the average kb in ID+ cases 
versus controls for both deletions and duplications at the >100kb cut off. This is the 
weakest association in the study and it no longer remains significant when cases are 
removed from the analysis to control for the effects of ancestry. As evidenced by 
Figure 6-3 this results is likely driven by a small number of individuals with CNVs 
with large average kbs. Therefore, there does not appear to be major differences in the 
average CNV size between ID+ cases and controls. 
Surprisingly, no significant differences in CNV burden were identified between 
schizophrenia cases and controls. The rate, proportion, total kb, and average kb 
remained very similar between cases and controls at all size cut offs and for both 
deletions and duplications. A limitation of the analysis methodology was that the gene 
content of the CNV was not considered. The number of genes affected by CNVs has 
previously found to be the strongest signal of enrichment for schizophrenia burden 
analyses59. One explanation for the differences between this analysis and other 
published literature is that the study was underpowered to detect an effect, as the main 
schizophrenia CNV burden analyses to date have comprised much larger sample 
sizes59,204. Another factor may be that the schizophrenia samples recruited via the 
DPIM study are likely to be deselected for ID. Whilst having ID wasn’t an exclusion 
criteria for entry to the study, the study did require that the participant has capacity to 
consent to the research project. This may have reduced the number of participants at 
the lower end of the IQ spectrum. It is unclear what this result means for the 
interpretation of other schizophrenia CNV burden analyses to date. Recent work has 
shown that having a low IQ, or ID phenotype, does increase CNV burden in 
schizophrenia patients142. Also findings from a WES study found that more than half 
of the patients with a significantly enriched variant (in the SETD1A gene) also had 
learning difficulties. Data on the intellectual functioning of patients is not provided in 
the published large CNV burden studies59,204. This will be an important consideration 
for future research in the field. 
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Finally, significant differences in CNV burden were found in a case-case analysis of 
ID+ and schizophrenia only cases. The significant results were nearly identical to those 
found in the ID+ versus control analyses, except in this instance none of the average 
kb tests were significant. Given that there were no significant results when comparing 
schizophrenia cases against controls, the results indicate that differences in CNV 
burden are more pronounced as the severity of the NDD phenotype increases. In other 
words, there are greater differences in CNV burden between ID+ and schizophrenia 
compared with schizophrenia versus controls. 
This study has several potential limitations. Whilst all samples were analysed on the 
same platform, the PsychChip, the samples were processed at two different sites – The 
Broad Institute of MIT and Harvard and the University of Bonn. It could be that there 
were some differences in sample processing that are influencing the findings, for 
example differences in in-house genotype calling quality control measures. However, 
these results should still be more comparable than samples analysed on different 
platforms, whereby different densities of probes affect the calling sensitivity. CNV 
calling from SNP arrays is known to be less reliable than array CGH methodologies, 
which could have led to some false positive and negative CNV calls. Typically, there 
is greater noise – or a higher number of false calls – for small CNVs, which was 
attempted to be control for by only considering CNVs >100kb. However, it is unclear 
whether 100kb was the best size cut off to use as the previously referenced literature 
was published in 2008 and the Psychchip is a high-density array, which could 
potentially mean a smaller size cut off would have been more appropriate. 
A further limitation is that the cases were included in the filter to remove CNVs 
occurring at a >1% frequency in the dataset. It may be that some CNVs were removed 
which were absent in controls and only observed in cases. As the focus of this analysis 
was rare CNVs, and rare CNVs typically have much lower population frequencies, this 
is unlikely to have a major impact on the results. However, a more conservative 
common variant exclusion method would have been to use a publically available 
dataset with controls only to exclude common CNVs. The common CNV exclusion 
process was the same for participants from ethnic minority groups, whereas a more 
robust approach would have been to filter out common CNVs using ancestrally 
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matched control cases. Furthermore, the CNVs were only called using one calling 
algorithm – PennCNV. It has been shown that the number of CNVs per individual 
varies according to the algorithm used to call the CNVs221. Ideally multiple algorithms 
would be used and only CNVs that are called by more than one algorithm included in 
the analysis. Inheritance data was not available for this sample and so the role of de 
novo CNV burden could not be considered. Finally, the role of sex was not considered 
and this analysis was only undertaken on autosomal chromosomes due to the small 
group sizes for called X chromosome CNVs when dividing the groups by sex. Also it 
was not within the remit of this analysis to consider the gene content of CNVs, 
although this would be a natural next step for this work. 
6.6 Conclusion 
It has been hypothesized that psychiatric disorders lie on a neurodevelopmental 
continuum, of which ID is the most severe brain insult, followed by ASD and 
schizophrenia96. This CNV burden analysis compared, for the first time, ID plus co-
morbid psychiatric disorder cases, schizophrenia patients and controls with CNVs 
called from the same SNP array platform. One could hypothesize that ID with co-
morbid mental disorders lies at the extreme end of the neurodevelopmental continuum. 
Interestingly, ID+ appears to be more different from schizophrenia than schizophrenia 
does from controls, suggesting that CNV burden becomes more pronounced at the 
severest end of the neurodevelopmental continuum. 
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Chapter 7 Future directions 
Historically, research has followed psychiatric nosology systems, ascertaining patients 
for the presence of distinct NDDs of interest. It soon became clear that, for the main 
part, psychiatric disorders do not follow simple Mendelian patterns of inheritance and 
that they are polygenic in nature, with a range of rare and common variants 
contributing to risk of developing the disorder. This extreme genetic heterogeneity, for 
example with over 700 ID related genes identified, presents challenges for uncovering 
molecular mechanisms of disease pathology. Furthermore, studies of pathogenic 
CNVs and SNVs have revealed that the same variant can be involved in risk for 
multiple NDDs. The full extent of this genetic pleiotropy is still under investigation, 
however it appears that there is a complex pattern of risk conferred by different loci. 
Cross-disorder genetic investigations, whereby groups ascertained for different NDDs 
are analysed together, are becoming common-place in psychiatric genetics. However, 
there remains a paucity of research in individuals with co-morbid NDD phenotypes. 
7.1 Summary of research findings 
This thesis has focused on the investigation of CNVs in individuals with co-morbid 
NDDs. In Chapter 2, findings from clinical practice were investigated, with a survey 
of child and adolescent and adult ID psychiatrists. The survey aimed to determine the 
extent to which genetic investigations are being utilised by psychiatrists working with 
patients with ID, and psychiatrists’ opinions around genetic testing practices. A need 
for increased training was identified, given the challenges clinicians face in keeping 
up to date with the genomic advances relevant to ID psychiatry. Currently, 
psychiatrist’s training curriculum fail to cover genetic disorders and there is a wide 
geographical variability in links and access to genetic testing services and genetic 
counselling. It is important to address these issues to ensure that the advances in 
genetic testing reach patients, this is particularly important given the health 
inequalities already faced by individuals with NDDs. It would be of interest to 
undertake further research on clinical management changes following genetic 
diagnoses, which were rarely reported in clinical practice, despite there being a large 
number of disorder guides with clinical management guidelines. 
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In Chapter 3 adults with idiopathic ID and co-morbid psychiatric disorders (N=202) 
were recruited from ID psychiatry services with the aim of determining the frequency, 
type, and associated phenotype of pathogenic CNVs.  An 11% frequency of pathogenic 
CNVs was identified, an important finding for clinical practice – that over 1 in 10 ID 
psychiatry patients have an undiagnosed aetiological CNV. This argues for more 
routine consideration of CMA in ID psychiatry services. The majority of pathogenic 
CNVs were found at recurrent loci, which have already been described in the literature. 
A higher proportion of pathogenic CNV carriers were forensic in-patients, as 
compared to non-pathogenic CNV carriers (OR 4.1). It would be an interesting avenue 
of future research to undertake CMA in forensic populations, however no cohorts 
could be identified to undertake this analysis within the remit of this thesis. No other 
significant differences in the frequencies of psychiatric symptomatology were 
identified between pathogenic and non-pathogenic CNV groups. This may mean that 
presence of a particular psychiatric disorder might not be a useful marker for 
prioritising patients for CMA testing. Again, further research on the phenotypic profile 
of pathogenic and non-pathogenic CNV carriers is needed to further investigate this. 
In Chapter 4, the findings of Chapter 3 were replicated in a larger multi-population 
patient cohort (N=599). A similar frequency of pathogenic CNVs was identified in 
these patients with ID and co-morbid pscyhiatric disorders (13%). To further 
investigate the genetic architecture of the pathogenic CNVs the rate of established 
NDD risk CNVs, as compared to single-disorder cohorts, was analysed. Again, 
pathogenic CNVs were frequently found at recurrent CNV sites, with 70% of 
pathogenic CNVs at sites already known to be involved in NDD risk. Taking this 
sample and comparing it to large healthy control, schizophrenia, and ID/ASD cohorts 
from previous studies unveiled the highest sample rate of NDD CNVs. This large 
multi-centre cohort also enabled the detection of overlapping likely pathogenic CNVs, 
providing valuable contributions to the literature on the pathogenicity of the CNTN 
and CHD gene families and 16p12.1 deletions. Future research could focus on adding 
further samples to this existing dataset, which will likely lead to the emergence of other 
multiply occurring rare pathogenic CNVs.  
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In Chapter 5, deep phenotyping was undertaken in patients with CNVs at the 2q13 
locus (N=25). Whilst developmental and psychiatric phenotypes had been described 
in previous published studies, these phenotypes had not been systematically 
investigated. A common phenotype of DD, mild intellectual impairment and a high 
frequency of psychiatric and behavioural disorders was identified. There appeared to 
be a global risk to developing a psychiatric disorder, with a wide-range of symptoms 
and diagnoses. However, the frequency of clinical ADHD diagnoses was particularly 
striking – with 44% of participants being diagnosed. Delineation of the phenoypes 
associated with rare CNVs is important to enable syndrome-specific phenotype 
information, which may guide therapeutic interventions. Furthermore, the 
identification of a high rate of ADHD diagnoses may guide functional follow up in 
this region in investigations of the neuropathological mechanisms of ADHD. This 
multi-faceted research approach – utilising RGCs, a patient support group and a rare 
CNV database, was particularly successful and enabled the largest case series of 2q13 
patients reported to date. A similar approach could be undertaken in future research to 
facilitate phenotypic delineation of rare CNVs. Another further avenue of research 
would be to undertake WES or WGS in the 2q13 participants to test the second-hit 
model as a theory for the incomplete penetrance of this CNV.  
Finally in Chapter 6, a burden analysis was undertaken to compare the individuals with 
co-morbid NDDs (ID+) to controls and schizophrenia only patients. Significant 
differences in rates of CNVs per individual, the proportion of cases with at least one 
CNV event and the total kb of CNVs spanned per person were found between the ID+ 
and controls. When filtering by CNV type and size this only remained true for CNV 
deletions at the larger size cut offs. No differences were found between schizophrenia 
cases and controls, although it may be that this analysis was underpowered. The ID+ 
cases showed significant differences in CNV burden, as compared to schizophrenia 
patients, indicating that the CNV burden is particularly high in the co-morbid ID+ 
cohort. There were several limitations of this analysis and further analysis is required 
to investigate this finding, in particular re-calling the CNVs using a different 
algorithm, investigating the impact of sex, and undertaking a gene-set analysis would 
be appropriate extensions of this analysis.  
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7.2 Insights from participant recruitment 
Being personally involved in participant recruitment has afforded me unique insights 
into the challenges of undertaking psychiatric research. One observation, which 
recurred throughout my research visits, is that family members are hesitant to divulge 
mental health information. On many occasions a family member would answer ‘no’ 
when asked whether themselves or their child had a diagnosed mental health problem. 
However, it would emerge through later questioning in the interview that this was 
incorrect. For example, one family member said their child did not have a mental 
health problem, however following a discussion about medication history it emerged 
that the child was taking anti-depressants and did have a diagnosis of depression. It 
was far less frequent that a family member would misanswer questions relating to 
physical health. It is unclear why this phenomenon occurred, it may have arisen from 
family members’ misunderstanding of the term ‘mental health’. It could also be linked 
to that fact that mental health problems are more stigmatised than physical health 
problems, and thus the family finds it difficult to discuss or they are reluctant to share 
the information. 
Another interesting observation was that during collection of family history 
information for patient pedigrees, family members would refer to their relatives using 
terms such as ‘a bit odd’ or ‘a bit of a loner’. These relatives were never investigated 
for psychiatric illness, although family members often felt that they would meet 
diagnostic criteria. From a historical context awareness of, and screening for, mental 
health problems is much improved in current healthcare systems. There is an ongoing 
debate about whether mental health problems are increasing in prevalence or whether 
the increase is a consequence of improvements in psychiatric screening. For example, 
it is thought that raising awareness and screening for ASD may explain the rapidly 
increasing prevalence rates of the disorder. Research utilising US special education 
enrolment data has shown that as diagnoses of ASD have risen those of ID have 
decreased, suggesting that misdiagnosis of ASD as ID in the past may in part account 
for the increasing prevalence of the disorder222. This highlights the difficulties of 
ascertaining an accurate psychiatric family history from research participants. Ideally 
all family members would be re-screened using modern assessment procedures – 
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however the requirement for trained clinicians and lengthy screening processes are a 
barrier to implementing this in research practice. 
Another element of the recruitment process required review of available medical 
records. This comprised records from a variety of practitioners involved in the care of 
the participant, including: psychologists, speech and language therapists, occupational 
therapists, psychiatrists, and clinical geneticists. Surprisingly, patient information was 
often inconsistent between reports. In some instances the wrong genetic or medical 
diagnosis was included on practitioner reports, or the reports failed to mention 
important information relating to the participant’s diagnosis. This issue is particularly 
pertinent for individuals with ID and co-morbid mental illness, as there are often 
multiple medical professionals involved in the patient’s care who have not necessarily 
communicated directly about the patient. This raises the important issue of whether 
medical records are a reliable source of information about the medical and psychiatric 
history of these individuals. Due to the study design, direct liaison with an informant 
and the treating psychiatrist made it feasible to resolve any discrepancies during the 
recruitment process. However, study designs which only utilise medical records are 
likely to be more error prone.  
7.3 NDD risk CNVs and clinical heterogeneity  
CNVs associated with risk for developing NDDs have been shown to have variable 
phenotypic outcomes. Taking the 2q13 CNV as an example, a wide range of medical, 
dysmorphic, behavioural and psychiatric features were identified in participants with 
2q13 CNVs. However, nearly half of the individuals (44%) had an ADHD diagnosis. 
This work provides support for the asymmetric risk model, whereby rare CNVs confer 
both shared risk and distinct aetiology108. In this instance, shared risk for general 
psychiatric pathology, with a propensity for ADHD pathology.  
It is important to consider the potential modifying factors that influence outcomes for 
these CNV carriers. Firstly, only one type of genetic variation – CNVs – was taken 
into account and many other forms of genetic variants affect phenotypic outcomes. For 
example, it is typical for every individual to have around 1-2 de novo exonic SNVs223, 
and the rate is likely higher in severe NDD cohorts51. Furthermore, rare inherited 
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variants, identifiable by WES and WGS, also modify phenotypic outcomes. Research 
investigating the contribution of both rare and common variants to schizophrenia 
pathology has provided support for a polygenic threshold model, whereby a multitude 
of common and rare risk variants are involved in the disease phenotype74. Common 
variants were also not considered in this thesis, and it is likely that the burden of 
common risk variants acts as a modifier of phenotypic outcomes. 
Currently, separate tests are required to reliably detect each type of genetic variant, 
making it challenging to consider all the contributing genetic factors. As WGS 
becomes cheaper and the methods for detection of other variants (such as CNVs) from 
sequencing data improve, it is likely that genetic testing in the future will be more 
comprehensive. Another challenge is that little is known about how modifier genes or 
gene-gene interactions modify phenotypic outcomes. Large well-phenotyped samples 
with comprehensive genetic data will be required to delineate these relationships. It is 
of interest to identify variants operating in the same molecular pathways, which likely 
exacerbate disease phenotypes, and compensatory or protective variants. For the 2q13 
CNV carriers, 25% of participants had a family history of ID and mental health 
problems on the other side of the family from which the variant was transmitted. It 
may be that assortative mating and/or multiple hits in NDD gene pathways are 
contributing to the diverse phenotypic outcomes observed. A further challenge will be 
ascertaining genetic history for available family members, and teasing out the 
contribution of inherited variants. 
It is not only genetic factors which contribute to phenotypic outcomes. Recent 
estimates of the concordance rates between monozygotic twins for schizophrenia are 
around 33%57, highlighting that outcomes are often variable for genetically identical 
individuals. Non-genetic factors, including environmental factors – such as obstetric 
complications, drug abuse, and migration – have been shown to contribute to 
phenotypic outcomes in schizophrenia224. Stochastic, or chance factors, also play a 
role, given that the brain is a highly complex organ and neuronal development is error 
prone. Similar to the novel de novo mutations that arise by chance at the genetic level, 
there are comparable chance errors in the cellular processes involved in the developing 
brain.  
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7.4 Complexities with phenotyping and co-morbid phenotypes 
One of the primary differences between the research presented in this thesis and other 
large cohort studies in psychiatric genetics is the degree of phenotypic information 
collected. GWAS analyses typically class disease as a categorical phenotype. For 
example, the presence or absence of schizophrenia defines the case and control groups 
respectively. Whereas, the term deep phenotyping is used for studies that comprise 
measurements on a number of clinical, behavioural, and neuropsychiatric assessments. 
The challenge for more comprehensive phenotyping is that there is no standardised 
method for deep phenotyping in psychiatry, meaning there is methodological 
inconsistency across the measures used. Deep phenotyping is also very time 
consuming, resulting in a limited number of subjects and often requiring collaboration 
with other researchers225. As previously discussed, family members do not necessarily 
answer research questions correctly and the information available from medical notes 
is not necessarily accurate. This poses questions about the validity of shallow 
phenotyping techniques, whereby limited information is collected.  
A complexity with interpreting the findings from this thesis, with a more 
comprehensive phenotyping protocol, is that it is unclear how the research participants 
relate to those presented in other studies. As discussed in Chapter 4, the large paediatric 
severe developmental disorder cohorts are poorly phenotyped and it is unclear exactly 
how many had DD/ID and/or psychiatric disorders. Also the paediatric nature of the 
cohort means that the age of onset for many psychiatric disorders is yet to be reached. 
Furthermore, diagnosis of psychiatric illness in ID is challenging, and it is not routine 
practice for a standardised set of psychiatric assessments to be undertaken. Thus, 
diagnostic practices are variable, and it may be that individuals categorised as having 
ID only also have undetected mental health problems. This is particularly the case at 
the severe end of the ID spectrum, where non-verbal individuals are unable to self-
report psychiatric symptoms.  
The work in this thesis shows that patients with ID plus psychiatric co-morbidities 
have a greater frequency of CNVs at NDD risk loci and a higher burden of rare CNVs, 
as compared to other patient groups. The neurodevelopmental continuum model has 
already proposed that ID is the most severe early brain insult which has a higher burden 
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of CNVs and deleterious mutations96,226. It may be that ID plus co-morbid 
neurodevelopmental or neuropsychiatric phenotypes is located on the most severe tail 
of the neurodevelopmental continuum model, being a more severe phenotype than ID 
alone. However, the aforementioned limitations with a lack of suitable reference 
populations precludes confirmation of this hypothesis. Ideally, a comparable reference 
population of patients with ID and the absence of co-morbid mental illness would be 
required to fully test the difference between groups. However, this is a difficult 
population to ascertain.  
The challenges in ascertaining an ID population with the absence of co-morbid 
psychiatric phenotypes is multifold. One could only study this in adulthood, after the 
age of onset for most psychiatric disorders. As previously discussed there is a historical 
context whereby many adults with ID will have not undergone psychiatric screening. 
It may be that there has been diagnostic overshadowing – whereby the ID is thought 
to be the cause of the phenotype, so appropriate screening for other disorders wasn’t 
undertaken. Also previous versions of the psychiatric diagnostic manuals precluded 
some co-morbid diagnoses, for example only in DSM5 was it possible to diagnose 
ADHD and ASD in the same individual226. In order to rule out psychiatric co-
morbidities, the most robust approach would be to re-screen everyone with ID using 
modern psychiatric screening schedules – although this would be complex and 
resource intensive. 
Several lines of evidence suggest that diagostic categories, used in clinical psychiatric 
practice, map poorly onto the underlying biology. From a phenotypic perspective, 
there is also a wide variability within diagnostic categories and symtom overlap 
between diagnostic categories226. There is also a movement towards recognising the 
complex continuous nature of NDDs, and how their different patterns of impairments 
lie on a continuum marked by the severity of the brain insult1. However, it is difficult 
to determine where an individual with mild ID and schizophrenia lies in relation to an 
indiivudal with severe ID. Perhaps a better measure of impairment, rather than crude 
diagnostic status alone, would be to undertake a functional assessment of the degree 
of impairment to daily living skills. This might take into account some of the 
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complexities of studying co-morbid diagnoses, but would require an overhall of 
current research practices.  
7.5 Further discussion of ascertainment bias 
As discussed in previous chapters, one of the limitations of the findings of this thesis 
is that there is likely to be an ascertainment bias arising from the methodology used to 
recruit participants. Routine genetic testing for CNVs in psychiatric practice is 
currently only taking place in the context of paediatric DD/ID, MCA and ASD25. The 
next obvious group for routine genetic testing is adults with co-morbid psychiatric 
phenotypes, the target population for this body of research. This research aimed to 
sample participants directly from clinical services, with ID psychiatrist being the main 
point of contact for recruitment. It is hard to determine the extent to which 
ascertainment bias affected the results, as the bias could have operated in both 
directions – both in terms of psychiatrists selecting patients who they suspect have 
underlying genetic disorders, and de-selecting participants with more severe 
phenotypes who are harder to recruit.  
Individuals with ID and co-morbid psychiatric disorders are a particularly hard-to-
reach population. The recruitment strategy employed in this thesis was very successful, 
recruiting nearly 250 individuals in 18 months. It is challenging to think of alternative 
research methods to reduce ascertainment bias whilst maintaining recruitment levels. 
Indeed, all of the severe developmental disorders studies will have an element of 
recruitment bias, as many have captured patients referred for clinical genetic testing 
and a certain threshold of impairment must be passed to reach referral for clinical 
testing44,45. Ideally, a large population based longitudinal study, with available genetic 
data, would be the most representative sample, as it would enable detection of 
neurodevelopmental CNV carriers across the whole phenotypic spectrum – from 
healthy controls to patients with co-morbid phenotypes. 
7.6 Clinical implications and utility 
Several participants in this study received a genetic diagnosis, of previously 
undiagnosed pathogenic CNVs that were related to the individual’s ID and/or 
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psychiatric condition. The implications of receiving a genetic diagnosis for patients 
and their families are widespread. For some families receiving a genetic diagnosis can 
help to alleviate feelings of self-blame, particularly for mothers who may falsely 
believe that they did something wrong during pregnancy. One study investigated self-
reported quality of life scores in mothers whose child had received a genetic diagnosis 
from array CGH. They found that having an aetiological diagnosis for the child’s 
DD/ID and/or MCA improved maternal quality of life. It is described as an ‘emotional 
relief’ to have a name for the disorder and understand the cause of the child’s 
diability137.  
Confirmation of an aetiological diagnosis can also aid clinical symptom-based 
diagnosis. An aetiological diagnosis can facilitate screening for associated medical and 
psychiatric disorders, and in some instances provide information on likely 
responsiveness to treatments. Information leaflets with clinical guidelines are available 
for an increasing number of rare genetic syndromes134,135. More clear cut information 
about a syndrome can be helpful, particularly if it helps the patient understand 
phenotypic presentations. For example, a patient who has a syndrome which has a 
common phenotype of self-injurious behaviour136.  
A genetic diagnosis can also be empowering for patients and families, enabling them 
to access disorder-specific or general support groups, such as the Unique chromosomal 
disorder support group. For school age children a genetic diagnosis can be beneficial 
for a statement of special educational support, or access to disorder-specific support 
services. Furthermore, a genetic diagnosis may have broader implications for the 
family and indicate genetic counselling, genetic risk to subsequent offspring, and 
cascade testing via Regional Clinical Genetics Services. Genetic counselling in 
schizophrenia patients, who had been fed back aetiological CNV results, was found to 
improve understanding of the disorder, and significantly reduce internalized stigma 
and self-blame227. Recurrence risk information can be hugely beneficial to family 
planning, for example if a rare variant is found to be de novo in origin then there the 
recurrence risk for siblings is equal to the population prevalence of the disorder.  
The full range of CNVs implicated in NDD risk are still being delineated. It is likely 
that many of the highest penetrance variants have already been identified, given their 
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stronger associations with specific phenotypic outcomes. However, more 
neurosusceptability CNVs (which are present at higher frequencies in NDD patients, 
but also present at low frequencies in healthy controls) may yet be identified. 
Neurosusceptability CNVs, at the 2q13 locus, were described in detail in this thesis. 
Further delineation of the phenotype, and it’s association with childhood onset 
psychiatric disorders, could have important clinical implications for screening for 
psychiatric disorders. However, there were also a diverse range of medical and 
dysmorphology phenotypes observed. It is clear that the relationship between 
neurosusceptability CNVs and phenotypic outcomes will be even more challenging to 
delineate, and will pose greater challenging for genetic counselling of patients and 
their families. Description of the phenotype of participants with VOUS likely 
pathogenic CNVs in Chapter 4 may also help to guide the clinical interpretation of 
these CNVs in the future, given that reviewing published literature on the CNVs is an 
integral part of the categorisation process14. As evidenced in Chapter 2, there are 
barriers to translating the advances in genetic understanding of NDDs into clinical 
practice. Psychiatrists lack confidence in genetic testing practices and require further 
training and better links with genetic services. It is unclear how these findings link to 
other areas of medicine where genomic testing is on the rise. For example, many 
advances have been seen in genetic testing for various cancers and it would be 
interesting to research clinician’s views in this branch of medicine. One of the major 
challenges in psychiatric research is that it still relies on self-reported symptom 
information to diagnose patients, whereas parallel tests in oncology have biological 
markers from blood tests and tumor biopsies.  
In the broad field of psychiatry, ID psychiatry is likely to have the most utility for 
genetic testing in the clinic given the high rate of pathogenic variants. However, as it 
currently stands the onus is on psychiatrists to choose which patients, if any, to refer 
for clinical genetic testing. Implementing a routine genetic screening programme, at 
least for pathogenic CNVs, in ID psychiatry would enable comparable – or greater – 
success rates as in paediatric DD/ID. However, this would need to be supported with 
training for clinicians in the genetic testing process and the additional demand for 
genetic counselling would need to be supplemented by increased service provision in 
Regional Genetics Services. If the current scope of routine testing is expanded to 
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encompass this patient group this could also facilitate the discovery of further risk 
variants for NDDs.  
There are currently limited therapeutic success stories that have arisen from discovery 
of underlying NDD genetic aetiologies. Drug discovery in psychiatry in general has 
stagnated, with no major developments in the previous 40 years and many 
pharmaceutical companies scaling down psychiatric drug research226. In cancer 
genetics the pathogenic effects of genetic variants arise at the cellular level, and drugs 
can be targeted to biochemical pathways. In psychiatry there is a complex myriad of 
genetic interactions, which has cascading effects on complex neural circuits and 
pathways. One study has reported a pharmacologically guided treatment in a patient 
with 15q13.3 deletion syndrome who had an aggressive phenotype. The CNV deletion 
was found to encompass the Cholinergic Receptor Nicotinic Alpha 7 Subunit 
(CHRNA7) gene. Administration of galatamine, a modulator of nicotinic cholinergic 
receptor function, led to a decline in the frequency and intensity of rage outbursts228. 
Further advances in pharmacogenomics will be dependent upon better characterisation 
of the region specific molecular consequences of pathogenic CNV. 
7.7 Concluding remarks 
One of the greatest challenges to the future of psychiatric research is how to reconcile 
these findings within the current system of psychiatric nosology and determine the 
type of patient stratification that is most appropriate for genetic analyses. More studies 
of rare pathogenic CNVs, with a focus on functional analysis of candidate genes and 
pathways, will be required to delineate the nature of asymmetric loci-specific risk. It 
will be imperative that this research cuts across cohort groups, traversing from healthy 
controls to individuals with co-morbid NDDs. Concurrently, phenotyping methods 
need to be developed – currently phenotyping is basic and the lack of standardised 
methods preclude comparisons between studies. Indeed, investigations of ‘healthy 
controls’ with pathogenic CNVs have revealed that many do show cognitive 
impairments and psychiatric symptomatology. Thus, better psychiatric and cognitive 
phenotyping, to encompass sub-clinical aetiology, is important for future genetic 
studies. Additionally, consideration of familial genetic background and the interaction 
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between genetic variants is likely to uncover protective mechanisms for the pentrance 
of pathogenic CNVs and expressivity of disease phenotypes. 
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Appendix 
Clinically significant CNV questionnaire 
Did you feel it was appropriate to feedback the genetic test result to your patient?  
Yes ☐ No ☐ 
If YES what was your experience of feeding back the result? 
If NO why did you not feel it was appropriate to feedback the result? 
Did you feel it was appropriate to feedback the genetic test result to the patient’s 
family members/carers?  
Yes ☐ No ☐ 
If YES what was your experience of feeding back the result? 
If NO why did you not feel it was appropriate to feedback the result? 
Was the patient referred to clinical genetics?  
Yes ☐ No ☐ 
If so what was your experience of the referral process?  
Have family members of the patient undergone genetic testing?  
Yes ☐ No ☐ Unknown ☐ 
If so have you been informed of the results?  
What do you think was the psychological impact of receiving the diagnosis 
outcomes (for patient/family/carer)? 
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Has the patient been in contact with any support groups? 
Yes ☐ No ☐Unknown ☐ 
Please provide details if known 
Has your patient’s GP been informed of the genetic test result?  
Yes ☐ No ☐ 
Have any other professionals involved in the patient’s care been informed of the 
genetic test result?  
Yes ☐ No ☐ 
If so please provide details 
Have there been any management changes (medical and social) for the patient 
related to their genetic diagnosis? Examples given below; please provide relevant 
details 
Medical screening investigations (e.g. blood tests, echocardiogram, neuroimaging) 
Specialist medical referral (e.g. cardiology, ophthalmology, endocrinology) 
Discontinuation of previously recommended medical screening 
Changes in medication 
Changes to medical services input or eligibility 
Changes to social circumstances or eligibility including care/housing/benefits 
Other, please describe
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Prep_calling.sh script 
## Script to prepare for penncnv call of illumnia psychchip samples 
projectdir=/home/rejujht/molpsych/projects/penncnv/psychchip 
listdir=$projectdir/lists 
# mkdir -p $listdir 
## 1) Generate listfiles for array submission of penncnv jobs 
# find $projectdir/psychchip_intensity-data/ -iname "*.gtc.txt" -type f > 
$listdir/listfile_all.txt 
## 1b) (OPTIONAL) Remove very bad samples identified from first round from the 
list 
### Script takes 3 arguments: 1) listfile to update, 2) very_bad_exclude list as 
generated by qc_cnvs_find_really_BAD.R, 3) sampleSheet cleened 
# Rscript remove_very_bad_from_list.R $listdir/listfile_all.txt cnv-
calls_130317/pchip.penn_really_BAD.excluded SampleSheet_cleaned.txt 
# ## 1- continued) split listfile all into 10 
# awk 'NR>=1&&NR<=500' $listdir/listfile_all.txt > $listdir/listfile1.txt 
# awk 'NR>=501&&NR<=1000' $listdir/listfile_all.txt > $listdir/listfile2.txt 
# awk 'NR>=1001&&NR<=1500' $listdir/listfile_all.txt > $listdir/listfile3.txt 
# awk 'NR>=1501&&NR<=2000' $listdir/listfile_all.txt > $listdir/listfile4.txt 
# awk 'NR>=2001&&NR<=2500' $listdir/listfile_all.txt > $listdir/listfile5.txt 
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# awk 'NR>=2501&&NR<=3000' $listdir/listfile_all.txt > $listdir/listfile6.txt 
# awk 'NR>=3001&&NR<=3500' $listdir/listfile_all.txt > $listdir/listfile7.txt 
# awk 'NR>=3501&&NR<=4000' $listdir/listfile_all.txt > $listdir/listfile8.txt 
# awk 'NR>=4001&&NR<=4500' $listdir/listfile_all.txt > $listdir/listfile9.txt 
# ## awk 'NR>=4501&&NR<=5500' $listdir/listfile_all.txt > $listdir/listfile10.txt 
# ## 2) Strip header to file and change name of B-allel and R header to prepare for pbf 
file creation and CNV calling 
# while read p;  
# do echo $p 
#     idcode=$(basename $p) 
#     head -n12 $p > $p.header 
#     sed -i '1,11d' $p 
#     sed -i 's/bAllele Freq/${idcode}.B Allele Freq/g' $p 
#     sed -i 's/Log R Ratio Illumina/${idcode}.Log R Ratio/g' $p 
#     sed -i 's/SNP Name/Name/g' $p 
#     sed -i 's/Chromosome/Chr/g' $p 
# done < $projectdir/lists/listfile$SGE_TASK_ID.txt 
## 2) Generate pbf file 
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# /share/apps/genomics/PennCNV-1.0.3/compile_pfb.pl --listfile 
$listdir/listfile_all.txt --output $projectdir/pchip.pfb 
## 3) Generate GCmodel 
# wget http://hgdownload.cse.ucsc.edu/goldenPath/hg19/database/gc5Base.txt.gz 
# gzip -fd gc5Base.txt.gz     
# sort -k 2,2 -k 3,3n gc5Base.txt > gc5Base.sorted.txt 
## use pennCNV function to calulate GC 
/share/apps/genomics/PennCNV-1.0.3/cal_gc_snp.pl $projectdir/gc5Base.sorted.txt 
$projectdir/pchip.pfb -output $projectdir/pchip.gcmodel 
## clean up 
# rm $projectdir/gc5Base.sorted.txt 
# rm $projectdir/gc5Base.txt 
## 4) Generate a sex file with updated info from the gwas data 
Rscript generate_sex-file.R 
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Call_cnvs_array.sh script 




outdir=$projectdir/cnv-calls # output dir for raw cnv calls 
penncnv=/share/apps/genomics/PennCNV-1.0.3 # Penncnv executables 
outprefix=pchip.penn 
mkdir -p $outdir 
## Autosome detection 
$penncnv/perl-5.10.1/bin/perl $penncnv/detect_cnv.pl -test \ 
  -hmm $projectdir/hhall.hmm \ 
  -pfb $projectdir/pchip.pfb \ 
  -gcmodel $projectdir/pchip.gcmodel \ 
  -list lists/listfile$SGE_TASK_ID.txt \ 
  -confidence \ 
  -log $outdir/$outprefix.$SGE_TASK_ID.log \ 
  -out $outdir/$outprefix.$SGE_TASK_ID.rawcnv \ 
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# ## ChrX detection 
$penncnv/perl-5.10.1/bin/perl $penncnv/detect_cnv.pl -test \ 
  -hmm $projectdir/hhall.hmm \ 
  -pfb $projectdir/pchip.pfb \ 
  -gcmodel $projectdir/pchip.gcmodel \ 
  -list lists/listfile$SGE_TASK_ID.txt \ 
  -chrx -sexfile $projectdir/pchip_penncnv_gender.txt \ 
  -confidence \ 
  -log $outdir/$outprefix.$SGE_TASK_ID.sex.log \ 
  -out $outdir/$outprefix.$SGE_TASK_ID.sex.rawcnv \




outdir=$projectdir/cnv-calls # output dir for raw cnv calls 
prefix=pchip.penn 
Rpath=/share/apps/R-3.1.1/bin/Rscript 
## Convert output to coloumn style 
cat $outdir/*.rawcnv > $outdir/$prefix.rawcnv 
mkdir $outdir/sexlog 
mv $outdir/*sex.log $outdir/sexlog 
cat $outdir/*.log > $outdir/$prefix.log 
# Clean up  
rm $outdir/$prefix.*.rawcnv 
rm $outdir/$prefix.*.log 
# Arguments: 1) rawcnv file, 2) Sample_id file 
$Rpath $projectdir/convert_cnv_output.R $outdir/$prefix.rawcnv 
$projectdir/SampleSheet_cleaned.txt 
## Get values from log 
pennlog=$outdir/$prefix.log 
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grep "NOTICE: quality summary for" $pennlog | sed 's/NOTICE: quality summary for 
//g' > ${pennlog/.log/.log.qc} 
## Run QC 
mkdir -p $outdir/plots 
# Arguments: 1) cnv-call dir, 2) penncnv output prefix, 3) penncnv log, 4) listfiles, 5) 
Sample_id file 
$Rpath $projectdir/qc_cnvs.R $outdir $prefix $pennlog $projectdir/lists/listfile_all.txt 
$projectdir/SampleSheet_cleaned.txt 
## Find CNV regions of interest # Arguments: 1) cnv-call dir, 2) cnv-inputfile, 3) 
region of interest file path 
$Rpath $projectdir/call_regions_of_interest.r $outdir $prefix.qc 
$projectdir/input/regions_of_interest_80.txt
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